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ABSTRACT
Localized Scleroderma (LoS), also known as morphea, encompasses a group of idiopathic 
sclerotic skin diseases. The spectrum ranges from relatively mild phenotypes, which generally 
cause few problems besides local discomfort and visible disfigurement, to subtypes with 
severe complications such as joint contractures and limb length discrepancies. Eosinophilic 
fasciitis (EF, Shulman syndrome) is often regarded to be part of the severe side of the morphea 
spectrum.
The exact driving mechanisms behind morphea and EF pathogenesis remain to be elucidated. 
However, extensive extracellular matrix formation and autoimmune dysfunction are thought to 
be key pathogenic processes. Likewise, these processes are considered essential in systemic 
sclerosis (SSc) pathogenesis. In addition, similarities in clinical presentation between morphea 
and SSc have led to many theories about their relatedness. Importantly, morphea may be 
differentiated from SSc based absence of sclerodactyly, Raynaud phenomenon, and nailfold 
capillary changes. The diagnosis of morphea is often based on characteristic clinical findings. 
Histopathological evaluation of skin biopsies and laboratory tests are not necessary in the 
majority of morphea cases. On the contrary, full-thickness skin biopsies, containing fascia and 
muscle tissue, are required for the diagnosis of EF.
Monitoring of disease activity and damage, especially of subcutaneous involvement, is one 
of the most challenging aspects of morphea care. Therefore, data harmonization is crucial 
for optimizing standard care and for comparability of study results. Recently, the localized 
scleroderma cutaneous assessment tool (LoSCAT) has been developed and validated for 
morphea. The LoSCAT is currently the most widely reported outcome measure for morphea. 
Care-providers should take disease subtype, degree of activity, depth of involvement, 
and quality-of-life impairments into account when initiating treatment. In most patients 
with circumscribed superficial subtypes, treatment with topical therapies suffices. In more 
widespread disease, UVA1 phototherapy or systemic treatment with MTX, with or without 
systemic corticosteroids combination, should be initiated. Disappointingly, little alternatives 
for MTX have been described and additional research is still needed to optimize treatment for 
these debilitating conditions. In this review, we present a state-of-art flow chart, which guide 
care providers in treatment of morphea and EF. 
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Localized Scleroderma (LoS), also known as morphea, encompasses a group of idiopathic 
sclerotic skin diseases. Controversy exists with regard to nomenclature of the disease 
spectrum. In some countries, localized scleroderma is the preferred overarching term, 
because morphea is regarded one of the subtypes of the wider disease spectrum. However, 
morphea is the preferred term in the United States, because localized scleroderma could lead 
to unwanted confusion with the term systemic sclerosis a systemic disorder with a different 
plethora of clinical and pathological signs and symptoms.1 For the purpose of this review, we 
will use the term LoS.
The spectrum of LoS consists of heterogeneous disease phenotypes. Solitary sclerotic lesions, 
which generally cause few problems besides local discomfort and visible disfigurement, reflect 
the mild side of the spectrum.2 3 Conversely, sclerosis can cause severe complications in the 
linear subtype; limb length discrepancies and joint contractures may occur.1 4 5 
This review encompasses a description of the clinical aspects of the LoS subtypes. Eosinophilic 
fasciitis (EF, also known as Shulman Syndrome), often regarded part of the LoS spectrum, 
is included in this review. Additionally, we describe recent developments in understanding of 
disease pathogenesis and potential outcome measures. Lastly, we present two state-of-art 
flow charts, which guide care providers with regard to 1) diagnostic work-up and disease 
monitoring and 2) treatment of LoS and EF. 
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EPIDEMIOLOGY, CLASSIFICATION AND PRESENTATION
Epidemiology
The rarity of LoS is reflected in the annual incidence rates which are reported to be between 
3.4 and 27 cases per 1.000.000.6-8 Females are more frequently affected than males (ratio: 
2.4–5.0 to 1).1 9-11 The peak incidence is bimodal with peaks between 7 and 11 years for 
paediatric-onset disease 1 10-13 and 44 to 47 years for adult-onset disease.10 12 The incidence 
and prevalence of EF is unknown. The disease predominantly affects patients in their 4th and 
5th decade of life.14-16 Only a few case reports describe childhood-onset disease.11 14 15 17-21 
Main Group Subtype Description
I) Circumscribed LoS Superficial Oval or round circumscribed areas of induration limited to 
epidermis and dermis, often with altered pigmentation and 
violaceous, erythematous halo (‘lilac ring’). They can be single or 
multiple.
Deep Oval or round circumscribed deep induration of the skin 
involving subcutaneous tissue extending to fascia and may 
involve underlying muscle. The lesions can be single or 
multiple. Sometimes the primary site of involvement is in the 
subcutaneous tissue without involvement of the skin.
II) Linear LoS Trunk/
limbs
Linear induration involving dermis, subcutaneous tissue and, 
sometimes, muscle and underlying bone and affecting the limbs 
and the trunk.
Head En coup de sabre (ECDS). Linear induration that affects the face 
and the scalp and sometimes involves muscle and underlying 
bone.
Parry Romberg or progressive hemifacial atrophy loss of tissue 
on one side of the face that may involve dermis, subcutaneous 
tissue, muscle and bone. The skin is mobile.
III) Generalized LoS Induration of the skin starting as individual plaques (four or more 
and larger than 3 cm) that become confluent and involve at 
least two out of seven anatomic sites (head–neck, right upper 
extremity, left upper extremity, right lower extremity, left lower 
extremity, anterior trunk, posterior trunk).
IV) Pansclerotic LoS Circumferential involvement of limb(s) affecting the skin, 
subcutaneous tissue, muscle and bone. The lesion may 
also involve other areas of the body without internal organs 
involvement
V) Mixed LoS Combination of two or more of the previous subtypes. The order 
of the concomitant subtypes, specified in brackets, will follow 
their predominant representation in the individual patient [i.e. 
mixed morphoea (linear-circumscribed)]
Table 1 classification of LoS subtypes by Zulian and Laxer. (22)
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Multiple classification schemes have been proposed throughout the years. However, 
consensus with regard to 1 superior classification system is currently lacking. Classification 
by Zulian and Laxer22 describes the following 5 subtypes: I) circumscribed LoS (including a 
superficial and deep variant), II) linear LoS (including a limb/trunk variant and head variant), 
III) generalized LoS, IV) the pansclerotic subtype and V) the mixed subtype (table 1). Other 
classification systems include more uncommon subtypes such as guttate and bullous LoS.23 24 
Secondly, these systems include diagnoses which are debated to be part of the LoS spectrum, 
such as atrophoderma of Pasini and Pierini, extragenital lichen sclerosis et athrophicus and 
EF. In the authors’ opinion, EF belongs to the spectrum of LoS, based on fact that the largest case 
series reported concomitant morphea en plaque (circumscribed superficial LoS) in 29 % to 40% of the 
patients.14-16
Clinical characteristics
General findings
Early, progressive LoS is characterized by erythematous or violaceous cutaneous lesions. As 
the disease progresses, sclerotic plaques develop at the centre of these lesions. This leads to 
the appearance of a yellow-white sclerotic plaque with an erythematous or violaceous border, 
the so called ‘lilac ring’ (figure 1). In some patients, development of hyperpigmentation is 
the predominant feature and sclerosis can be limited or absent (figure 2). In the majority of 
patients, skin softens in months to years. Consecutively, signs of residual damage, such as 
pigment alterations, cutaneous and subcutaneous atrophy, may develop. In most patients, the 
disease is self-limiting within 3 to 5 years. However, in some patients LoS remains progressive 
for multiple years or flares of disease occur frequently.1 10 25 
Circumscribed superficial LoS
In circumscribed superficial LoS, also known as ‘morphea en plaque’, involvement is limited to 
the dermis.9 10 13 Solitary or few plaques predominantly affect the trunk, waist and submammary 
region. Circumscribed superficial LoS is the most common subtype in adults and generally 
causes few problems besides local discomfort and visible disfigurement.
Circumscribed deep LoS
In circumscribed deep LoS (morphea profunda), sclerosis reaching into the subcutis is present 
and may extend into the fascia and muscle. Deep LoS is a rare subtype in both the adult and 
paediatric populations (~5%).1 9 10 Lower extremities are often affected symmetrically, where 
sclerosis might cause contractures and lead to subcutaneous atrophy. 
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Linear LoS
In linear LoS, sclerosis may be limited to the dermis, but deeper involvement is often present. 
The ‘band-like’ cutaneous sclerosis (figure 3) frequently causes contractures.1 4 Additionally, 
limb-length discrepancies may occur1 (figure 4). In the majority of patients, the disease 
remains unilateral. Linear LoS is the most common subtype in childhood-onset LoS (~65%)11, 
but disease onset might occur during adulthood as well.4 10 Linear LoS of the limbs and trunk 
is characterized by a chronic disease course, as the disease may remain active after many 
decennia26 27 and recurrences are reported in a large proportion of both adults and children.4 
10 25 28 29 
The ‘en coup de sabre’ (ECDS) subtype most frequently affects the paramedian forehead. 
Linear lesions may extent onto the scalp, where they cause alopecia (figure 5). This 
subtype might be accompanied by ocular30 31, neurological1 11 32 and odontostomatologic33-35 
complications. Progressive hemifacial atrophy (Parry-Romberg syndrome) is characterized 
by diffuse unilateral subcutaneous atrophy of the face. This subtype is often regarded part of 
a spectrum with ECDS because 71% of the patients have overlaying cutaneous sclerosis.32 36 
However, studies that investigated the connection of these two conditions are lacking.
Generalized LoS
Generalized LoS is characterized by large superficial coalesced plaques on multiple body sites 
(figure 6). Generalized LoS is more frequently present in adults than children.9 10 13 Sclerosis is 
usually present on the trunk, arms and legs with sparing of the face, hands and feet. 
Eosinophilic fasciitis
The disease onset is characterized by acute or subacute development of pitting-edema and 
erythema. As the disease progresses, edema is gradually replaced by a ‘peau d’orange’ 
aspect as deep sclerosis starts to develop (figure 7). Extremities are affected symmetrically, 
with exclusion of hands and feet. Neck and truncal involvement are reported in widespread 
disease. Cutaneous involvement may be accompanied by general symptoms such as weight 
loss, myalgia and asthenia. 14 15 21
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Figure 1 Circumscribed superficial LoS (morphea en plaque). A yellow-white sclerotic plaque with an 
erythematous or violaceous border, the characteristic ‘lilac ring’.
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Figure 2 Generalized LoS. Example of a patient with absence of induration, but extensive 
hyperpigmentation. 
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Figure 3 Linear LoS of the upper extremity. 
535444-L-bw-Mertens
Processed on: 12-9-2019 PDF page: 20
CHAPTER 1.1
20                                   
Figure 4 Linear LoS of the lower extremity. Limb length discrepancy and subcutaneous atrophy in burned 
out disease (left leg).
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Figure 5 Linear LoS on the paramedian forehead (en coup de sabre) crossing onto the scalp causing 
alopecia.
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Figure 6 Severe case of generalized LoS on the trunk with atrophy of both breasts.
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Figure 7 Peau d’orange aspect on upper extremity in a patient with eosinophilic fasciitis.
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HISTOPATHOLOGY
Skin biopsy in LoS
Histopathological characteristics correlate with the clinical state of LoS. Evaluation of early 
active LoS, represented by a biopsy of the inflammatory border, reveals a perivascular 
infiltrate composed of lymphocytes and plasma cells, possibly accompanied by eosinophils 
and macrophages. Evaluation of sclerotic skin demonstrates thickened and homogenized 
collagen bundles at the papillary and reticular dermis. The abundant collagen bundles enclose 
eccrine glands and few dermal blood vessels with fibrotic walls and narrow lumina may be 
observed as the sclerosis progresses. Subcutaneous infiltration and sclerosis reflect deeper 
involvement.
We recommend a diagnostic skin biopsy only in case of an unclear clinical presentation of 
LoS. The clinical appearance of the biopsy site (inflammatory border versus sclerotic centre) 
should be mentioned to the pathologists for optimal clinicopathological correlation.
Full-thickness biopsy in EF
A full-thickness biopsy, containing fascia and muscle, is the golden standard for the diagnosis 
of EF. Histology typically displays a thickened fascia infiltrated by lymphocytes accompanied by 
eosinophils, plasma cells, and macrophages.14 15 The presence of eosinophils is transient and 
may be absent if patients have prolonged disease or receive systemic corticosteroids (SCS) 
or immunosuppressive drugs (ISD). Adjacent myositis is frequently observed.37 Presence of 
thickened dermal collagen fibres may reflect the presence of concomitant superficial LoS.14 
15 More recently, magnetic resonance imaging (MRI) 38-40, ultrasound (US) 41 42, and positron 
emission tomography (PET) 43-45 have been reported to be helpful in establishing the diagnosis 
by decreasing the likelihood of sampling errors for deep biopsies or by visualizing the fasciitis. 
PATHOGENESIS
Pathological hallmarks of LoS
The exact driving mechanisms behind LoS pathogenesis remain to be elucidated. However, 
extensive extracellular matrix (collagen) formation and autoimmune dysfunction are thought 
to be key pathogenic processes.46-48 Likewise, these processes are considered essential in 
systemic sclerosis (SSc) pathogenesis. The similarities between the 2 diseases have led to 
many theories about their relatedness. Based on this possible connection, most theories for 
LoS pathogenesis are deduced from SSc. Endothelial dysfunction, immune dysregulation and 
excessive collagen deposition are regarded key hallmarks for SSc pathogenesis49 50. In recent 
years, research in SSc has led to some insight in these hallmarks and their inter-relationship. 
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following sections.
Vascular dysfunction
For SSc, endothelial dysfunction is clinically reflected in the presence of Raynaud’s phenomenon 
and visible changes on capillaroscopy (nailfold lesions). 51 No such clinicopathological 
correlation exists for LoS. However, the propensity of pericyte hyperplasia in capillar and 
venular walls and increased capillary density in active LoS lesions have been reported.52 
Immune dysregulation
Autoimmunity
Autoimmunity is likely involved in the pathogenesis because of the presence of autoantibodies 
in a proportion of the LoS patients.9 11 53-58 Secondly, presence of concomitant autoimmune 
diseases in LoS patients and their relatives supports involvement of autoimmunity. 5 11 13 59 
Recently, a study including 211 LoS patients and 726 matched controls investigated HLA class 
I and II typing. The strongest associations with LoS were found with the HLA Class II allele 
DRB1*04:04 and class I allele HLA–B*37. Comparison of the risk alleles for the LoS cohort 
versus other autoimmune diseases revealed only one allele in common between LoS and 
SSc. However, many more alleles showed similarity with other autoimmune diseases such as 
rheumatoid arthritis.60 
Cytokines & Chemokines
Increased serum levels of the adhesion molecules Vascular Cell Adhesion Molecule-1 (VCAM-
1), Intracellular Cell Adhesion Molecule-1 (ICAM-1) and E-Selectin have been reported in LoS 
patients.61 62 These molecules might be involved in early recruitment of inflammatory cells 
such as T-cells, monocytes and other immune cells. 
Initial studies demonstrated elevation of classic profibrotic T helper cell 2 (TH2) cytokines IL-4 
and IL-13 (and IL-2, 6, and 8) in serum of 48 LoS patients. Likewise, IL-4 and -13 elevation 
has been demonstrated in circulation, skin and lung tissue of SSc patients.63-65 Recently, a 
cross-sectional study performed a 29-plex Luminex, which included TH1, -2 and -17 cyto- and 
chemokines, on plasma of 69 paediatric LoS patients and 71 controls. Elevation of Interferon-
Gamma-Induced protein 10 (IP-10, CXCL10), Il-12p70 and IFN- γ suggested a proinflammatory 
TH1 predominance, whereas IL-17a elevation signified a proinflammatory TH17 predominance. 
Elevation of these proinflammatory TH1 and-17 cyto- and chemokines correlated with shorter 
disease duration. In contrast to the TH1/17 predominance, TH2 cytokines IL-4, IL-5, and IL-13 
were not significantly elevated.66 Interleukine-17a gene upregulation has also been reported 
in peripheral blood mononuclear and skin samples from LoS patients. This study confirmed 
the correlation between IL-17a elevation and shorter disease duration.67 Tumour-necrosis-
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factor-α (TNF- α), an effector cytokine affiliated with the TH1 and -17 lineage was shown to 
be increased in active disease versus inactive disease.66 The association of TNF-α levels and 
disease activity was also shown in a previous study.68
In conclusion, it is unclear whether a TH1/17 or TH2 predominance is present in LoS. One 
postulated theory is TH1 and -17 predominance in early, active disease and TH2 predominance 
in the fibrotic phase of the disease. 
Excessive extracellular matrix formation 
Development of cutaneous or subcutaneous fibrosis is the key characteristic of LoS. Fibrosis 
is a result of excessive collagen synthesis and decreased degradation. Transforming 
growth factor-β1 (TGF-β1) has been shown to increase the expression of several collagen 
types and other ECM components in LoS and SSc.69-71 Additionally, TGF-β1 has inhibitory 
effects on matrix degradation. Therefore, TGF-β is regarded a key-player in LoS and SSc 
pathogenesis. However, the processes leading to excessive TGF-β synthesis in LoS remain 
poorly understood. Recent reports in SSc showed TGF-β-dependent fibrosis development via 
toll-like-receptor (TLR) signaling.72-75 Most interestingly, some of these reports demonstrated 
endogenous ligands (mitochondrial DNA72, fibronectinEDA73 and tenascin-C75) for these 
TLRs. These findings integrate innate immunity and fibrosis development. The role of the 
innate immune system, via TLR-signalling, in fibrogenesis remains to be investigated in LoS. 
However, a previous report of tenascin upregulation in LoS skin samples might hint towards 
involvement of the innate immune system in LoS pathogenesis.76
Epigenetics
Low concordance rates of autoimmune diseases in monozygotic twins suggest additional 
pathogenic mechanisms, besides genetic factors.77 The field of epigenetics investigates 
heritable changes that influence gene expression without altering the DNA sequence; these 
changes include DNA methylation, post-translational modification of histones and microRNAs 
(miRNAs).78 MiRNAs are short non-coding RNAs of 18-23 nucleotides that bind messenger 
RNAs (mRNA) and thereby inhibit their translation or induce mRNA degradation. A study 
in 2013 was the first to report miRNA dysregulation in LoS. This study reported let-7a 
downregulation in LoS skin and circulation. Additionally, experimental let-7a overexpression 
or inhibition, affected protein expression of type I collagen.79 A second study reported 
miRNA-196a downregulation in serum and involved skin of LoS patients. Transfection of a 
miRNA-196a inhibitor into normal cultured fibroblasts upregulated type 1 collagen protein 
in vitro.80 Lastly, a recent study reported upregulation of miRNA-155 in SSc and LoS skin. 
Most interestingly, this study showed the potential of miRNAs as a therapeutic target by 
decreasing the dermal thickness, collagen deposition and number of activated fibroblasts 
upon topical administration of a miRNAs-155 blocking agent in a murine bleomycine-induced 
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investigated in a phase I trial with MRG-201, a molecule which mimics miRNA-29 activity. 
(clinicaltrials.gov NCT02603224)
Environmental factors 
Multiple environmental factors have been proposed to be involved in LoS development. 
The role of friction, long-term pressure, or mechanical factors, such as vaccination or other 
injections is repeatedly reported in 13 to 16% of LoS patients. 1 11 82 Secondly, LoS is an 
uncommon complication after radiation therapy. A recent literature review summarized 
66 cases with radiation induced morphea (RIM).83 Radiation may lead to secretion of TH2 
cytokines (Il-4 and 5) which leads TGF-β mediated fibrogenesis.  
For multiple decades, studies have reported inconsistent results with regard to the association 
of Borrelia burgdorferi (B. Burgdorferi) and LoS. Results vary from detection of B. Burgdorferi 
in case reports and large proportions of patients in case series 84-87, to complete absence 
of detectable B. Burgdorferi in other studies.88-97 Different techniques being reported, in 
combination with different borrelia strains present on different geographical locations, makes 
it difficult to come to a conclusion for a large group of LoS patients. In the authors’ opinion, it 
is unlikely that B. Burgdorferi is involved in a large proportion of patients in LoS pathogenesis.
 
Interestingly, recent case reports almost exclusively report TNF-α inhibitors in drug-induced 
LoS.98-101 Conversely, two cases have described beneficial effects of Infliximab in severe LoS 
cases.102 103 Moreover, elevation of TNF-α in circulation in active LoS endorses the role of 
this cytokine in the development of LoS.66 68 However, the exact role of TNF-α still remains 
to be elucidated. In addition to TNF-α inhibitors, multiple other drugs and injections have 
been implicated in cases of drug-induced LoS. A review including 15 cases of drug-induced 
LoS concluded that drug-induced LoS was extremely rare, drug withdrawal did not lead to 
remission in most patients and some of the drugs could directly be linked to connective tissue 
metabolism.104
Pathogenesis of EF
The pathogenesis of EF remains unknown. Numerous associations with potential etiological 
factors have been proposed in case reports. Most of these factors have also been reported 
in association with LoS (i.e. B. Burgdorferi infection 105, radiation therapy 106, and insect bites 
107). The most commonly reported etiological factor for EF is strenuous exercise or trauma 
preceding disease onset. Two case series, consisting of 5215 and 63 patients16, reported 
exercise to be suggestive for disease induction in 46% and 28% of the patients, respectively. 
However, the mechanisms leading to clinical phenotype remain unknown.  
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LABORATORY TESTING
Autoantibodies
To date, no LoS-specific autoantibodies have been discovered. This is in contrast to SSc 
for which multiple specific autoantibodies (anticentromere, anti-topoisomerase 1 and anti-
RNA polyisomerase III antibodies) have been reported and routinely are being screened in 
standard care.108
Antinuclear antibodies have been reported in 5.9 to 68% of LoS patients.9 11 13 54-56 58 Previous 
retrospective studies reported increased ANA frequencies in severe subtypes such as linear 
and generalized LoS.13 54 Recently, a prospective study with 187 LoS patients could not confirm 
differences in ANA prevalence between the different subtypes. This study reported ANAs to 
be present in 34% of the complete group, with ANA prevalences only varying between 33 
and 36% in the different disease subtypes.53 Additionally, this study showed single-stranded 
DNA antibodies (ssDNA abs) only to be present in 8% of the complete group, and 13% in the 
linear subtype, versus 7% in controls. Retrospective studies reported single-stranded DNA 
antibodies (ssDNA abs) in 29-39% of the linear subtype.54 55 Antihistone antibodies (AHAs) are 
consistently reported to be increased in the linear subtype (18-42%)53 54 56, whereas conflicting 
results exists with regard to AHA and the generalized subtype.53 56 Lastly, antibodies to 
cardiolipin11 109-111, phospholipid110, U1 ribonucleoproteins112, U3 ribonucleoproteins113, MMP-1114 
and antinucleosome58 have been described in LoS. 
For LoS, autoantibodies remain of limited clinical use; no specific autoantibodies have been 
identified and no associations have been reported between any of the previously reported 
antibodies or titres and clinical activity or severity measures in the complete group of LoS 
subtypes. 
In conclusion, we do not recommend testing of autoantibodies for diagnostic and disease 
monitoring purposes. 
Borrelia burgdorferi
Section 4.3. encompasses a more detailed description of the role of B. Burgdorferi in 
LoS development. Based on evidence, serological testing may be considered in atypical 
presentation of LoS.
Other laboratory tests
Inflammatory serological markers are upregulated in a minority of LoS patients and do 
not correlate with disease activity.11 Therefore, we do not recommend routine testing of 
inflammatory serological markers. 
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Peripheral eosinophilia and elevation of inflammatory markers may be present in the early 
stages of EF. However, these findings are transient and may be absent in later stages of the 
disease or when patients receive SCS or ISD treatment. We recommend routine testing of 
absolute eosinophil counts and inflammatory markers in the initial phase of the disease and 
for the detection of disease reactivation. 14 15 Autoantibodies may be detected in 15-20% of the 
patients, whereas specific antibodies are absent in the majority of patients. Autoantibody testing 
may be useful in the differentiation versus SSc. 14 15 In addition, anti-neutrophil cytoplasmic 
antibody (ANCA) testing can be performed in cases where eosinophilic granulomatosis with 
polyangiitis (EGPA) is considered as part of the differential diagnosis.115
OUTCOME MEASURES 
Validated outcome measures for disease activity and damage are essential for optimal 
standard care. Secondly, data harmonization is crucial for comparability of study results. 
Recently, a comprehensive systematic review described tools for determining disease activity 
in LoS.116 In the following sections, we describe the most promising outcome measures. 
Clinical scores 
The localized scleroderma cutaneous assessment tool (LoSCAT) is a composite of the modified 
localized scleroderma severity index (mLoSSI)117 and localized scleroderma skin damage index 
(LoSDI).118 The mLoSSI assesses signs of disease activity (expansion of disease, presence 
of erythema and skin induration). The LoSDI scores cutaneous and subcutaneous atrophy, 
and pigment alterations; signs which reflect disease damage. In addition to the LoSCAT, 
physician global assessment of disease activity (PhysGA-A) and damage (PhysGA-D) have 
also been investigated in the development of the LoSCAT score.117 118 The Dyspigmentation, 
Induration, Erythema and Telangiectasia (DIET)-score poorly discriminates between disease 
activity and disease damage; similar scores can either reflect active or inactive disease.119 
120 Lastly, several 1 or 2 dimensional clinical scores, such as the modified Rodnan skin 
score121-123 (mRSS), the modified skin score (mSS, by Zachariae)124 125 and the computerized 
skin score (CSS)126 have been described. These scores share the downside of only capturing 
skin sclerosis as a sign of disease activity. Therefore, based on current literature, LoSCAT in 
combination with PhysGA-A and PhysGA-D are the recommended clinical outcome measures 
for superficial LoS assessment.
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Miscellaneous outcome measures 
Ultrasound is widely reported  for the assessment of LoS activity.116 However, downside of 
US is the wide variability in equipment reported between studies. The Localized Scleroderma 
Clinical and Ultrasound Study Group (LOCUS) has developed a standardized US imaging 
protocol, which should guide to data harmonization.127 Another technique commonly reported 
is infrared thermography (IRT). Multiple studies have demonstrated correlations between 
lesion temperature and clinical activity status of the LoS lesions. 116 Lastly, durometry is a tool 
used to measure material hardness. Originally, durometry was described as reliable method 
for the assessment of LoS skin hardness.124 Recently, a study with 23 paediatric patients 
demonstrated that durometry was able to discriminate between affected and unaffected skin 
and that it was sensitive to detect change in lesions.128 The usefulness of durometry remains 
limited as lesions located at bony surfaces, such as scalp and skin lesions, are not suited to 
asses with durometry.129 130 
In conclusion, in superficial LoS high frequency US and IRT are the most promising techniques 
for monitoring of disease activity, in addition to the LoSCAT.
Outcome measures for EF
To our knowledge, no outcome measures have been validated for EF. Therefore, we recommend 
the use of outcome measures known from SSc and LoS research. We recommend LoSCAT 
in combination with PhysGA-A and PhysGA-D, possibly accompanied by US and IRT, for the 
assessment of superficial involvement. Lastly, movement restrictions may be assessed by 
passive range of motion measurements.
ASSESSMENT OF MUSCOLOSKELETAL INVOLVEMENT
Slow progression of musculoskeletal involvement may be notoriously difficult to measure 
between consecutive visits, but accumulated damage may be significant over a longer period 
of time. This emphasizes the necessity of additional imaging tools or biomarkers which reflect 
active deep disease. 
Recommendations for LoS
A retrospective study reported MRI findings in 43 LoS patients; MRI enabled to confirm 
musculoskeletal abnormalities in all but 1 of the patients in whom musculoskeletal involvement 
was clinically suspected.131 A recent retrospective study confirmed the potential of MRI in 
detection of musculoskeletal involvement.132 More importantly, a longitudinal study reported 
MRI findings to be sensitive to changes in patients with deep LoS whom were being treated 
with ISDs.133 
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dysfunction in patients with linear LoS.134 Lastly, US has been reported in the monitoring of 
muscle involvement in deep LoS. However, the usefulness of this technique is highly operator-
dependent.135 In conclusion, the exact role of EMG and US requires further investigation. Based 
on the current evidence we recommend MRI for monitoring of musculoskeletal involvement in 
LoS when indicated. However, we do not recommend routine MR imaging assessment.
Recommendations for EF
A retrospective study described serial MRI findings in 6 EF patients. Pre-treatment MRI 
evaluation showed strong fascial enhancement, especially after intravenous (IV) administration 
of an extracellular gadolinium-based contrast agent. Posttherapy MRI evaluation during 
follow-up showed complete resolution of the characteristic MRI changes of the superficial 
and deep muscle fasciae in those patients who had complete clinical remission (n=5).40 
Another case series described MRI findings in 6 EF patients. Pre-treatment MRI findings 
(n=6) showed fascial thickening and hyperintense signal within the fascia in fluid-sensitive 
sequences. The posttherapy images (n=3) showed marked improvement in 2 and mild but 
definite improvement in the other.136 Case reports confirm the added value of MRI for both 
diagnostic purposes137 and for the assessment of the fasciitis.39 138 In addition, US41 42 and 
positron emission tomography (PET)43-45 have also been reported to be helpful for similar 
purposes. In conclusion, MRI may be considered for the assessment of EF.
Differential diagnosis
Differential diagnosis of LoS
Evaluation of the differential diagnosis for the complete LoS spectrum is beyond the scope of 
this review and is described elsewhere.24 Differentiation between LoS and SSc is commonly 
requested in an outpatient clinic. In the vast majority of patients, differentiation between the 
two diseases should be based on clinical findings and no additional testing is necessary in the 
absence of SSc suspicion. 
Raynaud’s phenomenon or gastro-intestinal problems are early signs of SSc and should 
therefore be checked in the patients’ history. Signs of SSc such as: sclerodactyly, digital 
ulcers, pitting scars, puffy fingers, calcinosis cutis, telangiectasia and diffuse facial sclerosis 
are rarely present in LoS and should be excluded by clinical examination. 
Two studies investigated differentiating characteristics between LoS and SSc skin biopsies. 
These studies identified abundant cellular infiltrates in LoS compared to SSc, even in the 
sclerotic phase of LoS. However, most signs overlapped and differentiation remained difficult.139 
140 Therefore we do not recommend routine skin biopsies for the purpose of differentiation 
between LoS and SSc. 
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If SSc suspicion is present at any of the aforementioned steps, complete screening for SSc 
including extensive laboratory testing, pulmonary imaging and functional testing, cardiac 
imaging and nailfold capillaroscopy, is recommended.108
Differential diagnosis of EF 
The initial presentation of EF is characterized by an acute or subacute onset of pitting-edema, 
erythema, myalgia, and arthralgia, accompanied by elevated inflammatory markers (ESR and 
CRP) and peripheral eosinophilia. After this initial inflammatory phase, sclerosis gradually 
starts to the develop at affected body sides. 15 21 The differential diagnosis of EF consists of 
LoS, SSc, scleroderma-like conditions and miscellaneous diseases characterized by signs of 
inflammation and peripheral eosinophilia. 
Differentiation between LoS and EF is mainly based on the characteristic distribution of 
cutaneous sclerosis in different LoS subtypes (i.e. linear LoS).48 In addition, histological 
demonstration of a fasciitis accompanied by eosinophils in the infiltrate support the diagnosis 
of EF.15 However, histological differentiation with deep LoS, especially in the presence of 
widespread sclerosis, may be challenging. In such cases, clinical findings such as symmetrical 
distribution, a pronounced inflammatory phase and detection of peripheral eosinophilia point 
towards EF.
Eosinophilic fasciitis and SSc are both characterized by initial inflammation, followed by 
cutaneous fibrosis. Facial and acral involvement are uncommon in EF and point toward SSc. 
In addition, presence of Raynaud’s phenomenon, abnormal nailfold capillaroscopy, specific 
autoantibodies, and internal organ involvement are absent in EF and frequently found in SSc. 
Lastly, histopathological demonstration of a fasciitis supports the diagnosis of EF.108
Eosinophilia-myalgia syndrome (EMS)141, caused by L-tryptophan ingestion, and toxic oil 
syndrome142, are two examples of scleroderma-like syndromes which may be difficult to 
differentiate from EF, even by full-thickness biopsies. However, internal organ involvement 
differentiates the conditions from EF. Likewise, the hyper-eosinophilic syndrome (HES)143 and 
EGPA144, are also characterized by organ involvement. In addition, the absence of cutaneous 
sclerosis in both HES and EGPA, should aid differentiation with EF. 
Lastly, nephrogenic systemic fibrosis should be suspected in patients with advanced 
renal failure, or a history of gadolinium administration. In addition to the patients’ history, 
involvement of the acra and absence of eosinophilia supports the diagnosis of nephrogenic 
systemic fibrosis. 
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Figure 8 displays a flowchart which guides the care-provider with regard to diagnoses and 
complication management.
Linear LoS of the head (ECDS) and progressive facial hemiatrophy (Parry-Romberg 
syndrome)
Referral to an ophthalmologist should be considered to detect complications such as eyelid 
abnormalities, anterior uveitis and episcleritis.30 Odontostomatologic complications should be 
managed accordingly in corporation with an oral maxillofacial surgeon and/or dentist. 33-35 
Lastly, neurological manifestations, consisting of seizures and headaches145 may occur and 
referral to a neurologist could be considered to rule out central nervous system involvement.32 
146-150
Eosinophilic Fasciitis
Eosinophilic fasciitis manifests secondary to malignancy in a minority of patients (5-10%). 
Association with haematological malignancy is more common than association with solid 
neoplasms. 14 15 151 Various screening modalities, such as laboratory testing, X-ray, CT or 
PET-scan, US and endoscopy, may be employed, dependent on the patient risk profile and 
additional signs of malignancy.
Musculoskeletal complications
Musculoskeletal complications (arthralgia, contractures and arthritis) are reported in up to 
40% of LoS and EF patients.1 5 15 We recommend consultation of a rheumatologist in the 
presence of musculoskeletal complications.
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Care-providers should take disease subtype, degree of activity, depth of involvement, and 
quality-of-life impairments into account when initiating treatment. In most patients with 
circumscribed superficial subtypes, treatment with topical therapies suffices. In widespread 
superficial disease phototherapy or systemic treatment with MTX should be initiated. For 
deep involvement, methotrexate (MTX) is considered first line treatment. The addition of SCS 
should be considered in case of severe disease, rapid progression or (looming) contractures. 
Figure 9 shows an algorithm which guide care-providers in treatment decisions for the 
different subtypes, including EF. 
Topical therapy
Topical and intralesional corticosteroids
Topical corticosteroids (TCS) are first line therapy for superficial LoS. However, no studies 
have reported efficacy of TCS in LoS. Based on expert opinion, we regard TCS first-line 
treatment for superficial circumscribed LoS. We recommend highly potent TCS once a day 
for up to 4 weeks or moderately potent TCS once a day for up to 3 months. Additionally, long-
term TCS therapy should be in the form of interval therapy.24 Comparable to TCS there are no 
studies reported for intralesional corticosteroids.
Topical tacrolimus 0.1% ointment
A double-blind randomized controlled trial (RCT) with tacrolimus 0.1% ointment reported 
significant improvement in durometry and clinical scores.152 A 3-month open-label study 
with topical tacrolimus 0.1% ointment twice daily under occlusion demonstrated complete 
resolution of early lesions and softening of late sclerotic lesions.153 Another open-label study 
reported improvement in 9 out of 13 patients with topical tacrolimus 0.1% ointment, twice 
daily without occlusion.154 We recommend topical tacrolimus 0.1% ointment, either with or 
without occlusion, twice daily as an alternative or additional topical therapy for superficial 
LoS. Additionally, based on a recent case-report, we do not recommend topical tacrolimus in 
radiation induced LoS.155
Topical calcipotriol 0.005% ointment
Two uncontrolled studies investigated topical calcipotriene 0.005% ointment, either with156 or 
without occlusion157. These studies included 31 patients and both studies reported beneficial 
effects in all patients. Lastly, an uncontrolled study with 6 patients reported efficacy of 
combination therapy with betamethasone-dipropionate and calcipotriol 0.005%.158 Based on 
literature, we recommend topical calcipotriol 0.005% ointment, once or twice daily, with or 
without occlusion as an alternative topical therapy for superficial LoS. Additionally, topical 
calcipotriol 0.005% ointment may be prescribed combined with TCS therapy.
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Miscellaneous topical therapies
A proof of concept study with topical imiquimod 5% cream reported effectiveness, measured 
by decrease of DIET and VAS score in 9 paediatric patients159. A second prospective vehicle 
controlled study with 25 adult patients confirmed these results. Imiquimod 5% cream was 
superior to vehicle in reducing DIET-scores at month 3, 6, 9 and 12.120 Both prospective studies 
reported no study withdrawals and adverse effects were minimal. Lastly several case reports 
and series confirm the beneficial effects of imiquimod 5%.119 160 161 Despite these positive study 
results, German guidelines do not recommend the use of imiquimod 5% cream, based on the 
authors’ experience.24 
Interestingly, an open phase-II trial with 12 LoS patients reported significant reduction of 
mLoSSI and durometer scores at month 6 compared to baseline with 8% Pirfenidone gel three 
times daily. Pirfenidone gel was well tolerated and no side effects were reported.162 
Phototherapy 
Several phototherapy modalities (UVB, PUVA, broadband UVA and UVA1) have been 
investigated for LoS. Lower wave length phototherapy (UVA) has greater potency of tissue 
penetration than UVB and therefore has been studied more extensively.
UVA1 
The treatment potential of UVA1 (wavelength of 340 – 400mm) is superior compared to 
broadband UVA (320 – 400mm), because of the lower risk for sunburn. This allows for higher 
dosage delivery with fewer side effects. Three different UVA1 dose regimens exist and have 
been investigated for LoS: low-dose (LD, 10–20 J/cm²)163-168, medium-dose (MD, 30–50 J/
cm²)121 122 167-170 and high-dose (HD, 60– 130 J/cm²).164 One study demonstrated superior results 
for HD compared to LD-UVA1.164 Additionally, one randomized prospective study compared 
LD-UVA1, MD-UVA1 and UVB. This study showed superior efficacy of MD-UVA1 versus 
UVB but not versus LD-UVA1.167 Noteworthy, the first true randomized, blinded and placebo 
controlled trial with UVA1 is currently including patients (clinicaltrials.gov NCT01799174). The 
maximum dose investigated in a study consist of a cumulative dose of 3900 J/cm2. At our 
centre, we treat patients with 60J/cm2 3 to 5 times/week to a cumulative dose of 1460 J/cm2. 
In contrast to the excellent short-term results with UVA1, a study of 37 adults showed two-year 
and three-year recurrence rates of 44.5% and 48.4% after UVA1 treatment, respectively.29 No 
data exists with regard to effectiveness of repeated treatment with UVA1. 
Miscellaneous phototherapy modalities 
One study investigated broadband UVA (320-400mm) in 3 dose regimens (5, 10 and 20J/cm2) 
for 20 sessions in 63 patients. All regimens were effective and none of them was superior 
compared to the other regimens.171 Two prospective studies report beneficial effects of 
psoralen plus broadband UVA (PUVA) in 30 patients.172 173 Additionally, a retrospective single-
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demonstrated equal effectiveness of UVB and low-dose UVA1.167 
Summary and recommendations
Based on literature, we recommend UVA1 as first-choice phototherapy modality for adult 
patients. Although supported by less evidence, UVA1 phototherapy may also be used in 
a paediatric LoS. Despite the deeper penetration potential of UVA1, phototherapy should 
primarily be used for superficial subtypes of LoS. Additionally, it may be used as add-on 
therapy to systemic treatment in patients with both superficial and deep manifestations
Systemic Treatments
Systemic Corticosteroids (SCS)
One open study investigated oral SCS (Prednisone, starting dose 0.5-1mg/kg/day followed 
by tapering) in 17 patients with severe LoS. Patients were treated for 5 to 70 months. This 
study reported a rapid response. However, in 6 patients (35%) disease relapse was observed 
after treatment discontinuation.175 Additionally, a retrospective study with 28 adult patients 
reported a favourable response in 24 patients (86%) with oral SCS (Prednisone, starting 
dose 0.3-1.0mg/kg/day). Patients were treated for 3 to 39 months. Similar to the first study, 
recurrence rates were 45% after treatment discontinuation.176 High recurrence rates combined 
with an unfavourable long-term side effect profile, leads to the recommendation that oral SCS 
monotherapy is no viable long-term treatment option for LoS. Intravenous methylprednison 
(IVMP) has only been investigated in combination with methotrexate (MTX) and will be 
discussed in the following section.
Methotrexate
Methotrexate, with or without the combination of IVMP and/or oral SCS, is the most reported 
systemic treatment for LoS. Best evidence results from a double-blind RCT with 70 paediatric 
LoS patients, which investigated oral MTX (15 mg/m²/week, max. 20 mg) versus placebo for 
twelve months. Both arms received oral SCS (Prednisone, starting dose 1 mg/kg/day, max. 50 
mg, followed by tapering) for the first 3 months. Reported outcome measures consisted of a 
computerized skin score rate and IRT. Improvements in outcome measures at month 12 could 
only be observed in the MTX treatment arm, whereas the placebo-arm showed worsening.28 
Two prospective non-controlled studies investigated MTX in combination with IVMP177 or oral 
SCS178 in children. One study included 10 paediatric patients who received subcutaneous 
MTX 0.3 – 0.6 mg/kg/week (max. 20mg/week) and of which 9 patients simultaneously received 
IVMP (30mg/kg for 3 days, monthly for 3 months). At the last follow-up visit, all patients who 
continued (n=9) had inactive skin lesions.177 The second study investigated subcutaneous 
MTX (1mg/kg/week max. 25mg) in combination with oral SCS (Prednisone 2mg/kg/day, 
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maximum 60mg/day followed by tapering) in 36 paediatric patients. All patients demonstrated 
significant improvement in mLoSSI and PhysGA-A at a median of 1.77 months.178 
Two additional prospective studies investigated adult patients. One study investigated oral 
MTX (15mg/week) in combination with IVMP (1000mg for 3 days, monthly) for at least 6 
months in 15 patients with severe LoS. In the majority of patients (n=14), a significant decrease 
in mSS was observed, supported by histologic and US assessments.179 Another uncontrolled 
prospective study investigated oral MTX (15mg/week) monotherapy for 24 weeks in 9 adult 
LoS patients.180 Significant improvements in MSS and VAS for tightness were observed at 
week 24. 
In addition to prospective trials, we identified 11 retrospective studies which report MTX with 
or without IVMP and/or oral SCS.1 4 25 27 32 109 181-185 A total of 353 unique patients were identified 
(124 adults and 229 paediatric patients). Response rates to MTX with or without IVMP and/or 
oral SCS ranged between 80-94%. In contrast to the high short-term response rates, (long-
term) disease recurrences are reported in 28-44% in of the patients after MTX discontinuation.1 
25 182 184 A prospective long-term follow-up study described that MTX treatment duration was 
a predictor for relapse, suggesting that longer treatment duration prevent disease relapse.186 
Lastly, some of the retrospective studies report superior response rates for combination 
therapy with MTX plus systemic CS compared to MTX monotherapy.4 185 However, these 
studies are prone to bias because of confounding by indication as a result of the retrospective 
design of these studies. 
In conclusion, MTX is an effective treatment for LoS. However, no comparative studies between 
MTX monotherapy and MTX plus SCS have been reported. Therefore, no recommendations 
can be given whether MTX should be applied with or without SCS. However, addition of either 
oral SCS or IVMP to MTX should at least be performed in the case of severe disease, rapidly 
progressive disease or in the presence of (looming) contractures. Recommended dosages 
are displayed in the legend of the flowchart (figure 9). Optimal timing of systemic treatment 
discontinuation remains a difficult aspect in therapeutic management.
Folic/Folinic Acid suppletion:
A retrospective analysis of MTX treatment in 107 adult patients showed that folic acid (5-10mg 
once a week) protected against MTX discontinuation due to adverse events.181 Additionally, 
folic acid (0.4-1mg/day) or folinic acid (5mg/week) is recommended by CARRA.187
Mycophenolate Mofetil (MMF)
Two studies reported MMF in severe refractory LoS. The first study, retrospectively described 
10 MTX and CS refractory paediatric LoS patients whom were treated with MMF (dose, 600-
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of disease progression was reported in 8 patients (80%) and a reduction of erythema in 7 
(70%), skin softening in 9 (90%) and extracutaneous manifestations in 4 patients (40%). MMF 
was well tolerated in all patients.188 The second study retrospectively described MMF in 7 LoS 
patients (3 adults and 4 paediatrics). Doses ranged from 500 to 2500mg. This study reported 
disease remission in 4 patients (57%) and maintenance of disease remission in 1 patient 
(14%). In the remaining two patients (29%) MMF treatment was discontinued due to disease 
progression or side effects.189 Despite the limited evidence for MMF in LoS, two studies 
showed extensive experience with MMF in large proportions of involved care-providers.187 190 
Based on current evidence, we recommend MMF (dose adults: 1000mg twice daily, dose 
paediatrics: 600-1200mg/m2/day twice daily) as an alternative for MTX.
Miscellaneous systemic treatment options
Recent case reports describe imatinib 191-194, infliximab102 103, rituximab98 abatacept195, the 
mTOR-inhibitors; tacrolimus196 and everolimus197 and mesenchymal stem cell therapy198 as 
alternative treatment options in severe LoS. The authors recommend restraint from the use 
of TNF-α inhibitors in the treatment of LoS as multiple reports show LoS can be provoked by 
these agents.98-101 
Recommendations for EF
Historically, HD SCS monotherapy (Prednisone, dose 0.5 – 2.0mg/kg/day) was regarded 
first line treatment for EF.14 15 199 However, multiple recent retrospective studies have shown 
superior response rates in patients whom are treated with a combination of HD SCS and an 
ISD, especially for weekly MTX (15-25mg/week).14 16 200 These studies are retrospective and 
thus prone to confounding by indication. Future prospective studies should investigate the 
additional (long-term) effect of MTX as it was done for paediatric LoS.28
Case series reported non- or partial responses to conventional treatment in a proportion 
of patients.14-16 Until recently, only case reports or small case series described alternative 
treatment options.21 However, a recent study prospectively investigated HD pulse intravenous 
(IV) MTX (4mg/kg/month; median monthly MTX dose 288mg) as an alternative treatment 
option in 12 patients with EF. The median mSS improved significantly after 6 pulses (p=0.001). 
Additionally, the range of motion of affected joints and patient reported outcomes showed 
significant increases. Treatment was well-tolerated and adverse events could be managed 
accordingly. In this study one patient had to be withdrawn due to an adverse event.201 Another 
recent prospective study reported superior clinical improvement in severe EF patients 
treated with D-penicillamine (D-pen) plus oral SCS (n=10) versus SCS monotherapy (n=6). 
Disappointingly, 4 out of 10 patients in the d-penicillamine-arm had to discontinue treatment 
due to adverse events.202 Lastly, the following alternative treatments have been reported 
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in case reports and series: infliximab203, azathioprine204 205 sulfasalazine206, cyclosporine207, 
cyclophosphamide 208 Rituximab209, Tocilizumab 210, sirolimus211, PUVA 212, intravenous immune 
globulins213 and bone marrow transplantation.214 215
We recommend a combination of SCS and MTX as first line treatment for EF. Induction 
therapy may consist of HD oral SCS (Prednisone 1mg/kg/day, followed by tapering) or IVMP 
(1000mg for 3 days monthly, followed by oral SCS) started simultaneously with weekly MTX 
(15-25mg/week) maintenance therapy.
Treatment of disease damage
Multiple studies report effective strategies for correction of disease damage. However, timing 
of these correctional procedures is crucial, as disease flare has frequently been reported even 
after many years of disease quiescence. 10 26 A recent study, reviews the surgical treatment 
options for Parry-Romberg syndrome and ECDS and describes the debate with regard to timing 
of these procedures. 36 Autologous fat grafting in ECDS is reported in multiple case reports 
and series. 216-221 Lastly, one case report describes correction for limb-length discrepancy in 
linear LoS of a lower extremity. 222 In the authors opinion, these procedures should only be 
performed in long-term quiescent disease by a care-provider with (extensive) experience in 
this field. Lastly, although evidence is lacking, physical therapy should be considered in case 
of decreased range of motion of an affected joint or when postural deformities are present as 
a result of limb-length discrepancies. 
CONCLUSIONS
LoS and EF pathogenesis remains to be elucidated as well as the exact immunological relation 
with SSc. This may lead to insight in disease mechanisms behind these debilitating conditions 
and the identification of new therapeutic targets.
Progression has been made in standardization of outcome measures for LoS. Currently, 
LoSCAT is the most promising and used outcome measure. This should lead to data 
harmonization and the potential to compare future studies.
Monitoring of deep involvement of LoS is one of the most difficult aspects of the disease. 
The lack of validated outcome measures for deep involvement emphasizes the need for new 
biomarkers. 
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The overarching theme of this thesis is to gain more knowledge of the heterogeneity of the 
disease spectrum of localized scleroderma (LoS), including eosinophilic fasciitis (EF) and try 
to gain insight in clinical determinants for long-term disease outcome (Chapter 2.1 and 2.2). 
In addition, we investigated improved conventional treatments as well as new therapeutic 
options with the aim to improve therapeutic success (Chapter 3.1, 3.2 and 3.2). Next, we 
analysed possible biomarkers for disease activity, as clinical markers and currently available 
measurements are not sufficient to identify patients with early (re)activation or remission of 
the disease (Chapter 4.1 en 4.2).  Lastly, aims and results are reviewed in the discussion 
(chapter 5).
Localized Scleroderma (LoS) encompasses a group of idiopathic skin conditions which are 
characterized by an early inflammatory phase in which cutaneous and subcutaneous fibrotic 
lesions develop and expand. Consecutively, this active phase is followed by development of 
irreversible sequelae, such as cutaneous and subcutaneous fibrosis, atrophy and pigment 
alterations. Early and aggressive treatment is important to prevent or reduce development 
of complications such as contractures of joints, limb atrophy or irreversible fibrosis restricting 
movement or respiration. Textbooks describe the active phase of LoS to generally last for 
3 to 5 years before the disease becomes quiescent. However, in our outpatient clinic we 
often evaluate patients which experience a more erratic course of the disease; patients 
regularly present themselves with recurrent episodes of disease activity, often requiring 
additional immunosuppressive treatment. In chapter 2.1, we investigate the frequency and 
characteristics of these disease recurrences in paediatric- and adult-onset LoS, and aim to 
identify patient characteristics that are associated with a higher risk of disease recurrence. 
Identification of these patients should lead to adequate follow-up and counselling of patients, 
ultimately leading to a reduced delay in treatment initiation. 
The heterogeneous phenotype of LoS is also reflected in the amount of irreversible sequalae 
patients develop. This especially holds true for the EF subtype; in our outpatient clinic we 
observe patients who develop severe irreversible sequalae, while others recover without any 
functional impairment. The heterogeneous long-term outcome makes it difficult to determine 
the treatment patients should receive; undertreatment may lead to the development of 
more irreversible sequalae, while overtreatment with glucocorticoids has several known 
disadvantages, such as increased risk of osteoporosis and weight gain.223 224 In summary, little 
is known about the long-term outcome of EF as a result of the rarity of the disease. In chapter 
2.2, we therefore aim to evaluate the presence and extent of residual disease damage in 
patients with EF after long-term follow-up. Secondly, we want to identify clinical determinants 
that are associated with the risk of residual disease damage.
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The development of irreversible sequelae underscores the importance of early and accurate 
treatment in LoS and EF. Early topical- and systemic anti-inflammatory treatment aims to 
prevent disease progression, thereby limiting irreversible sequalae to develop. Care-providers 
should take disease subtype, degree of activity, depth of involvement, age of the patient (adult 
vs paediatric), and quality-of-life impairments into account when initiating treatment. In most 
patients with circumscribed superficial subtypes, treatment with topical therapies suffices. In 
widespread superficial disease, both adult- and paediatric patients can be treated with weekly 
systemic methotrexate (MTX), while for the adult population (UVA1-) phototherapy is also 
an alternative or additional treatment option. For deep involvement, methotrexate (MTX) is 
considered first line treatment. The addition of systemic corticosteroids should be considered in 
case of severe disease, rapid progression or (looming) contractures. Until recently, guidelines 
were lacking and treatment was based on local protocols. Last year however, the European 
Dermatology Forum S1‐guideline225 was published. Interestingly, systemic corticosteroids 
seem to have a more pronounced role in the suggested treatment algorithm, compared to the 
treatment patients receive at our study centre. In addition, in the European guidelines the role 
for MTX is limited to patients with involvement of deeper tissue layers exclusively. In contrast, 
a recent review by Zulian et al.226 describe MTX as a viable option in the refractory disease 
in paediatric patients, regardless of the disease subtype. In conclusion, no uniform algorithm 
consists for the treatment of LoS and EF. At our study centre we regard systemic treatment 
(including MTX) still a viable treatment option in refractory or widespread disease regardless 
of depth of the sclerosis.
The chronicity of LoS often requires prolonged treatment with the previously described 
treatment options. This especially holds true for MTX, as this treatment modality is most often 
used in patients with more severe disease and is especially recommended for long term 
treatment, whereas systemic corticosteroids are advised in the induction phase of therapy. 
Although we have extensive experience with MTX as therapeutic option at our study centre, 
little evidence exists for MTX in adults with localized scleroderma.227 In chapter 3.1, we aim to 
investigate drug survival for MTX treatment in a large long-term daily practice cohort of adult 
LoS patients. Drug survival analyses allows to evaluate the treatment duration with a particular 
drug with regard to different outcomes of interest. Drug survival is a comprehensive outcome 
covering effectiveness, safety, and patients’ and doctors’ preferences. 228 We investigate drug 
survival split for disease remission and treatment failure with the aim to gain insight in rates 
of treatment success and failure, respectively. Additionally, by identifying predictors of drug 
survival for MTX we aimed to improve MTX treatment strategies for LoS patients. 
Despite the availability of MTX and systemic glucocorticoids, additional systemic treatment 
options are sometimes required either as a result of treatment ineffectiveness or side effects. 
Alternative treatment options often originate from systemic sclerosis treatment algorithms. 
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Mycophenolate mofetil (MMF, Cellcept) is an ester derivative of mycophenolic acid (MPA), 
which selectively and non-competitively inhibits an important enzyme, inosine monophosphate 
dehydrogenase, required for the proliferation of lymphocytes. Therefore, blocking this enzyme 
may specifically inhibit multiple functions of lymphocytes. Mycophenolate mofetil was initially 
used for prevention of organ transplant rejection and several years later use of MMF for 
dermatological conditions ensued. In systemic sclerosis, patients are frequently treated with 
MMF, leading to a decrease of fibrosis. 229 In chapter 3.2, we describe a case series of LoS 
patients treated with MMF with the aim to add evidence for an alternative treatment option for 
LoS.
Conventional treatment of EF consists of high-dose systemic glucocorticoids combined 
with low-dose weekly MTX. However, disappointing results are described in a proportion of 
patients. Therefore, additional therapeutic options are necessary. We observed increased 
efficacy of MTX exceeding the conventional dosages (maximum 50mg/week) at our outpatient 
clinic in the past. Irrespective of these increased beneficial effects, clinical results were still 
not satisfactory enough. By using high-dose MTX we expected to induce a more pronounced 
effect on the involved skin. Furthermore, we hypothesized that intravenous (IV) administration 
would lead to fewer adverse effects. In chapter 3.3, we investigate the safety and effect of 
monthly high-dose IV pulse MTX in patients with EF. 
In chapter 2 we investigate clinical parameters to gain additional information of phenotypes of 
LoS at risk for a poor outcome. However, currently available clinical scoring tools and imaging 
modalities fail to accurately assess disease activity in large proportions of patients. Specifically, 
deep involvement is notoriously difficult to monitor, but has tremendous potential leading to 
debilitating sequelae. The lack of available tools underscores the need for biomarkers of 
disease activity in LoS. Identification of additional tools to determine disease activity should 
ultimately aid caregivers to individualize and optimize treatment regimens. 
A recent study by O’Brien et al. reported that CXCL9 and CXCL10 are present at increased 
concentrations in serum from (LoS) patients and that CXCL9, but not CXCL10, serum 
concentrations correlate with measures for disease activity.230 In chapter 4.1, we investigate 
CXCL9 and CXCL10 serum concentrations and gene expression levels in circulating and 
cutaneous immune cells in a cohort of 80 LoS patients. In addition to CXCL9 and CXCL10, 
37 other chemokines and cytokines, involved in angiogenesis and inflammation, were 
investigated in our LoS and EF cohort. In chapter 4.2, we investigate what analyte has the 
greatest potential to function as biomarker of disease activity.
535444-L-bw-Mertens
Processed on: 12-9-2019 PDF page: 50
CHAPTER 1.2
50                                   
SUMMARY OF THE AIMS:
Chapter 2.1: To investigate the frequency and characteristics of disease recurrences in 
paediatric- and adult-onset localized scleroderma, and to identify patient variables that are 
associated with a higher risk of disease recurrence.
Chapter 2.2: To evaluate presence and determinants of residual disease damage in patients 
with eosinophilic fasciitis after long-term follow-up.
Chapter 3.1: To describe drug survival for MTX treatment in a large long-term daily practice 
cohort of adult localized scleroderma patients. Additionally, to identify predictors of drug 
survival for MTX to improve treatment strategies.
Chapter 3.2: To assess the efficacy and safety of mycophenolate mofetil (MMF) in paediatric 
and adult patients with localised scleroderma resistant or intolerant to previous treatment with 
MTX.
Chapter 3.3: To examine effects and safety of monthly high-dose IV pulse MTX in adult 
eosinophilic fasciitis.
Chapter 4.1: To investigate CXCL9 and CXCL10 serum concentrations and to investigate 
the biomarker potential of these analytes in localized scleroderma and eosinophilic fasciitis. 
In addition, to investigate CXCL9 and CXCL10 gene expression levels in skin samples and 
circulating immune cells.
Chapter 4.2: To investigate serum concentrations of 39 cytokines and chemokines implicated 
in inflammation and angiogenesis in localized scleroderma and eosinophilic fasciitis and to 
explore their potential to be utilized as biomarker of disease activity. Additionally, to investigate 
the implication of potential biomarker candidates in disease pathogenesis. 
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ABSTRACT
BACKGROUND: Localized Scleroderma (LoS) is characterized by a phase of disease activity 
followed by remission. However, disease recurrences occur. Knowledge concerning these 
recurrences can help prompt treatment, thereby preventing disease damage to develop.
OBJECTIVES: To investigate the frequency and characteristics of disease recurrences in 
paediatric- and adult-onset LoS, and to identify patient variables that are associated with a 
higher risk of disease recurrence.
METHODS: Retrospective chart reviews were performed of patients with LoS. Data concerning 
the frequency and characteristics of the disease recurrences were collected. A multivariate 
analysis was performed to identify patient variables that were associated with a higher risk of 
disease recurrence.
RESULTS: In total of 344 patients were included in the analysis, of whom 119 (35%) had 
paediatric-onset LoS and 225 patients (65%) had adult-onset LoS. Disease recurrence was 
present in 27% (n=32) of the paediatric-onset group and 17% (n=39) of the adult-onset 
group (p=0.037). Multivariate analysis identified a statistically significant association between 
disease recurrence and the linear LoS of the limbs subtype, independent of age at disease 
onset.
CONCLUSIONS: Recurrences in LoS occurred in almost one-quarter of the patients and 
were most frequent in the linear LoS of the limbs subtype, independent of age at disease 
onset. These disease recurrences can occur even after many years of quiescent disease. 
Awareness of the high recurrence rates may help treating physicians to adequately recognize 
reactivation of the disease leading to a decreased delay in treatment reinitiation.
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INTRODUCTION
Localized scleroderma (LoS) encompasses a spectrum of sclerotic skin disorders. The disease 
subtypes are classified based on the pattern and depth of the sclerotic lesions.231 232 The course 
of disease starts with a period of active disease, which is characterized by the presence of 
an erythematous border (‘lilac ring’), itching sensations, expansion of existing lesions or the 
development of new lesions . This active phase is followed by disease remission in which 
different degrees of residual damage can be present, such as hypo- or hyperpigmentation and 
atrophy of affected tissue.48 233
Disease remission typically occurs after 3-5 years; however, recurrences can occur. A small 
number of studies have described recurrence rates in LoS.1 25 26 29 182 184-186 234 These studies 
are limited in their sample size or in the fact that they only describe recurrence rates in 
certain subgroups of patients. More importantly, none of the studies describe the frequency 
or characteristics of recurrences in a large cohort of patients containing all subtypes of LoS in 
both paediatric and adult-onset LoS.
Gaining knowledge concerning the course of the disease can lead to more awareness of 
possible recurrences in patients with presumed quiescent disease and could help determining 
the intensity of follow-up in these patients. Moreover, this could lead to early recognition of a 
disease recurrence by the treating physician and patients themselves, which in turn should 
lead to a reduced time to treatment (re)initiation. This could possibly prevent the development 
of irreversible damage caused by the LoS.235
The main objective of this study was to describe the frequency and characteristics of disease 
recurrences in a retrospective daily practice cohort of patients with paediatric and adult-onset 
LoS. Additionally, we aimed to identify patient characteristics that were associated with the 
risk of disease recurrences. 
METHODS
Data collection
A retrospective chart review was performed of patients in the Radboud University Medical 
Centre between 1January 1990 and 1September 2013. Information was collected from each 
patient’s medical record regarding sex, age at disease onset, subtype of LoS, prescribed 
treatments, and course of disease. The collected data were entered in a database. Patients 
were grouped into having paediatric (≤17 years) or adult-onset (≥ 18 years) LoS based on the 
date of first signs or symptoms as reported by the patient or parent. To identify patient variables 
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that were associated with disease recurrences, patients were also grouped into having disease 
recurrence or not. Disease subtype classification was based upon the classification system as 
proposed by Kreuter et al.,231 232 with the addition of a ‘mixed disease’-subtype. Patients were 
classified as having this mixed subtype if more than one subtype concurred simultaneously or 
during the course of disease. 
Course of the disease
The disease activity was scored as ‘active’ or ‘inactive’ at each visit to the outpatient clinic. 
Active disease was defined as the presence of an erythematous border (‘lilac ring’) surrounding 
a lesion, or as the presence of disease progression (development of new lesions, expansion 
of existing lesions, expansion of sclerosis, a decrease of the range of motion of an affected 
limb or imaging studies showing signs of disease activity). Inactive disease was defined as the 
absence of signs of disease activity. Disease remission was defined as no signs of disease 
activity reported for six consecutive months. Patients without signs of disease activity at the 
first presentation at our outpatient clinic were scored as having ‘achieved disease remission 
previous to first contact’. A remaining group of patients who showed signs of disease activity at 
the end of follow-up were scored as ‘not having achieved remission during follow-up’. The time 
to disease remission could only be calculated for patients who achieved disease remission 
during follow-up. Disease recurrence was defined as the presence of signs of disease activity 
after achieving disease remission. 
Statistical analysis
Descriptive statistics including median (range) for continuous variables and percentages for 
categorical data, were used for exploring baseline and patient characteristics. The Mann-
Whitney test was used to compare continuous variables between groups. The chi-square 
test was used to examine differences in categorical variables between groups. The chi-
square test was performed to examine the association between categorical patient variables 
and the presence of disease recurrence (univariate analysis). Variables with a p-value<0.1 
in the univariate analysis were selected for multivariate analysis. A multivariate binary 
logistic regression was performed to analyse which variables were associated with disease 
recurrence. Results were displayed by means of Odds Ratios (OR) and the 95% Confidence 
Intervals (CIs). A p-value ≤ 0.05 was considered statistically significant. Statistical Analyses 
were performed using SPSS Statistics v.20 (IBM, Armonk, NY, U.S.A.).
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RESULTS
Demographics and subtype distribution
Data were available for a total of 344 patients. The demographics and subtype distribution are 
summarized in Table 1. In total 199 (35%) had paediatric-onset LoS and 225 patients (65%) 
had adult-onset LoS. In the paediatric-onset group, linear subtypes were most frequently 
observed, with 56% (n=67) having either linear LoS of the limbs (20%, n=24), scleroderma 
en coup de sabre (18%, n=21) or a mixed subtype (19%, n=22). In the adult-onset group, 
morphea en plaque was the most frequently observed subtype (50%, n=112).
Paediatric-Onset
N=119
Adult-Onset
N=225
Gender
No
Male 31 60
Female 88 165
Male:female ratio 1:2.8
Median Age at Disease Onset, y (range) 10 (1-17) 47 (18-86)
Disease Subtype 
No. (%)
Limited Type Morphea en plaque 34 (29%) 112 (50%)
Atrophoderma of 
Pierini and Pasini
5 (4%) 12 (5 %)
Generalized 9 (8%) 44 (20%)
Linear Of the limbs 24 (20%) 21 (9%)
En coup de sabre 21 (18%) 10 (5%)
Deep 4 (3%) 12 (5%)
Mixed 22 (18%) 14 (6%)
Table 1 Demographics and subtype distribution in 119 subjects with paediatric-onset localized scleroderma 
and 225 subjects with adult-onset localized scleroderma.
Follow-up
In total, 311 patients visited the outpatient clinic multiple times, leading to a median follow-up 
time of 38 months [range 1 week to 26 years] in the paediatric-onset group and 18 months 
[range1 week to 31 years] in the adult-onset group (p=0.01). Twelve patients with paediatric-
onset LoS and 21 with adult-onset LoS only visited our outpatient clinic once. Most of these 
patients had inactive disease and were instructed to be re-evaluated if disease progression 
occurred.
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First disease remission
Figure 1 summarizes the course of disease until the first disease remission. First disease 
remission was achieved during follow-up in 54 patients (45% of 119 patients) with paediatric-
onset LoS and in 115 patients (51% of the 225 patients) with adult-onset LoS (p=0.312). The 
median time between the disease onset and the first disease remission was 30 months [range6 
months to26 years) for the paediatric-onset group and 23 months [range 5 months to16 years] 
for the adult-onset group (p=0.099). In the paediatric-onset group, 50 patients (42% of 119 
patients) were withdrawn from analysis due to achieving disease remission previous to the 
first contact at our hospital, and 15 patients (13%) due to having active disease at the end of 
the follow-up. In the adult-onset group, 64 patients (28% of 225 patients) were withdrawn from 
analysis due to achieving disease remission previous to the first contact at our hospital, and 
46 patients (21%) due to having active at the end of the follow-up.
Figure 1 First disease remission in 119 subjects with paediatric-onset localized scleroderma and 225 
subjects with adult-onset localized scleroderma. 
*Reasons for active disease at last contact were: ongoing disease activity due to still being treated at the 
moment of the chart review, being discharged with active disease or being lost to follow up
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Details of disease recurrence
Figure 2 displays the frequency and characteristics of diseases recurrences. There was no 
report of disease recurrence in 87 patients with paediatric-onset LoS (73% of 119 patients) 
and in 186 patients with adult-onset LoS (83% of 225 patients). A higher proportion of patients 
with paediatric-onset LoS experienced an episode of disease recurrence compared to patients 
with adult-onset LoS: 27% (n=32) vs. 17% (n=39) (p= 0.037). The median time between the 
first disease remission and the onset of the first recurrence was 26 months [range 8 months 
to 21 years] in the paediatric-onset group and 27 months [range 11 months to 10 years] in the 
adult-onset group (p=0.72).
Of the 32 patients with paediatric-onset LoS patients who experienced a disease recurrence, 
26 achieved disease remission after a median of 8 months [range 2-45]. The remaining 6 
patients did not achieve disease remission due to having ongoing disease activity at time of 
the chart review (n=2), being lost to follow-up (n=2) or being discharged with disease activity 
(n=2). Of the 39 patients with adult-onset LoS who experienced a disease recurrence, 30 
achieved disease remission after a median of 9 months [range2-86]. Nine patients did not 
achieve disease remission due to having ongoing disease activity at time of the chart review 
(n=6), being lost to follow-up (n=1) or being discharged with disease activity (n=2). 
A second episode of disease recurrence was present in seven patients (6%) in the paediatric-
onset group and eight patients (4%) in the adult-onset group. Lastly, two patients (1%) with 
adult-onset LoS experienced a third episode of disease recurrence.
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Figure 2 Frequency and characteristics of disease recurrences in 119 subjects with paediatric-onset 
localized scleroderma and 225 subjects with adult-onset localized scleroderma.
* No known recurrence during follow-up.
** No remission= ongoing disease activity due to still being treated at the moment of the chart review, 
being discharged with active disease or being lost to follow up
The recurrence rates within the different disease subtypes are displayed in Figure 3. The 
highest recurrence rates (in paediatric-onset and adult-onset LoS as a complete group) were 
present in the linear LoS of the limbs (31%) and in the mixed subtype (39%), whereas the 
scleroderma en coup the sabre and the atrophoderma subtype showed recurrence rates of 
only 7% and 6%, respectively. The recurrence rates in the remaining subtypes were 16% in 
morphea en plaque, 25% in generalized LoS and 25% in the deep LoS. A second episode 
of disease recurrence was seen in four patients with morphea en plaque (3%), three with 
generalized LoS (6%), five with linear LoS of the limbs (11%) and three with a mixed subtype 
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(8%). Finally, the two patients who experienced a third episode of disease recurrence were 
both classified as having linear LoS on a limb.
Figure 3 Disease recurrence in the different disease subtypes in 344 patients with localized scleroderma.
Table 2 represents data concerning the different treatments prescribed to the subgroups of 
patients with (n=71) and without (n=273) a recurrence. MTX was prescribed to 72% of the 
patients who experienced a recurrence, compared to 34% of the patients without a recurrence 
(p<0.01). Other types of treatments, except for topical vitamin D analogues, were also more 
frequently prescribed to patients with a recurrence than to patients who did not experience a 
recurrence. This would suggest that receiving a certain treatment would be a risk factor for the 
development of a recurrence. However, this result is confounded by indication, as the group 
of patients who experienced a recurrence contained more severe disease subtypes. Patients 
affected by these severe subtypes require more aggressive treatment since they are known 
to develop more serious complications.234 236 237
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Recurrence
n=71
No recurrence
n=273
P-value
Topical, 
No (%)
Corticosteroids 60 (85%) 190 (70%) 0.012
Vitamin D analogues 4 (6%) 19 (7%) 0.690
Calcineurin-inhibitors 18 (25%) 40 (15%) 0.032
Phototherapy, n (%) 20 (28%) 47 (17%) 0.038
Methotrexate, n (%) 51 (72%) 92 (34%) <0.01
Systemic Corticosteroids, n (%) 17 (24%) 31 (11%) <0.01
Table 2 Treatments prescribed in 71 subjects with a disease recurrence and 273 subjects without a 
disease recurrence in LoS.
Risk factors for disease recurrence
Univariate analysis showed that age at disease onset was a risk for factor for recurrence; 
recurrence rates for paediatric and adult-onset LoS were 27% and 17% (p=0.037) respectively. 
Another risk factor was disease subtype; 36% of the patients with linear LoS of the limbs, 
either as solitary diagnosis or as part of the mixed subtype, experienced disease recurrence 
compared to 17% of patients having other disease subtypes (p<0.01). Sex (p=0.081), family 
history of autoimmune disease (p=0.527), personal concomitant autoimmune disease 
(p=0.944) and positive Antinuclear antibodies (p=0.21) were not significantly associated with 
the risk of a recurrence. 
The variables with a P-value <0.1 in the univariate analysis were put into to the multivariate 
model. Table 3 displays the odds ratios and 95% confidence intervals from the multivariate 
analysis. Patients with linear LoS of the limbs, either as a solitary diagnosis or as part of the 
mixed subtype, were more likely to develop a recurrence compared to the other disease 
subtypes (OR 2.95, 95% CI 1.65-5.29. p<0.01). The OR of 1.90 (95% CI 0.97-3.71) showed 
that females tended to have greater risk of recurrence than males, although this OR was not 
statistically significant. Lastly, the difference in recurrence rates between paediatric and adult-
onset LoS did not remain significant in the multivariate model. 
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Recurrence Rates Odds Ratio (95% Confidence Limit) P-value
Subtype Linear LoS of the limbs * 36% 2.95 
(1.65-5.29)
<0.01
Other subtypes 17%
Gender Female 23% 1.898 
(0.97-3.71)
0.061
Male 14%
Table 3 Multivariate analysis of patients variables associated with the risk of recurrence in 344 patients 
with localized Scleroderma
DISCUSSION
The current lack of knowledge on determinants for disease recurrence in LoS that could 
guide clinical care pushed us to perform this study with the objective to determine recurrence 
rates and the risk factors for disease recurrence in LoS. We found that disease recurrence 
occurred in 27% of the patients with paediatric-onset LoS compared to 17% in the adult-
onset group (p=0.037). A second episode of disease recurrence occurred in 6% and 4% of 
the paediatric and adult-onset group, respectively. Multivariate analysis identified that the 
difference in recurrence rates between paediatric and adult-onset LoS should be attributed 
to the difference in subtype distribution between these two groups. Our results showed that 
patients with linear LoS of the limbs, as a solitary diagnosis or as part of the mixed subtype, 
more frequently develop disease recurrences, independent of the age of disease onset. 
Morphea en plaque and generalized LoS, the two most frequently observed subtypes in adult-
onset group, had recurrence rates of 16% and 25% respectively. The two subtypes with the 
lowest recurrence rates were the en coup de sabre (7%) and atrophoderma subtype (6%). 
Differences in recurrence rates between the paediatric and adult-onset group were mainly 
explained by the difference in subtype distribution between these two groups.
There are only few studies that describe disease recurrences in LoS. To our knowledge, this 
is the first study that describes recurrence rates in a cohort of patients with LoS containing all 
disease subtypes and patients with both paediatric- and adult-onset disease. Christen-Zaech 
et al.1 described a recurrence rate of 3.7% in a cohort of only paediatric patients. The lack of a 
definition for disease recurrence in that study makes it difficult to explain its lower recurrence 
rate. Piram et al.234 reported a recurrence rate of 28% in a group of patients with paediatric-
onset linear LoS of the limbs. Pequet et al.237 described a recurrence rate of 27 % in a group 
of 114 paediatric-onset LoS patients. These results are comparable with ours in paediatric-
onset LoS, studies report recurrence rates of 14-44 % after cessation of MTX treatment.25 182 
184 186 These studies are limited in their sample size and contain a large proportion of patients 
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affected by more severe disease subtypes. The selection of more severe disease subtypes 
most likely leads to the higher recurrences rates present in most of these studies.25 182 184 In 
adult-onset LoS, Kroft et al.185 reported a recurrence rate of 29% after discontinuation of MTX 
treatment. The inclusion of sclerotic skin disorders other than LoS makes it difficult to compare 
the results. Lastly, Vasquez et al.29 recently reported recurrence of active morphea lesions 
after successful UVA1 phototherapy in 47% of the patients. The fact that this study describes a 
group of patients being treated by a specific treatment makes it difficult to compare the results 
with others.
In the present study, all types of treatment, except for topical vitamin D analogues, were 
relatively more frequently prescribed to patients with recurrences than to patients without 
recurrences. This could lead to the presumption that being treated with a specific treatment is 
associated with the risk of a recurrence. However, this result was confounded by indication as 
the group of patients who experienced a recurrence contained more severe disease subtypes 
such as linear LoS of the limbs. Patients affected by these more severe subtypes require more 
and more aggressive treatments since they develop more serious complications.234 236 237
Despite the more aggressive treatments given in those severe subtypes, they recur more 
often. This could imply that treatments were not aggressive enough or not given long enough 
after remission. Indeed, a recent study in children suggests that a prolonged period of MTX 
treatment leads to reduced recurrence rates.186 In addition, the results of this study could 
argue for a more aggressive and prolonged treatment, especially in patients with linear LoS 
of the limbs.
This study describes a median time between the initial episode of disease activity and a 
recurrence of 26 months in paediatric-onset LoS and 27 months in adult-onset LoS. In some 
patients recurrences occurred after up to 20 years of disease remission. Saxton-Daniels and 
Jacobe et al.26 described recurrences up to 18 years after disease onset. These results stress 
the fact that both patients and treating physicians should be aware of disease recurrences, 
even after many years of disease remission.
In the event of a recurrence, the median time to disease remission was 8 and 9 months 
for paediatric and adult-onset LoS respectively. This was considerably shorter than the first 
episode of disease activity, which was 30 months [range 6 months to 26 years] for paediatric-
onset LoS and 23 months [range 5 months to 16 years] for adult-onset LoS (p=0.13). A 
possible explanation for this shorter disease duration could be that a recurrence is recognized 
earlier than the primary onset of the disease, resulting in an earlier, and possibly also more 
aggressive, treatment. 
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Lastly, our demographical data(female to male ratio and age at disease onset) were similar 
to those reported  by previous investigations.1 9 13 234 238-242 1 9 13 232 238 243;. This study is limited by 
the retrospective design, which leads to missing data and secondly to selection bias; more 
severe subtypes might be over-represented in this cohort as this study was performed at a 
tertiary referral centre.
To our knowledge, this is the first study that describes recurrence rates in a cohort of patients 
with LoS containing all of the LoS subtypes and patients with both paediatric and adult-onset 
disease. This study shows that recurrences in LoS occurred in up to almost one-quarter of the 
patients, and were most frequent in the linear LoS of the limbs subtype, independent of age at 
disease onset. Differences in recurrence rates between the paediatric and adult-onset group 
were explained mainly by the difference in subtype distribution between these two groups. 
Disease recurrences can occur even after long periods of quiescent disease. Awareness of 
the high recurrence rates may lead to early recognition of disease activity, therefore leading to 
a decreased delay in treatment reinitiation in the case of disease recurrence. 
535444-L-bw-Mertens
Processed on: 12-9-2019 PDF page: 68
535444-L-bw-Mertens
Processed on: 12-9-2019 PDF page: 69
2.2
LONG-TERM OUTCOME OF EOSINOPHILIC 
FASCIITIS: A CROSS-SECTIONAL EVALUATION 
OF 35 PATIENTS
J.S. Mertens, M.D.1,4; R.M. Thurlings, M.D., PhD2; W. Kievit, PhD3; M.M.B. Seyger, M.D., PhD1; 
T.R.D. Radstake, M.D., PhD 4; E.M.G.J. de Jong, M.D., PhD1,5.
1 Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
2 Department of Rheumatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
3 Department of Epidemiology, Health evidence, Radboud university medical centre, Nijmegen, The Netherlands.
4 Department of Rheumatology and Clinical Immunology and Laboratory of Translational Immunology, University Medical 
Centre Utrecht, Utrecht, The Netherlands.
5 Radboud University, Nijmegen, The Netherlands
J Am Acad Dermatol. 2017 Sep;77(3):512-517.e5. doi: 10.1016/ j.jaad.2017.05.018. Epub 
2017 Jul 19
535444-L-bw-Mertens
Processed on: 12-9-2019 PDF page: 70
CHAPTER 2.2
70                                   
ABSTRACT 
BACKGROUND: Eosinophilic fasciitis (EF) is a connective tissue disease with an unknown 
long-term course.
OBJECTIVE: To evaluate presence and determinants of residual disease damage in patients 
with EF after long-term follow-up.
METHODS: Biopsy-proven EF patients were included for this cross-sectional study. Outcome 
measures included physician’s global assessment of disease activity (PhysGA-A) and damage 
(PhysGA-D), skin pliability scores, passive range of motion (RoM) and health-related quality 
of life (HRQoL) questionnaires. 
RESULTS: In total, 35 patients (24 females, 68.6%), median age 60 years, participated. All 
patients had detectable residual damage. HRQoL-impairment, assessed by DLQI and SF-36, 
correlated to the extent of residual damage. PhysGA-D at participation correlated to signs of 
severe disease at presentation, such as increased CRP (rs=0.486, P .006), involvement of 
the neck (rs=0.528, P .001) and trunk (rs=0.483, P .003), prolonged time to disease remission 
(rs=0.575, P .003), and presence of concomitant morphea (rs=0.349, P .040). Lastly, maximum 
MTX doses correlated negatively to PhysGA-D at study participation (rs=-0.393, P .022).
LIMITATIONS: Sample size.
CONCLUSION: All EF patients had detectable residual damage. HRQoL-impairment 
correlated to the extent of residual damage. Advanced age and signs of severe disease at 
presentation were associated with the severity of residual damage.
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INTRODUCTION
Eosinophilic fasciitis (EF) is a rare connective tissue disorder characterized by subacute onset 
of edema, erythema, and induration of the extremities and trunk (Figure 1a). Subsequently, 
these manifestations are replaced by fibrosis of the fascia, leading to a cobblestone 
appearance (Figure 1b), and to thickening of the overlaying skin.14 15 244
Figure 1 Eosinophilic fasciitis. Typical images of the lower limbs during the inflammatory phase (a), and 
of a cobblestone appearance on the right arm (b). 
In the majority of patients, progression of the disease is halted by administering medium 
to high-dose systemic glucocorticosteroids (SCS), and weekly methotrexate (MTX).14-16 
200 Despite adequate treatment, some patients recover with minimal damage while others 
develop severe damage 245, with consequential functional impairment.246 247 
Identification of patients at risk to develop severe residual damage should lead to individualized 
treatment; these patients could benefit from more aggressive treatment. However, currently 
little is known about determinants for a poor disease outcome. The aim of this cross-sectional 
study was to evaluate the extent of residual disease damage and the influence on health-
related quality of life (HRQoL). A secondary objective was to identify determinants for a poor 
outcome. 
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METHODS
Study design and patients
A cross-sectional study was conducted at the tertiary referral centre Radboud University 
Medical Centre, Nijmegen, The Netherlands. The study was conducted in accordance with 
principles of the Declaration of Helsinki and approved by our local ethical board. Eligible 
patients were ≥18 years old with biopsy-proven EF, who visited the outpatient clinics of 
dermatology and rheumatology between January 1st, 1990, and October 1st 2016.
Assessments
The physician’s global assessment (PhysGA) of disease activity (PhysGA-A) and disease 
damage (PhysGA-D) were assessed by the same physician (JM) in all patients. PhysGA was 
graded on a 100mm visual analogue scale. Components of PhysGA-A and PhysGA-D were 
based on localized scleroderma (LoS) literature117 118(Supplemental Appendix).
Extent of skin fibrosis was assessed by the modified Rodnan skin thickness score (MRSS)248 
and the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT). LoSCAT is a reliable 
and valid tool for the evaluation of disease activity and damage of LoS.117 118 The score is 
a composite of the modified Localized Scleroderma Skin Severity Index (mLoSSI117) and 
Localized Scleroderma Skin Damage Index (LoSDI118)(Appendix A).
Joint contractures were evaluated by measuring passive range of motion (RoM), and limitations 
were assessed with a semiquantitative score (0: absent, 1: mild, 2: moderate, and 3: severe). 
Patient reported outcome measures consisted of HRQoL-questionnaires. Participants filled 
out the dermatology quality of life index (DLQI), a skin specific health questionnaire.249 250 
For DLQI, higher scores reflect decreased quality of life. In addition, 36-item Short Form 
Survey (SF-36)251 general health questionnaires were assessed. Results from the SF-36 were 
scored using previously reported methods.252 Overall, physical and mental impairment are 
summarized in the physical component summary (PCS), and mental component summary 
(MCS), respectively. For SF-36, lower scores represent decreased quality of life.
Statistical Analyses
Descriptive statistics including median [range] for continuous variables and percentages 
for categorical data were used. Spearman’s correlation was used to explore correlations 
among different outcome measures, and between outcome measures and patient, disease or 
treatment characteristics. Correlations were reported by Spearman’s rho (rs) and P value. A P 
value of .05 or less was regarded statistically significant. Statistical analyses were performed 
using SPSS version 24 (IBM).
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RESULTS
Inclusion
In total, 57 adults with biopsy-proven EF were identified (supplemental figure 1). Eight 
patients were deceased at study initiation. Of the remaining 49 patients, 35 (71.4%) consented 
with study participation. The remaining 14 patients (28.6%) either refused participation (n=9, 
18.4%), or were unable to be contacted (n=5, 10.2%). Characteristics of the non-participants 
were similar to those of the participants.3
Patient and disease characteristics
Two thirds (n=24, 68.6%) of the patients were female (table 1). The median ages at disease 
presentation and study participation were 54 [range, 13-68 years] and 60 [range, 27-78 years], 
respectively. The median disease follow-up at participation was 100 months [range, 9-341 
months]. In patient history, 28 patients (80%) had achieved disease remission after a median 
time of 33 months [range, 9 – 293 months]. Disease recurrence occurred in 14 patients (40%) 
after a median 48 months [range 9-81 months] post disease remission. Concomitant morphea 
was present in 23 patients (65.7%)
Characteristics Value
Total patients, n (%) 35 (100)
Sex, n (%)
Male 11 (31.4)
Female 24 (68.6)
Median age (range), y
At disease onset 53 (13-68)
At participation 60 (27-78)
Median diagnostic delay (range), mo 7 (1-122)
Median follow-up at participation (range), mo 100 (9-341)
Concomitant AID, n (%)∆ 12 (34.3)
Concomitant morphea, n (%) 23 (65.7)
EF secondary to malignancy, n (%)α 2 (5.7)
Laboratory results at disease presentation
Peripheral Eosinophilia (abs. count ≥0.5x109/l), n (%) 22 (62.9)
Increased ESR (>20 mm/hr), n (%) 16 (45.7) *
Increased CRP (ref >10mg/l), n (%) 21 (67.7) **
ANAs, n (%) 11 (37.9) ***
Table 1 Patient and disease characteristics. 
AID; autoimmune disease; ESR, Erythrocyte sedimentation rate; CRP, C-reactive protein; ANA, 
Antinuclear Antibodies; 
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∆ Concomitant AID consisted of rheumatoid arthritis, coeliac disease, Hashimoto’s thyroiditis, psoriasis 
(n=3), lichen sclerosus (n=3), Graves’ disease, Crohn’s disease, Colitis Ulcerosa and Alopecia Areata,
α Malignancies consisted of prostate carcinoma and intestinal carcinoid tumour. 
* ESR test results were available for 33 patients (33 is the denominator for the proportion)
** CRP test results were available for 31 patients (31 is the denominator for the proportion)
*** ANA test results were available for 29 patients (29 is the denominator for the proportion)
Immunosuppressive treatment
Most patients (n=32, 91.5%) received combination of SCS and weekly MTX during the course 
of disease (table 2). The median time between SCS initiation and disease onset was 8 
months [range, 0-49 months]. The median maximum SCS dose was 30mg [range, 10-80]. 
The median time between disease onset and MTX initiation was 12 months [range 3-88] and 
the median maximum weekly dose was 20mg [range, 15-30mg]. At study participation, 15 
patients (42.9%) still received MTX and 16 patients SCS (supplemental table 1).
Characteristics Value
Systemic Corticosteroids (SCS)
Received, n (%) 32 (91.4)
Median delay in SCS initiation (range), mo* 8 (0-49)
Median maximum dose (range), mg 30 (10-80)
Median treatment duration (range), wk 90.5 (2-245)
Combination with methotrexate, n (%) 32 (91.4)
Methotrexate (MTX)
Received, n (%) 34 (97.1)
Median delay in MTX initiation (range), mo* 12 (3-88)
Median maximum dose (range), mg 20 (15-30)
Median treatment duration (range), wk 122 (1-911)
Route of administration, n (%)
Oral 23 (67.6)
SC 9 (26.5)
Both oral and SC 2 (5.9)
Table 2 Immunosuppressive treatment history.
MTX, methotrexate; SCS, systemic corticosteroids; SC, subcutaneous.
*Delay (in months) in initiation of SCS and MTX after first signs or symptoms.
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Outcome Measures at study participation
Disease activity and assessment
The majority of patients (n=25, 71.4%) were evaluated with inactive or minimally active disease 
(PhysGA-A<5). The remaining 7 patients (20%) had not yet achieved disease remission or 
experienced recurrent disease at participation (N=3, [8.6%]). 
Disease damage
All patients (n=35, 100%) had detectable disease damage (PhysGA-D>0); the extent of 
disease damage was highly variable (figure 2a). A major component of damage consisted of 
residual cutaneous fibrosis. This is reflected in similar distributions of the cutaneous fibrosis 
scores MRSS (Figure 2b, moderate correlation with PhysGA-D; rs=0.661, P <.001) and 
LoSCAT (Figure 2c, strong correlation with PhysGA-D (rs=0.706, P <.001) within the study 
population. Range of motion impairment, resulting from cutaneous fibrosis, was frequently 
observed; 20 patients experienced a decreased RoM of the ankles (57,1%; mild n=14 (40%), 
moderate n=4 (11.4%), severe n=2 (5.7%). Range of motion of the wrists was impaired in 11 
patients (31.4%), knees in 11 (31.4%) and elbows in 1 patient (2.9%) (Figure 2d). 
Figure 2 Disease damage in eosinophilic fasciitis. Distribution of results of administration of the Physician 
Global Assessment of Disease Damage (PhysGA-D) (a), modified Rodnan skin thickness score (mRSS) 
(b), and results of administration of the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) (c) 
are shown. Impairment of range of motion of the ankles, wrists, knees, and elbows (d).
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Patient reported outcome measures
Patients with more severe residual disease damage at participation demonstrated increased 
impairment in HRQoL, measured by DLQI and SF-36. The SF-36 predominantly demonstrated 
impairment in physical domains (supplemental table 2). The physical functioning domain of 
the SF-36, and DLQI scores correlated moderately with PhysGA-D, MRSS and LoSCAT 
scores (supplemental table 3).
Determinants of residual disease damage
Patient and disease characteristics
Involvement of the neck (rs=0.528, P .001) and trunk (rs=0.483, P .003), increased CRP 
(rs=0.486, P .006), presence of concomitant morphea (rs=0.349, P .040), advanced age 
at disease presentation (rs=0.449, P .007), and time to disease remission (rs=0.575, P 
.003), all correlated moderately with PhysGA-D (table 3). In other words, presence of the 
aforementioned characteristics was associated with a poor outcome.
Spearman’s rho (rs) P Value
Age at disease onset, y .449 .007
Diagnostic delay, mo -.011 .951
Follow-up at participation, mo .176 .313
Concomitant AID .278 .107
Time to disease remission, mo .575 .003
Recurrent episodes of disease activity .121 .487
Concomitant morphea .349 .040
Disease distribution
Neck .528 .001
Trunk .483 .003
Upper limbs -.017 .923
Lower limbs .128 .465
Laboratory tests
 Peripheral Eosinophilia (abs. count ≥0.5x109/l) .010 .569
Increased ESR (>20 mm/hr) .022 .901
Increased CRP (ref >10mg/l) .486 .006
ANA -.004 .983
Treatment history
MTX
MTX delay, mo .082 .649
Maximum dose, mg/week -.393 .022
Treatment duration, wk -.107 .553
SCS
SCS delay .107 .597
Maximum dose, mg/dag -.118 .536
Table 3 Correlation between Physician Global Assessment of disease damage (0-100) at participation 
and patient, disease and treatment characteristics.
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Immunosuppressive treatment history 
Patients that received higher maximum dosages of MTX had lower scores of PhysGA-D at 
study participation (rs=-0.393, P .022). Other characteristics of MTX treatment, such as MTX 
initiation delay or treatment duration, did not correlate to PhysGA-D, neither did any of the 
characteristics of the SCS treatment. 
DISCUSSION
The current lack of knowledge on the long-term course of EF propelled us to perform this 
cross-sectional study. This study encompasses a detailed description of 35 patients with close 
to 300 patient years of follow-up.
All patients (100%) experienced disease damage at participation. Damage most often 
consisted of residual cutaneous fibrosis and consequential decreased RoM of affected joints. 
Over half of the participants (57.1%) experienced a decreased RoM of the ankles, followed 
by one third in the wrists and knees. In addition, patients with more severe disease damage 
reported substantially decreased HRQoL, captured by DLQI and SF-36 questionnaires. Impact 
on physical functioning was previously reported in the active stage of EF.201 247 However, this 
study demonstrates that residual damage still impacts HRQoL after many years of quiescent 
disease. 
A significant proportion of patients were severely affected by residual disease damage. 
Additional analysis revealed a relationship between the extent of disease damage and signs 
of severe disease at presentation, such as increased CRP, involvement of the trunk and 
neck and a longer time until disease remission. Furthermore, this investigation confirms the 
concept, postulated by Endo et al245, that presence of concomitant morphea represents a 
subset of EF patients that develop more residual damage. Additionally, a relationship between 
advanced age at disease onset and a poor outcome was demonstrated. To our knowledge, 
one retrospective study14 and one systematic review245 have described residual fibrosis in EF 
and risk factors thereof. However, these studies only describe residual cutaneous fibrosis 
and extent of damage is lacking. In conclusion, this study demonstrates that older patients, 
and patients with a severe phenotype at presentation, including presence of concomitant 
morphea, are at risk to develop more residual disease damage. Identification of these patients 
could lead to improvement in treatment strategies and improved care for this subgroup of 
patients.
Treatment history with lower doses of MTX correlated to a poorer outcome at participation. 
However, a similar trend, favouring a more aggressive treatment regimen in other treatment 
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parameters, could not be demonstrated. Moreover, the correlation of retrospective treatment 
characteristics with cross-sectional outcome measures is prone to confounding by indication; 
severe patients received higher dosages of MTX or SCS for a reason. This limitation 
illustrates the need for prospective studies to compare different treatment regimens. To date, 
no standard treatment exists for EF. Recent studies report favourable results for treatment 
with a combination of SCS and weekly MTX16 200, compared to SCS monotherapy. The vast 
majority of patients in this study, were treated with a combination of medium- to high-dose 
SCS, followed by tapering, and weekly MTX. However, despite these treatment regimens 
there is still an unmet need in patients with EF. This unsatisfactory treatment result stresses 
the need for additional treatment approaches and novel anti-fibrotic therapeutics.
This study is subject to some limitations. First, the rarity of EF leads to a limited sample size. In 
addition, no outcome measures have been validated for EF; all outcome measures we report, 
originate from LoS and systemic sclerosis research.
CONCLUSION
In this study, residual disease damage was demonstrated in all EF patient, by using well 
defined (patient reported) outcome measures. Advanced age and signs of severe disease at 
presentation, such as truncal involvement, increased inflammatory markers and presence of 
concomitant morphea were associated with the severity of residual damage. Lastly, HRQoL-
impairment, scored by DLQI and SF-36, correlated to the extent of residual damage.
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SUPPLEMENTAL FIGURES
Supplemental Figure 1 Participant inclusion. 
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SUPPLEMENTAL TABLES
Value
MTX
Patients, n (%) 15 (42.9)
Median dose (range), mg/week 20 (5-30)
SCS
No. of patients 16 (45.7)
Median dose (range), mg/day 8.75 (2.5-60)
Imatinib 1 (2.9)
Supplemental Table 1 Immunosuppressive treatment at participation.
Outcome Measure Value
Median MRSS (range) 8 (0-33)
Median LoSCAT (range) 17 (1-74)
Median mLoSSI (range) 9 (0-47)
Median LoSDI (range) 5 (0-36)
PhysGA
Median PhysGA-A (range) 2 (0-30)
Median PhysGA-D (range) 12 (2-82)
Median DLQI (range) 3 (0-18)
SF-36
Median PCS (range) 45.14 (22.9-58.9)
Median MCS (range) 54.23 (30.3-65.1)
Supplementary table 2 Summary of outcome measures at study participation. 
LoSCAT, Localized Scleroderma Cutaneous Assessment Tool; mLoSSI, modified Localized Scleroderma 
Skin Severity Index; LoSDI, Localized Scleroderma Skin Damage Index; PhysGA, physician’s global 
assessment; PhysGA-A, physician’s global assessment of disease activity; PhysGA-D, physician’s global 
assessment of disease damage; MRSS, modified Rodnan skin score; DLQI, dermatology quality of life 
index; SF-36, 36-item short form survey; PCS, Physical Component Summary; MCS, Mental Component 
Summary.
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Outcome measure DLQI SF-36  
Physical Functioning
rs P Value rs P Value
PhysGA
Damage .585 .001 -.368 .045
Activity .465 .007 -.408 .025
LoSCAT .478 .006 -.475 .006
mLoSSI .561 .001 -.498 .004
LoSDI .331 .065 -.359 .044
MRSS .538 .002 -.511 .003
Supplementary Table 3 Correlation between the patient reported outcome measures and outcome 
measures scored by the physician. 
LoSCAT, Localized Scleroderma Cutaneous Assessment Tool; mLoSSI, modified Localized Scleroderma 
Skin Severity Index; LoSDI, Localized Scleroderma Skin Damage Index; PhysGA, physician’s global 
assessment; PhysGA-A, physician’s global assessment of disease activity; PhysGA-D, physician’s 
global assessment of disease damage; MRSS, modified Rodnan skin score; PtGA, patient’s 
global assessment; DLQI, dermatology quality of life index; SF-36, 36-item short form survey. 
 Spearman’s rho (rs) and P values are displayed. Higher DLQI scores reflect more HRQoL-impairment. 
Lower SF-36 scores reflect more HRQoL-impairment.
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APPENDIX
Localized Scleroderma Cutaneous Assessment Tool (LoSCAT)
The Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) assesses 18 cutaneous 
anatomic sites, capturing both disease activity (mLoSSI) and damage (LoSDI) parameters. 
Scores for each site are based on the most severe score for each parameter. To minimize 
intersubject variability, all skin changes are compared with the contralateral or ipsilateral skin 
area.
Modified Localized Scleroderma Skin Severity Index (mLoSSI)
The mLoSSI includes the sums of 3 separate activity scores as follows: (1) erythema, using 
the colour of the lesion’s edge with 0 = no erythema, 1 = slight erythema/pink, 2 = red/
clearly erythema, and 3 = dark red or marked erythema/ violaceous; (2) skin thickness with 
0 = normal skin thickness and freely mobile, 1 = mild increase of thickness and mobile, 2 = 
moderate increase of thickness impaired skin mobility, and 3 = marked increase of thickness 
or no mobility of skin; and (3) new lesion/lesion extension: new lesion development and/or 
enlargement of an existing lesion within the past month (score of 3).
Localized Scleroderma Damage Index (LoSDI).
Three cutaneous damage domains are summated to obtain the LoSDI as follows: (1) dermal 
atrophy with 0 =normal-appearing skin, 1 = mild skin atrophy (ie, shiny skin), 2 = moderate 
atrophy (ie, visible blood vessels or mild ‘‘cliff-drop’’ sign), and 3 = severe skin atrophy (ie, 
obvious cliff-drop sign); (2) subcutaneous atrophy with 0 = normal subcutaneous thickness, 1 
= flattening or 1/3 fat loss, 2 = obvious concave surface or 1/3 to 2/3 fat loss, and 3 = severe 
subcutaneous fat loss ([2/3 loss); and (3) dyspigmentation, assessing hyperpigmentation 
or hypopigmentation, whichever is most prominent with 0 = normal skin pigment, 1 = mild 
dyspigmentation, 2 = moderate dyspigmentation, and 3 = severe dyspigmentation.
Physician’s Global Assessment of Disease Activity (PhysGA-A)
The PhysGA-A was developed based on consensus agreement by paediatric LoS experts and 
is typically used in conjunction with the mLoSSI. The 100-mm analogue scale is anchored by 
‘‘inactive’’ at 0 and ‘‘markedly active’’ at 100. The following cutaneous variables were included 
when scoring the PGA-A: new lesions within the previous month, enlargement of existing 
lesion within the previous month, and erythema/violaceous colour and/or skin thickening/ 
induration at the border of lesion. For the purpose of EF activity assessment, stable skin 
thickening/induration for multiple years, was not regarded active disease.
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Physician’s Global Assessment of Disease Damage (PhysGA-D)
The PhysGA-D is anchored by ‘‘no damage’’ at 0 and ‘‘markedly damaged’’ at 100. 
Based on consensus agreement, both cutaneous and extracutaneous manifestations 
(ECM) are considered when scoring the PGA-D. The cutaneous manifestations include 
hyperpigmentation or hypopigmentation, and subcutaneous and dermal atrophy. The ECM 
include musculoskeletal involvement (skeletal muscle atrophy, bone atrophy, facial atrophy, 
limb length discrepancy, physical disability, joint contracture), neurologic involvement (central 
nervous system symptoms, abnormal brain magnetic resonance imaging findings, eye 
involvement), and psychosocial quality-of-life impairment.
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SURVIVAL AND PREDICTORS OF DRUG 
SURVIVAL FOR METHOTREXATE TREATMENT 
IN A RETROSPECTIVE COHORT OF ADULT 
PATIENTS WITH LOCALIZED SCLERODERMA 
J.S. Mertens1,4, J.M. van den Reek1, W. Kievit2, P.C.M van de Kerkhof1, R.M. Thurlings3, T.R.D. 
Radstake4, M.M.B. Seyger1, E.M.G.J. de Jong1.
1 Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
2 Department of Epidemiology, Health evidence, Radboud university medical centre, Nijmegen, The Netherlands.
3 Department of Rheumatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
4  Department of Rheumatology and Clinical Immunology and Laboratory of Translational Immunology, University Medical 
Centre Utrecht, Utrecht, The Netherlands.
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ABSTRACT 
Data regarding efficacy and safety of Methotrexate (MTX) in adults with Localized Scleroderma 
(LoS) is scarce. We gathered data from a retrospective cohort of adult patients with LoS 
(n=107), treated with MTX (1993-2015). We analysed MTX drug survival and predictors thereof. 
After 1 and 2 years, 26% and 63% stopped MTX due to disease remission, respectively. 
Younger age at MTX initiation (HR 1.159 (95% CI, 1.052– 1.277)) and patients without other 
autoimmune diseases (HR 3.268 (1.334–8.009)) more often stopped MTX due to disease 
remission. In addition, 24% stopped MTX due to treatment failure within a year. Patients 
affected by circumscribed superficial LoS (HR 0.221 (0.081 – 0.601)) less often experienced 
treatment failure compared to other LoS-subtypes. Lastly, adding folic acid (HR 0.184 (0.079 - 
0.425)) and reducing treatment delay (HR 1.056 (1.004 – 1.112)) could be the most important 
factors to minimize MTX treatment failure in LoS in clinical practice.
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INTRODUCTION
Localized scleroderma (LoS), also known as morphea, encompasses a spectrum of 
rare diseases causing fibrosis of the skin and underlying tissues such as fat, fascia and 
muscle.48 Local sclerosis can cause extensive morbidity such as joint contractures, limb 
length discrepancies and muscle weakness due to active myositis or muscle atrophy.232 This 
extensive morbidity in combination with the disease, in general, having significant impact on 
the quality of life, requires adequate treatment.3 246
Methotrexate (MTX), with or without concomitant systemic corticosteroids, is recommended 
as the primary treatment option in patients with moderate to severe or treatment refractory 
disease.235 253 254 However, data regarding the efficacy and safety of MTX in adult patients 
with LoS is scarce; with only three studies reporting original data regarding MTX treatment in 
adults with LoS.179 180 185 As MTX is the most prescribed systemic treatment for LoS, there is a 
high need for more evidence regarding treatment strategies.
The main objective of this study was to describe drug survival for MTX treatment in a large 
long-term daily practice cohort of LoS patients. Drug survival analyses allows to evaluate 
the treatment duration with a particular drug with regards to different outcomes of interest. 
Drug survival is a comprehensive outcome covering effectiveness, safety, and patients’ and 
doctors’ preferences. 255 We investigated the drug survival split for disease remission and 
treatment failure. Additionally, by identifying predictors of drug survival for MTX we aimed to 
improve treatment strategies. 
METHODS
Patients and data collection
A retrospective chart review was performed of adult patients with LoS treated with MTX. All 
patients were evaluated at the combined dermatology and rheumatology outpatient clinic 
at the Radboud University Medical Centre (Nijmegen, The Netherlands) between august 
1993 and July 2015. The first treatment episode with MTX was included for analysis. The 
following information was collected: age at treatment initiation, route of administration, dosage 
alterations, overall treatment duration and prescription of folic acid or concomitant systemic 
corticosteroids.
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Reasons for treatment discontinuation
The first reason of interest was disease remission. Disease remission was present if the 
treating physician reported a satisfactory result at treatment cessation. The next reason for 
treatment discontinuation was treatment failure. For sub analyses, this reason was split into 
side-effects and treatment ineffectiveness. Ineffectiveness was present if the treating physician 
reported an unsatisfactory treatment result. In addition, patients could be categorized as 
having a mix of stopping reasons (i.e. side-effects and ineffectiveness). Lastly, patients could 
be categorized as having another stopping reason (i.e. patient’s wish or elective surgery).
Predictors for drug survival
For understanding of the selection procedure of possible predictors the following has to 
mentioned: Cox-regression analyses allowed us to investigate associations between baseline 
variables and an outcome of interest. Treatment specific variables however, are in this context 
confounded by indication and should not be analysed via this method. Therefore, we selected 
the following baseline characteristics as candidate predictors: sex, age at disease onset, age 
year at MTX initiation, the time between the disease onset and MTX initiation (treatment 
initiation delay), disease subtype as reported by Zulian et al.22 , prescription of folic acid at 
MTX initiation, presence of Anti-Nuclear Antibodies (ANAs) and the presence of concomitant 
autoimmune diseases. To investigate whether drug survival of MTX was influenced by 
treatment behaviour, calendar year at MTX initiation was added as a possible predictor. 
Statistical analysis
Descriptive statistics, including median [range] for continuous variables and percentages for 
categorical data, were used to explore baseline and patient characteristics. Drug survival 
analyses were performed using Kaplan–Meier curves for MTX drug survival related to treatment 
failure and split for side-effects and treatment ineffectiveness. For purpose of visualization 
drug survival related to disease remission was displayed by one–minus-survival curves. 
Treatment episodes were censored for a particular survival analysis when patients were still 
being treated at data lock, lost to follow-up or discontinued MTX due to a reason other than 
the reason of interest. An MTX treatment episode was considered discontinued when MTX 
was interrupted for more than 21 days. Potential predictors were selected with a univariate 
Cox regression model for every different discontinuation reason separately. Determinants 
with a P-value ≤0,20 were imported in a multivariate Cox regression model with backward 
selection. As a rule of thumb, multivariate Cox regression analyses allows to import one 
predictor of interest per 10 events for the discontinuation reason of interest.255 If the amount 
of possible predictors identified by univariate analyses exceeded the amount of predictors 
allowed in a multivariate model, we selected the predictors with the strongest association 
based on p-values. Predictors are displayed by Hazard Ratios (HRs) with corresponding 95% 
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Confidence Intervals (CIs). Statistical analyses were performed using SPSS Statistics v.22 
(IBM, Armonk, NY, U.S.A.).
RESULTS
Baseline Characteristics
In total, 113 patients with LoS using MTX were identified. One hundred and seven (94.7%) 
were included for drug survival analysis. The remaining six patients were excluded due to 
incomplete data regarding the MTX treatment. Baseline characteristics, of the 107 patients, 
are displayed in Table 1. Seventy-seven patients were female (72.0%) and 30 males (28.0%) 
(Ratio 2.6:1). The median age at disease onset was 46 years [range, 2 - 77]. Subtype 
distribution is displayed in the table.
Characteristics Adults
N=107
Female : Male (ratio) 77, 33 [2.6:1.0]
Age at MTX [range] 49 [18-78]
Age at Onset [range] 46 [2-77]
Subtype 
(%)
Circumscribed Superficial 27 (25.2%)
Deep 12 (11.2%)
Linear Trunk/limbs 18 (16.8%)
Head 1 (0.9%)
Generalized 33 (30.8%)
Mixed 16 (15.0%)
Table 1 Demographics and subtype distribution in 107 subjects with localized scleroderma treated with 
methotrexate.
Treatment characteristics
Details regarding the MTX treatment are summarized in Table 2. The median age at MTX 
initiation was 49 years [18 - 78] and the median time between the disease onset and MTX 
initiation was 18 months [3 - 429]. The median MTX treatment duration was 49 weeks [4 - 261 
weeks]. In general, patients received 15mg MTX per week [5.0 - 26.9] during the treatment 
episode. The median maximum dose was 15mg [5.0 - 30). Lastly, 37 (34.6%) patients were 
concomitantly treated with systemic corticosteroids and 78 (72,9%) patients received folic 
acid. 
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Characteristics Adults
N=107
Age at MTX initiation (years) 49 (18-78)
Delay in MTX initiation (months) 18 (3-429)
Duration of MTX treatment (weeks) 49 (4-261)
Maximum MTX dose (mg per week) 15 (5-30)
Average MTX dose (mg per week) 15 (5-26.9)
Route of administration n, (%) Oral 90 (84.1%)
Subcutaneous 2 (1.9%)
Switch* 15 (14%)
Systemic Corticosteroids n, (%) 37 (34.6%)
Folic Acid n, (%) 78 (72.9%)
Table 2 Treatment characteristics in 107 subjects with localized scleroderma treated with Methotrexate
Delay in MTX initiation was measured as the time between disease onset and MTX initiation. 
*Fifteen (out of 107, 14%) patients switched from oral to subcutaneous (SC) MTX administration during 
the treatment episode. Reason for switching were side-effects in four patients or lacking efficacy in the 
remaining 11 patients.
Reasons for methotrexate discontinuation 
In 44 (41.1% of 107) patients, disease remission was the sole reason to stop MTX. Side-
effects or treatment ineffectiveness, without any other reason, was a reason to discontinue 
MTX treatment in 12 (11.2%) and 14 (13.1%) patients, respectively. In total, eight patients 
(7.5%) had a combination of stopping reasons: four (3.7%) had a combination of disease 
remission and side-effects and four (3.7%) experienced treatment ineffectiveness and side-
effects. Side-effects severe enough to lead to MTX discontinuation were gastro-intestinal 
symptoms (n=7, 6.5%), laboratory abnormalities (n=7, 6.5%), consisting of five patients 
(4.7%) with signs of hepatotoxicity and two (1.9%) of haematotoxicity, fatigue (n=3, 2.8%), 
pulmonary symptoms under suspicion of being related to MTX (n=3), renal impairment (n=1, 
0.9%), depression (n=1, 0.9%) and headache (n=1, 0.9%). Lastly, 12 (11.2%) patients were 
lost to follow-up, 13 (12.2%) were still being treated at data lock and four (3.7%) had other 
reasons for treatment discontinuation (i.e. patient’s wish, elective surgery).
Drug survival of methotrexate
Figure 1a displays the one minus drug survival curve for MTX related to disease remission. 
After 1 year, roughly a quarter (25,3%) of the patients stopped MTX because of disease 
remission. After two years this was 62.5%. The median time until discontinuation of MTX due 
to disease remission was 87 weeks. Figure 1b displays drug survival related to treatment 
failure. After 1 and 2 years, drug survival related to treatment failure was 75.7% and 54.7%, 
respectively. Subanalysis of drug survival related to the separated discontinuation reasons 
adverse events and ineffectiveness showed no significant differences. 
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Figure 1. Methotrexate (MTX) time to disease remission curves in 107 patients with localized scleroderma 
(a). MTX survival curves related to treatment failure (black line) segregated into side-effects (green line) 
and treatment ineffectiveness (grey line) (b).
Selection of candidate predictors of drug survival
Supplemental table 1. displays the HRs and 95% CIs for the Univariate Cox Regression 
analysis for all the variables tested. The variables with a P-value ≤0.2 in the univariate analysis 
were put into to the multivariate model.
Predictors of drug survival in LoS – Disease remission
Forty-eight patients discontinued MTX due to disease remission which allowed us to add five 
predictors of interest in a multivariate model. Univariate analysis identified age at MTX initiation 
(p=0.004, HR 1.144 (Confidence Interval, 1.043 – 1.255), absence of other autoimmune 
diseases (p=0.004, HR 3.636 (1.153 – 8.696)), absence of deep LoS (p=0.007, HR 5.155 
(1.572 – 16.949), absence of administration of folic acid (p=0.00 HR 5.051 (2.660 – 9.615) and 
the calendar year of MTX initiation (p=0.000, HR 0.859 (0.811 – 0.909) as possible predictors. 
Figure 2 displays the HRs and 95% CIs resulting from the multivariate analysis. The following 
three variables remained statistically significant in a multivariable model: the calendar year 
of MTX initiation was associated with a drug survival related to disease remission (HR 0.865 
(0.814 – 0.919). In other words, more recent MTX initiation, measured as a more recent 
calendar year, was associated with a decreased drug survival due to disease remission. More 
interestingly, patients who were exclusively affected by LoS showed a better drug survival 
related to disease remission compared to patients affected by multiple autoimmune diseases 
(HR 3.268 (1.334 – 8.009)). Lastly, younger age (boundary at 18 years old) at MTX initiation 
was associated with an increased drug survival related to disease remission (HR 1.159 (1.052 
– 1.277)).
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Figure 2 Prediction of methotrexate (MTX) drug survival in 107 patients with localized scleroderma, 
segregated for treatment discontinuation reasons: disease remission (a) and treatment failure (b). 
Displayed are Hazard Ratios and their confidence intervals resulted from multivariate cox regression 
analyses. The x-axis on panel A is on a LOG-2 scale.
Predictors of Drug Survival – Treatment Failure
Thirty-four patients discontinued MTX due to treatment failure, which allowed us to add three 
predictors of interest in the multivariate model. Univariate analysis identified the delay in 
treatment initiation (p=0.079, HR 1.044 (0.995 – 1.096), having circumscribed superficial LoS 
(p=0.020, HR 0.370 (0.160– 0.854)) and receiving Folic Acid (p=0.006, HR 0.368 (0.180– 
0.735)) as possible predictors. All three predictors remained significant in the multivariable 
model, leading to the following HRs and their interpretation: patients who received folic acid 
(HR 0.184 (0.079 - 0.425)) and patients affected by circumscribed superficial LoS (HR 0.221 
(0.081 – 0.601)) were protected against treatment failure. On the other hand, patients with a 
longer treatment initiation delay (HR 1.056 (1.004 – 1.112)) were at greater risk for treatment 
failure.
Subanalysis of MTX discontinuation due to side-effects and treatment ineffectiveness were 
restricted to multivariable models with two predictors due to the relatively low number of 
events for these two stopping reasons separately (20 and 18 events, respectively). Receiving 
folic acid (HR 0.279 (0.101 – 0.773)) protected against side-effects, whereas patients with a 
prolonged treatment initiation delay (HR 1.076 (1.014 – 1.142)) were at greater risk of stopping 
due to side-effects. Patients with a longer treatment initiation delay were also at greater risk of 
stopping MTX due to treatment ineffectiveness (HR 1.057 (1.000 – 1.117).
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DISCUSSION
In this study we present that 26% and 63% of the patients stopped MTX due to disease 
remission after 1 and 2 years, respectively. The median time to MTX discontinuation because 
of disease remission was 87 weeks. Additionally, we present that the drug survival related 
to treatment failure was 76% after 1 year. Consequently, this means that 24% stopped MTX 
within a year, because of side-effects or treatment ineffectiveness. Comparing our results to 
other studies is difficult, as we present the first data regarding drug survival of MTX in LoS. 
Most studies that describe MTX in LoS focus on a paediatric population.27 28 32 178 182-184 Only 
three original papers describe MTX as a treatment option in adult patients; Seyger et al. 
180 reported a beneficial effect of MTX in 66% of 9 patients after 24 weeks. Kreuter et al 179 
reported a beneficial effect of MTX in combination with pulsed intravenous methylprednisolone 
in 14 out of 15 patients. Lastly, Kroft et al 185 reported remission rates of 51% and 73% for MTX 
mono- and combination therapy with prednisone in a cohort that contained sclerotic diseases 
other than LoS.
In contrast to the papers published for LoS, drug survival studies are more frequently reported 
in other diseases. However, in most diseases, remission is not a reason to stop treatment. 
Shalom et al.256 present drug survival rates of MTX of only 59,3% after 1 year in 2632 patients 
with psoriasis. Consequently, this means that 40,7% stopped treatment within a year. However, 
the lack of detailed description of the discontinuation reasons in this study makes it difficult to 
compare the results we present.
With regards to predictors of drug survival, we show that younger age at treatment initiation 
was associated with higher rates of disease remission. (HR 1.159) A possible explanation 
could be that older patients are more frequently affected by comorbidities, which may lower 
the chance of treatment success. Secondly not being affected by other autoimmune diseases, 
also increased the chance of achieving disease remission (HR 3.268). The group of patients 
suffering from other autoimmune diseases might reflect a group of patients with more severe 
forms of the disease. Furthermore, we identified an association between calendar year at 
MTX initiation and disease remission (HR 0.865). A possible explanation for this association 
could be changing prescription behaviour, as this analysis contains treatment episodes from 
the early 1990s. Treatment has become more aggressive during the years; partly due to 
increased experience with MTX and partly due to literature advocating prolonged treatment 
with MTX in LoS.178 186 
Regarding treatment failure, we show that prescription of folic acid protected against treatment 
failure (HR 0.184). The protective effect of folic acid against side-effects caused by MTX is 
well known in other disease like rheumatic diseases and psoriasis.257-259 These findings, in 
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combination with scarcity of alternative treatments for MTX in LoS, emphasize the necessity 
of the prescription of folic acid to decrease the likelihood of MTX failure. Secondly, our results 
imply that more severe disease subtypes (i.e. the linear or deep subtypes) are more difficult 
to treat successfully as the milder superficial subtype was associated with a lower risk of 
treatment failure compared the severe subtypes (HR 0.221). Most interestingly, we showed 
that patients with a longer delay in MTX initiation were at greater risk of stopping MTX due to 
treatment failure (HR 1.056). These data suggest that early treatment, as is desired in other 
diseases such as rheumatoid arthritis, is also preferred in LoS. 260-262
A limitation of this study is its retrospective design. Secondly, the study is limited by relatively 
low number of events which hindered us to perform certain subgroup analyses. However, 
we maximized the amount of candidate predictors for each multivariable model based on 
the number of events in that model. Lastly, we investigated associations between predictors 
and outcomes and not causality. Further replication of these data is needed to investigate 
causations between the predictors and outcomes we identified in this study.
In conclusion, this is the first study to present data regarding drug survival and predictors 
for drug survival of MTX in adults with LoS in a large daily practice cohort. We have shown 
that 26% and 63% stopped MTX due to disease remission after 1 and 2 years, respectively. 
We have identified that younger patients and patients without other autoimmune diseases 
stopped MTX more frequently due to disease remission. In addition, 24% of the patients 
stopped due to treatment failure within a year. With regards to minimizing treatment failure, we 
showed that adding folic acid and a reduction of treatment delay could be the most important 
factors in clinical practice.
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SUPPLEMENTAL TABLES
 
  
P-value Exp (B) P-value Exp (B) P-value Exp (B) P-value Exp (B)
Age at Onset
'5 year intervals'
0.362
0.958
(0.874 : 1.051)
0.215
0.926
(0.820 : 1.046)
0.533
0.961
(0.846 : 1.090)
0.011*
0,898
(0.827 : 0.976)
Age Onset
Dichotomous  (adult vs. 
paediatric)
0.230
0.519
(0.223: 1.207)
0.192*
0.470
(0.152 : 1.459)
0.127*
0.412
(0.132 : 1.288)
0.069*
0.439
(0.180 : 1.066)
0.667
0.977
(0.880 : 1.085)
0.560
0.960
(0.838 : 1.101)
0.971
1.003
(0.868 : 1.159)
0.004*
0.874
(0.797 : 0.959)
Treatment initiation delay
'1 year intervals'
0.079*
1.044
(0.995 : 1.096)
0.034*
1.062
(1.005 : 1.122)
0.029*
1.065
(1.006 : 1.126)
0.491
1.023
(0.958 : 1.093)
Treatment initiation delay
Dichotomous (<2 vs  >2 
years)
0.142*
0.603
(0.307 : 1.184)
0.196*
0.558
(0.231 : 1.350)
0.071*
0.417
(0.162 : 1.078)
0.172*
0.670
(0,377 : 1.190)
Circumscribed Superficial
dichotomous (Yes vs No.)
0.020
0.370
(0.160 : 0.854)
0.131*
0.455
(0.163 : 1.266)
0.049*
0.286
(0.082 : 0.996)
0.682
0.886
(0.495 : 1.584)
En Coup De Sabre
dichotomous (Yes vs. No)
0.517 0.047 0.613 0.047 0.653 0.047 0.928
0.912
(0.125 : 6.666)
Generalized LoS
dichotomous (Yes vs. No)
0.088*
1.815
(0.914 : 3.597)
0.448
1.495
(0.568 : 3.597)
0.294
1.667
(0.643 : 4.310)
0.971
0.988
(0.508 : 1.919)
Deep LoS
dichotomous (Yes vs. No)
0.482
0.708
(0.270 : 1.855)
0.527
0.668
(0.190 : 2.336)
0.768
1.186
(0.381 : 3.690)
0.007*
0.194
(0.059 : 0.636)
Linear LoS on the limbs/trunk
Dichotomous (Yes vs. No)
0.779
0.896
(0.418 : 1.923)
0.858
1.092
(0.418 : 2.849)
0.904
0.938
(0.334 : 2.639)
0.076*
1.706
(0.945 : 3.077)
II - Remission (48 events) Ia- Side 
Effects (20 events)
Ib-Treatment
Ineffectiveness (18 
events)
A
g
e 
at
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t
Age at MTX
'5 year intervals'
I - Treatment
Failure  (34 events)
S
u
b
ty
p
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T
re
at
m
en
t
D
el
ay
Sign
I - Treatment failure (34 events)
 
Supplementary Table 1. P-values and Hazard Ratios (HRs) including 95% (CIs) of all predictors tested for drug survival for the separate 
discontinuation reasons in 107 localized scleroderma patients treated with methotrexate. Predictors with a p-value ≤ 0.2 were up for selection to 
be imported in a multivariable model. P-values ≤ 0.2 are displayed in bold and marked with an asterisk. The cells marked in grey represent the 
predictors which were included in the multivariate Cox-Regression analyses. 
 
P-value Exp (B) P-value Exp (B) P-value Exp (B) P-value Exp (B)
0.006*
0.368
 (0.180 : 0,754)
0.061*
0.400
(0.153 : 1.044)
0.119*
0.446
(0.162 :1.230)
<.001*
0.198
(0.104 : 0.376 )
0.413
0.974
(0.915 : 1.037)
0.968
0.998
(0.919 : 1,084)
0.975
1.001
(0.915 : 1.096)
<.001*
0.859
(0.811 : 0.909)
0.663
0.829
(0.385 : 1.788)
0.909
1.058
(0.401 : 2.789)
0.213
0.452
(0.129 : 1.577)
0.836
0.935
(0.493 : 1.773)
0.203
1.677
(0.756 : 3.731)
0.525
1.431
(0.474  : 4.310)
0.436
1.563
(0.509 : 4.785)
0.890
1.059
(0.469 : 2.387)
0.560
0.789
(0.355 : 1.751)
0.711
0.824
(0.297 : 2.294)
0.556
0.714
(0.233 : 2.193)
0.004*
0.275
(0.115 : 0.655)
0.746
1.148
(0.498 : 2.644)
0.261
0.423
(0.094 : 1.894)
0.083*
2.530
(0.886 : 7.227)
0.798
0.911
(0.446 : 1.859)
Sign
I - Treatment failure (34 events)
II - Remission (48 events)I - Treatment
Failure  (34 events)
 Ia- Side 
Effects (20 events)
Ib-Treatment
Ineffectiveness (18 events)
Concomitant 
Autoimmun Disease
dichotomous  (Present 
AntiNuclear 
Antibodies
Dichotomous  
Fol Acid
dichotomous (Yes vs. 
No)
Calendar Year at MTX 
initiation
' 1 year intervals' 
Sex 
dichotomous (♂ vs.♀)
Concomitant 
Cutaneous 
Autoimmun Disease
Supplemental Table 1. P-values and Hazard Ratios (HRs) including 95% (CIs) of all predictors tested 
for drug survival for the separate discontinuation reasons in 107 localized scleroderma patients treated 
with methotrexate. Predictors with a p-value ≤ 0.2 were up for selection to be imported in a multivariable 
model. P-values ≤ 0.2 are displayed in bold and marked with an asterisk. The cells marked in grey 
represent the predictors which were included in the multivariate Cox-Regression analyses.
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ABSTRACT
OBJECTIVE: To assess the efficacy and safety of mycophenolate mofetil (MMF) in patients 
with localised scleroderma (LoS) resistant or intolerant to previous treatment with methotrexate 
(MTX).
METHODS: A description of a case series of LoS patients treated with MMF. Outcome was 
assessed through clinical examination and adverse events were documented.
RESULTS: Seven patients with LoS were treated with MMF. Median age at MMF initiation 
was 15 years (range 7-74). Three patients received MMF due to MTX ineffectiveness and 
four patients due to MTX intolerance. Disease remission was achieved in four patients and 
maintained in one patient. One patient showed a favourable response but had to discontinue 
treatment due to elevated liver enzymes. The remaining patient experienced progression of 
disease.
CONCLUSIONS: MMF showed to improve the clinical condition in patients with refractory 
LoS and may be a relatively safe alternative in patients intolerant to MTX.
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INTRODUCTION 
Localised Scleroderma (LoS), also known as morphea, encompasses a spectrum of sclerotic 
skin diseases primarily affecting the dermis, but may also affect underlying tissues such as 
subcutaneous fat, fascia, muscle and underlying bone.253 The different subtypes of LoS may 
vary in severity and are classified into morphea en plaque, linear LoS, generalised LoS, deep 
LoS, pansclerotic morphea and the mixed subtype.22 Morphea en plaque is the most common 
variant in adults. Linear LoS is the most frequently observed subtype in children and is mostly 
accompanied by fibrosis of underlying tissues of limbs and face. In severe cases the disease 
results in muscle atrophy, growth restrictions of the limb and joint contractures leading to 
discomfort, dysfunctional use and psychological distress.48 232 246 In LoS, treatment consists of 
topical treatment with corticosteroids, vitamin D analogues or calcineurin inhibitors, low-dose 
methotrexate (MTX), systemic corticosteroids and UVA1 phototherapy.231 235 For some patients 
with severe debilitating deformities these treatments are not sufficient due to progressive 
disease and/or intolerance to treatment. In these refractory cases of LoS, mycophenolate 
mofetil (MMF) may be beneficial. However, literature supporting this evidence is scarce, with 
only one article reporting beneficial results of this treatment option in LoS.188 With this concise 
report, we aimed to provide more evidence on the efficacy and safety of MMF therapy in 
patients with severe LoS.
MATERIAL AND METHODS
A retrospective chart review was performed of LoS patients treated with MMF, at the Radboud 
University Medical Centre, Nijmegen, the Netherlands. Disease subtype classification was 
based on the classification system as proposed by Zulian et al.22. The diagnosis was made 
by clinical inspection and confirmed with skin biopsies if necessary. Treatment with MMF 
was initiated when treatment with MTX as a treatment for LoS, in combination with systemic 
corticosteroid therapy, did not result in disease remission or stabilisation, or when intolerance 
to MTX occurred. Active disease was defined as the presence of one of the following items: an 
erythematous border (‘lilac ring’) surrounding a lesion, or disease progression (development 
of new lesions, expansion of existing lesions, expansion of sclerosis, a decrease of the range 
of motion of an affected limb, or imaging studies showing signs of disease activity). Inactive 
disease was defined as the absence of the above-mentioned items for disease activity. Disease 
remission was defined as six consecutive months of inactive disease. A favourable response 
to treatment with MMF was defined as disease remission or absence of disease recurrence 
during follow-up. All patients were evaluated by both a dermatologist and rheumatologist, with 
extensive experience in the treatment of LoS, in paediatric and adult patients, respectively. 
Extracutaneous manifestations (ECMs) were recorded as previously reported by Zulian et al. 236
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RESULTS
Patients
Clinical characteristics are described in Table 1. Seven patients with LoS, six females and 
one male, were treated with MMF at our centre. The median age at MMF initiation was 15 
years (range 7-73). LoS subtypes included were deep (n=2), linear (n=1), generalised (n=2) 
and the mixed subtypes (n=2). Two patients, both classified with generalised subtype of 
LoS, had an overlap diagnosis with Systemic Sclerosis (SSc). One of these patients was 
diagnosed with a diffuse cutaneous Systemic Sclerosis (dcSSc), based on the presence 
of a Raynaud’s phenomenon, sclerodactyly, positive ANA, positive Anti-Topoisomerase-I, 
abnormal nailfold capillaries and a diffuse pattern of thickening of the skin. The other patient 
was diagnosed with a limited cutaneous Systemic Sclerosis (lcSSc), based on the presence 
of a Raynaud’s phenomenon, digital ulcera, sclerodactyly, positive ANA and Anti-centromeres 
and oesophageal dysmotility. In the two patients diagnosed with SSc, the MMF treatment 
was initiated due to progression of the LoS lesions. The remaining five patients were solely 
diagnosed with LoS. One patient (no 1.) was diagnosed with mild pulmonary restriction at 
the initial presentation of LoS, which remained stable during the six years of follow-up. This 
patient also suffered from a decreased range of motion (RoM) of a wrist and knee. No other 
ECMs, especially no arthritis, were reported in the patients.
Treatment
As shown in Table 2, all patients were treated with systemic corticosteroids and MTX, with 
maximum doses up to 25mg administered orally and subcutaneously, prior to start with MMF. 
Two patients (no. 6 and 7) had a history of treatment with azathioprine. The patient suffering 
from dcSSc had received cyclophosphamide because of progressive skin disease with good 
response on dcSSc, but not on LoS. Additionally, she was treated with rituximab previous 
to MMF initiation. Four patients had experienced MTX intolerance (nausea, abdominal 
discomfort, elevated liver enzymes) which was the incentive to start MMF therapy. In three 
patients MMF therapy was started because of ineffective prior treatment with methotrexate. 
Median duration of disease at start of MMF therapy was 46 months (range 21-194). Six out of 
seven patients showed signs of disease activity at start of MMF treatment. In the remaining 
paediatric patient, MMF was started as a treatment to maintain disease remission. All patients 
discontinued MTX treatment, ranging from 1 week to 3 years, prior to MMF initiation. Five 
patients (no. 1, 3, 4, 6 and 7) were concomitantly treated with prednisone treatment. Two 
of these five patients were being treated with 10mg prednisone daily for several years prior 
to MMF initiation already and no dose alterations were made during the treatment episode 
of MMF. One patient (no. 3) received 7,5mg prednisone daily for 6 weeks at the same time 
at which the MMF dose was increased. Another patient (no. 1) was being treated with up to 
30mg prednisone daily for the first 6 months of MMF treatment. The remaining patient (no. 
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4) received 20mg prednisone for the first two months of MMF treatment. The starting dose of 
MMF ranged from 500 to 2000 mg daily and the maximum dose prescribed was 2500mg daily. 
Median duration of MMF treatment at data lock was 15 (range 9-40) months.
Outcome – course of disease
As described in Table 2, six patients had a favourable response to MMF treatment. Of the 
patients who started MMF treatment, while having active disease (n=6), four patients (no. 1, 3, 
4, 6) achieved disease remission. After initial disease remission during MMF treatment, patient 
no. 1 had a disease recurrence, which responded favourably after dose increase of MMF. 
Additionally, the RoM returned to normal during treatment. Patient no. 3 also experienced 
disease remission after dose increase. Patient no. 4 experienced disease remission without 
dose increase. One patient with generalised LoS (no.6) experienced clinical improvement of 
the LoS, but progression of the systemic manifestations of SSc. Patient no. 7 experienced 
clinical improvement but had to discontinue MMF treatment after 3 months due to elevated 
liver enzymes. One patient (no. 2) already had disease remission prior to start with MMF, 
therapy with MMF was started due to MTX intolerance and aim of the treatment was to 
maintain disease remission. Only one patient (no. 5) was reported to show progression of 
disease during 12 months treatment with MMF.
Outcome – MMF discontinuation and Safety
Of the seven patients, three (no. 1, 2 & 6) were still being treated with MMF at the data lock. 
Patient no. 3 stopped on his own initiative at the moment of disease remission. There was 
no report of adverse events in this patient. In patient no. 4, MMF was discontinued after 
disease remission was present for one year. In patient no. 5, MMF turned out to be ineffective 
and therefore treatment was discontinued after 12 months. This patient also suffered from 
diarrhoea at doses greater than 1000mg daily. Lastly, patient no. 7 developed elevated liver 
enzymes after 3 months of MMF treatment, causing discontinuation of treatment.
DISCUSSION
The current paucity of evidence of MMF treatment in LoS patients motivated us to analyse 
the efficacy and safety of MMF in LoS patients from our hospital. Our findings indicate that 
MMF may be a suitable alternative to MTX in patients who experience MTX-intolerance or 
insufficient disease control, considering that the majority of our patients achieved disease 
remission when using MMF. One patient, with an extensive history of LoS refractory to various 
medications, showed disease progression under MMF treatment. 
535444-L-bw-Mertens
Processed on: 12-9-2019 PDF page: 106
CHAPTER 3.2
106                                   
Mycophenolate mofetil is an ester derivative of mycophenolic acid (MPA), which selectively 
and non-competitively inhibits an important enzyme, inosine monophosphate dehydrogenase, 
required for the proliferation of lymphocytes. Therefore, blocking this enzyme may specifically 
inhibit multiple functions of lymphocytes. Mycophenolate mofetil was initially used for prevention 
of organ transplant rejection and several years later use of MMF for dermatological conditions 
ensued. Additionally, in vitro studies have shown that MMF also inhibits proliferation of smooth 
muscle cells and fibroblasts, making it a potentially promising treatment for sclerodermatous 
conditions as well.263 264(10) A previous case series described stabilisation of lung disease in 
patients with dcSSc treated with MMF.265 Furthermore, one prospective observational study 
of MMF reported a marked improvement of skin involvement in patients with progressive 
dcSSc.266 A review by Cappelli et al. describes several observational studies with encouraging 
results of MMF on the modified Rodnan Skin Score in patients with SSc.267 Systemic Sclerosis 
and LoS likely share a common pathway given that the same cytokines and chemokines are 
activated, leading to increased collagen and extracellular matrix deposition.48 These findings 
further support that MMF could be efficacious in LoS patients as well. 
Compared to other immunosuppressant medications, including MTX, MMF has a favourable 
side-effect profile.268 Common side effects of MMF are gastro-intestinal symptoms such 
as diarrhoea and nausea. Haematological abnormalities, most frequently leukopenia, and 
increased susceptibility to infections, such as urinary tract infections, are also commonly 
observed.264 In this case series, one patient developed elevated liver enzymes after three 
months of MMF treatment, and another patient suffered diarrhoea at MMF doses exceeding 
1000mg daily. No other side effects were reported.
One of the limits of our study is that the effect of previous treatment, such as MTX, in LoS 
lasts for an unknown period of time. Six out of seven patients were treated with MMF for at 
least nine months, most likely dissipating an MTX effect. Another possibility is that the disease 
remission is due to the natural course of disease, given that an unknown percentage of lesions 
tend to slowly soften over a period of three to five years.48 However, all cases had a history 
of difficult to treat LoS with refractoriness to systemic treatments, which makes spontaneous 
remission less probable. It is also important to point out that five out of seven patients received 
concomitant prednisone treatment. Two of these patients were being treated with low-dose 
prednisone for multiple years prior to the MMF initiation already and no dose alterations were 
made during the treatment episode of MMF. In the remaining 3 patients, prednisone was 
either prescribed at the initiation or during the course of MMF treatment, making it difficult to 
attribute the favourable therapeutic effect solely to MMF. Additionally, this study is limited by 
its retrospective design and small sample size. Lastly, validated clinical scores, such as the 
LoScat118 269 or mRSS were not routinely performed, as these patients were treated in daily 
practice care. 
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Reviews on LoS treatment mention the use of MMF in LoS patients intolerant or refractory 
to MTX.253 270 271 However, to date, only one case series by Martini et al. described the 
effect of MMF in LoS patients, emphasising the need for additional evidence to support this 
proposition. Martini et al. describe continuation of MTX treatment, concomitantly with MMF 
in 6 patients.188 In our study, all patients discontinued treatment with MTX at start of MMF. 
Hence, our description of case series provides additional evidence for the efficacy and safety 
of MMF in LoS patients and facilitates the decision to opt for MMF in LoS. However, further 
randomised controlled studies are warranted to further evaluate the efficacy of MMF in LoS 
patients. 
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HIGH-DOSE INTRAVENOUS PULSE 
METHOTREXATE IN PATIENTS WITH 
EOSINOPHILIC FASCIITIS
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ABSTRACT
IMPORTANCE: Eosinophilic Fasciitis (EF) is a connective-tissue disorder in which conventional 
treatment leads to disappointing results in a proportion of patients. Therefore, we investigated 
high-dose intravenous (IV) pulse methotrexate (MTX) as a treatment for EF.
OBJECTIVES: To examine safety and effects of monthly high-dose IV pulse MTX in EF.
Design, Setting and Participants: For this prospective single-arm study, we recruited 12 
patients diagnosed with biopsy specimen-proven EF between 2006 and 2009 from the 
Department of Dermatology and Rheumatology at the Radboud University Medical Centre.
INTERVENTIONS: Intravenous MTX (4mg/kg) monthly for 5 months with folinic acid rescue 
24 hours after MTX administration
MAIN OUTCOMES AND MEASURES: The primary outcome was improvement of the 
modified skin score (mSS) at month 5 versus baseline. Secondary outcomes were durometry, 
range of motion (rom), visual analogue scale scores for disease activity and 36-item Short-
Form Survey health questionnaires.
RESULTS: Overall, 12 patients (11 women between 37-69 years old) received a median 
(range) monthly dose of 288 (230-336) MTX. Median (range) modified skin score improved 
from 17.5 (8.0-24.0) at baseline to 8.5 (1.0-20.0) at month 5 (P=0·001). Secondary outcome 
measures improved significantly, except for durometer scores and range of motion of the 
elbows. Adverse events included gastro-intestinal symptoms (n=9), mild stomatitis (n=5) and 
alopecia (n=4).
CONCLUSIONS AND RELEVANCE: High-dose IV pulse MTX is a safe and effective 
treatment option in EF.
TRIAL REGISTRATION: NCT00441961 (Clinicaltrials.gov)
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INTRODUCTION
Eosinophilic fasciitis (EF) is a rare connective tissue disorder of unknown etiopathogenesis. 
The disease is characterized by painful swelling and thickening of the skin and soft tissues 
of the extremities and less frequently the trunk.21 Invalidating joint contractures are often 
reported in EF.15 272 The diagnosis is established by histological examination of full thickness 
skin biopsy specimens containing subcutaneous fat and fascia.
Conventional treatment of EF consists of high-dose glucocorticoids combined with low-dose 
weekly methotrexate (MTX). However, disappointing results are described in a proportion 
of patients.14 185 200 272 Therefore, additional therapeutic options are necessary. We observed 
increased efficacy of MTX exceeding the conventional dosages (maximum 50mg/week) at 
our outpatient clinic. Irrespective of these increased beneficial effects, clinical results were still 
not satisfactory enough. By using high-dose MTX we expected to induce a more pronounced 
effect on the involved skin. Furthermore, we hypothesized that intravenous (IV) administration 
would lead to fewer adverse effects. In this prospective study, we analysed the safety and 
effect of monthly high-dose IV pulse MTX in patients with EF. 
METHODS
Patients and study design
Adult patients with biopsy proven progressive EF were recruited from the department of 
dermatology and rheumatology at the Radboud University Medical Centre between 2006 and 
2009. Both MTX naive and non-naive patients were eligible. A complete list of in- and exclusion 
criteria is displayed in supplemental table 1. The IV pulse MTX was administered in a dose 
of 4mg/kg IV every month for 5 months. Twenty-four hours after MTX administration, 5mg 
folinic acid was administered every 6 hours, to a maximum of 25mg for 1 day. The treatment 
regimen was based on an acute lymphoblastic leukaemia protocol from the department of 
haematology. Glucocorticoids (maximum 15mg/day), nonsteroidal anti-inflammatory drugs, 
analgesics and antiemetics were allowed throughout the study. Patients could receive an 
additional 3 consecutive monthly IV MTX doses, based upon the observation of a disease 
flare by the treating physician during follow-up without the study drug (glucocorticoids were 
continued during this follow-up). All patients gave their written consent. This study was 
registered (NCT00441961) and was approved by Radboud University Medical Centre local 
ethical board (NL13046.091.06). 
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Outcome measures
The primary outcome measure was the improvement in the modified skin score (mSS), 
according to Zachariae (Appendix A)125, at month 5 versus baseline. Additionally, skin hardness 
was measured by durometry (appendix 2).129 Joint contractures were monitored by measuring 
passive range of motion (RoM) of affected joints. Visual analogue scale (VAS) scores for 
disease activity were scored by the physician and patient. Lastly, study participants filled out 
36-Item Short-Form Survey (SF-36) health questionnaires. Safety laboratory investigations 
were performed and adverse events (AE) registered.
Statistical analysis
Descriptive statistics including median for continuous variables and percentages for categorical 
data were used. The Wilcoxon signed-rank test was performed to compare outcomes at 
baseline and month 5. The Mann-Whitney test was performed to compare outcomes between 
subgroups. A P-value ≤ 0·05 was regarded statistically significant. Statistical analyses were 
performed using SPSS v.22 (IBM, Armonk, NY, U.S.A.).
RESULTS
Demographics and disease characteristics
Twelve EF patients, 11 females, were enrolled. Baseline characteristics are shown in Table 
1. Six patients were MTX-naive and six patients had received glucorticoids and MTX weekly 
prior to study participation (treatment history details are displayed in supplemental table 2)
Effect of high-dose MTX on outcome measures
Patients received a median (range) monthly dose of 288 (230-336) mg MTX. The primary 
outcome measure, the median mSS (range), improved from 17.5 (8.0-24.0) at baseline to 8.5 
(1.0-20.00 at month 5 (P=0·001, figure 1a). No significant difference was observed between 
the ∆-mSS in MTX naïve patients and non-naive patients (p= 0.97, figure 1b). In addition, we 
observed no significant difference in ∆-mSS between the patients whom received concomitant 
glucocorticoids (n=8) and those who did not (n=4) (P=0.543). 
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Figure 1 The primary outcome measure, skin induration, scored with modified skin score (mSS) at 
baseline and at month 5 for each patient (a). Improvement in mSS at month 5 compared with baseline 
(Δ mSS); Δ mSS for MTX-naive (left column) and MTX non-naive (right column) are displayed by scatter 
plot and median. Comparison of median Δ mSS scores between the 2 subgroups showed no significant 
difference (P-value = .97) (b). For 2 patients (Nos. 6 and 8) mSS scores were missing at month 5 and 
observations from month 4 were carried forward.
In 1 patient (no. 5), a temporary dose increase in glucocorticoids (to 30mg), was required due 
to the severity of the disease. The median durometer score did not improve (table 2). The 
median VAS (range) for disease activity as judged by the physician decreased from 78 (60–90) 
to 47 (20-84) (P= 0.001). The median RoM of patients with affected wrists (n=9), ankles (n=11) 
and knees (n=9) improved significantly with 24°(P=0.004), 16° (P=0.01) and 35°  (P=0.02), 
respectively (Table 2). The RoM of affected elbows did not improve (2·2° increase=0.686). 
Individual RoM measures are displayed in figure 2.
Additionally, we observed a significant improvement in the domain (range) of physical 
functioning in the SF-36 (27.5 (5.0–65.0) to 47.5 (10.0–90.0) (P=0.01). The VAS (range) for 
disease activity as judged by the patient decreased from 69 (40–90) to 49 (5–81) (P= 0·001).
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 Outcome measure* Participants
Affected, No.
Median (range) P Value
Baseline Month 5
Modified skin score 12 17.5 (8.0-24.0) 8.5 (1.0-20.0) 0.001
Durometer score 12 44.0 (17.0-62.5) 44 (26.8-62.0) 0.58
Range of motion, degrees
Elbows 6 135.5 (112.0-139.0) 137.5 (126.0-145.0) 0.69
Wrists 9 80.0 (45.0-105.0) 104.0 (54.0-121.0) 0.004
Knees 9 92.0 (65.0-122.0) 127.0 (82.0-152.0) 0.02
Ankles 11 29.0 (5.0-56.0) 45.0 (19.0-75.0) 0.01
VAS-Activity
Physician 12 78 (60-90) 47 (20-84) 0.001
Patient 12 69 (40-90) 49 (5-81) 0.001
Table 2 Modified skin score (mSS) and secondary outcome measures at baseline and month 5.
Effect of second high-dose MTX treatment episode
In 6 patients, EF flared 2 to 5 months after completion of the primary treatment cycle. In 
these 6 patients, the treating physicians decided to restart treatment with 3 consecutive doses 
of IV pulsed MTX and all 6 patients responded favourable again to the IV pulse MTX. The 
remaining 6 patients were not eligible for a second treatment cycle: in 2 patients, no disease 
progression was observed, another patient was regarded non-responder and 2 patients 
preferred to be treated conventionally with weekly low-dose MTX consecutive to the primary 
treatment episode. Lastly, despite a favourable response, one patient was withdrawn from the 
study, because of adverse effects.
Safety
No serious AEs were reported during the study. However, 1 patient was withdrawn from the 
study due to elevated liver enzymes (alanine aminotransferase > 2 times upper limit of normal). 
These enzymes normalized after study withdrawal. Nausea was reported in the majority of 
the patients (n=9 [75%]). This was manageable with antiemetics in most patients, except for 
1 patient; a 1-time dose reduction (to 3mg/kg) was required to reduce nausea symptoms. 
Additional reported adverse effects were mild stomatitis (n=5) and alopecia (n=4). 
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Figure 2 Range of Motion (RoM), of affected joints, for individual patients at baseline and month 5 for the 
elbows (n=6) (a), wrists (n=9) (b), knees (n=9) (c), and ankles (n=11) (d). RoM of an affected joint was 
calculated by the mean of the left and right joint, if both joints were affected. For one patient (no. 10), the 
RoM measurements for the affected elbows and knees were missing; only restrictions were documented, 
not the complete range of motion. This patient is not included in the figure. Ns=not significant, *=p≤0·05.
DISCUSSION
In this study, we present high-dose IV pulse MTX as a safe and effective treatment option in 
EF. The mSS decreased significantly. In contrast, durometer scores did not improve. This is 
probably owing to the fact that skin hardness in EF is often present on skin overlying bony 
surfaces, such as the shins and lower arms. These locations are known, from localized 
scleroderma studies, to be less suitable for durometry.124 129 The improvements in RoM we 
presented are clinically relevant, because patients report a significant increase in physical 
functioning, measured by the SF-36.
Regarding safety, we observed no serious adverse events and the treatment was relatively 
well tolerated. Observed adverse events, such as gastro-intestinal symptoms and stomatitis 
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could be managed accordingly. Interestingly, IV pulse MTX was effective in a subgroup 
of patients in whom disease progressed during conventional treatment. These results 
implicate that pulsed IV MTX might be an alternative treatment option in patients who fail 
on conventional treatment. Alternative treatments to weekly MTX have only been reported 
in case reports.14 151 205 210 272-275 Comparing results of this study to observational studies with 
MTX in EF is difficult, as these studies are retrospective and only report partial and complete 
remission rates, without specifying outcomes in different disease parameters.14 185 200 272 
Some study specific limitations including the variability in treatment history and the variability 
in concomitant glucocorticoids prescription might have influenced results. In addition, the 
lack of validated outcome measures for EF complicates the interpretation of the results. 
However, despite these limitations, this study provides evidence for an alternative treatment 
in EF.
CONCLUSION
High-dose monthly IV MTX is a safe and effective treatment option in patients with EF.
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SUPPLEMENTAL TABLE
Inclusion 
criteria
By clinical judgement of an expert defined Eosinophilic Fasciitis
Full thickness skin biopsy compatible with Eosinophilic Fasciitis
Treatment naïve or non-naive
Signed informed consent
Exclusion 
criteria
Age ≤17 or ≥76 years
Laboratory 
results
AST/ALT level >2 times upper limit of normal
WBC count <3·5 x 109/l
Platelet count <150 x 109/l
Serum Creatinine > 130 µmol/l or clearance <50 ml/min
Chronic liver disease, insulin dependent diabetes mellitus, alcohol abuse
Restrictive pulmonary disease (total lung capacity or vital capacity < 40% of predicted) or 
interstitial lung disease (KCO < 60% of predicted)
Pregnancy or child bearing potential without adequate contraception
Presence of any serious comorbidity or malignancy
Use of other anti-folate drugs than methotrexate
Supplemental Table 1 In- and exclusion criteria for study participation.
# MTX Dose(mg)
Glucocorticoids
Max dose
(mg)
Start
1 300 10 Study start
2 296
3 300 10 Study start
4 250
5 252 30 Continuation
6 230 10 Continuation
7 330
8 316 15 Continuation
9 260
10 335 10 Continuation
11 280
12 260 15 Continuation
Supplemental Table 2 Treatment characteristics of study participants. MTX dosage was based on 4mg/
kg. 7 patients received glucocorticoids throughout the study: in 2 patients glucocorticoids were started at 
study initiation, in the remaining 5 patients it was continued in the same dose as was started previous to 
study participation.
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APPENDICES
Appendix 1: modified Skin Score (mSS), according to Zachariae 125 
The mSS is a clinical score in which the body is divided into seven regions (R): Head and 
neck region, trunk, arms, hands, fingers, legs and feet. The degree of thickening and pliability 
(T) is assessed on a 0 to 3 scale: 0, normal skin; 1, thickened skin; 2, decreased ability to 
pinch or move skin; 3. Skin that is unable to be pinched or moved (hide-bound). The most 
affected part of the region determines the score. In addition, involvement in each area (A) 
was determined by estimation and given the following score: 0, no involvement; 1, less than 
33%; 2, 33% to 67%; and 3, more than 67%. The sum of the numerical units for thickening 
and the percentage of area surface involved is the mSS. Thus, the MSS is ∑(T+A) R1-R7. The 
possible minimum score is 0, representing no affected skin, and the maximum score is 42, for 
extreme involvement in all areas.
Appendix 2: Durometer scores
The hardness of the lesions was examined by means of a handheld durometer (model 1600-
OO; Rex Gauge Co., Glenview.) with an affixed weight of approximately 400 gm. In this way 
measurements were carried out with a constant weight that did not allow additional pressure. 
The durometer is fitted with a calibrated gauge that registers linearly divided units on a scale 
from 0 to 100. Three consecutive readings were taken at the same site while the patients 
were lying flat, and contraction and muscle tension were avoided by putting a pillow under 
the extremities. The total durometer score of a site is the sum of the means of the three 
determinations at that site. The total score for a patient is the mean score of all localisations.
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REGARDING, TRANSCRIPTIONAL AND 
CYTOKINE PROFILES IDENTIFY CXCL9 AS 
A BIOMARKER OF DISEASE ACTIVITY IN 
MORPHEA
J.S. Mertens, M.D.1,2,3; E.M.G.J. de Jong, M.D., PhD3,4; A. Pandit, PhD1,2; M.M.B. Seyger M.D., 
PhD3; E.P.A.H. Hoppenreijs, M.D.5; R.M. Thurlings, M.D., PhD6; M.C. Vonk, M.D. PhD6; J. 
Wienke, M.D.2; F. van Wijk, PhD2; A. van Royen-Kerkhof, M.D., PhD7; W. Marut, PhD.1,2*; 
T.R.D. Radstake, M.D. PhD1,2*.
* These authors contributed equally
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2 Laboratory of Translational Immunology, University Medical Centre Utrecht, Utrecht, The Netherlands.
3 Department of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
4 Radboud University, Nijmegen, The Netherlands
5 Department of Paediatric Rheumatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
6 Department of Rheumatology, Radboud University Medical Centre, Nijmegen, The Netherlands
7 Department of Paediatric Rheumatology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Adopted from:
J Invest Dermatol. 2017 Dec. pii: S0022-202X(17)33265-7.doi: 10.1016/j.jid.2017.11.032. 
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ABSTRACT
A recent study by O’Brien et al. reported that CXCL9 and CXCL10 are present at increased 
concentrations in serum from localized scleroderma (LoS) patients and that CXCL9, but 
not CXCL10, serum concentrations correlate with measures for disease activity.230 In this 
study, we confirm increased CXCL9 and CXCL10 serum concentrations in a cohort of 80 
LoS patients. However, in contrast to O’Brien et al. we report similar correlations between 
measures for disease activity and both CXCL9 and CXCL10 serum concentrations. This 
observation suggests equal biomarker capabilities for both chemokines. In addition, high-
throughput transcriptome sequencing of LoS skin samples demonstrated increased gene 
expression of both CXCL9 and CXCL10 in LoS skin. Lastly, we did not observe altered CXCL9 
and CXCL10 gene expression in circulating monocytes, supporting the theory postulated by 
O’Brien et al., that LoS may result from skin-directed immune dysregulation rather than a 
systemic dysregulation as in SSc
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INTRODUCTION
Localized Scleroderma (LoS), also known as morphea, encompasses a group of idiopathic 
skin conditions which are characterized by development of cutaneous and subcutaneous 
fibrosis. Early clinical manifestations are characterized by the presence of inflammation and 
the expansion of sclerotic lesions. The goal/aim of anti-inflammatory treatment is to hamper 
disease progression and prevent irreversible sequalae, such as cutaneous and subcutaneous 
atrophy, to develop. Early and accurate disease activity assessment is vital for prompt 
treatment initiation. However, currently available clinical scoring tools and imaging modalities 
fail to accurately assess disease activity in large proportions of patients. Specifically, deep 
involvement is notoriously difficult to monitor, but has great/tremendous potential to lead to 
debilitating sequelae, such as severe atrophy of affected limbs. The lack of available tools 
underscores the need for biomarkers of disease activity in LoS. Identification of additional 
tools to determine disease activity should ultimately aid caregivers to individualize and 
optimize treatment regiments. 
Inflammation, and accompanying angiogenesis, are regarded the earliest pathophysiological 
mechanisms responsible for the progression of the disease. 46-48 Therefore, we aimed to 
investigate serum concentrations of cytokines and chemokines involved in angiogenesis and 
inflammation/these processes in LoS and investigate their potential as biomarker of disease 
activity in LoS.
MATERIAL, METHODS & RESULTS
In total, serum from 80 patients and 23 age- and gender matched healthy controls (HC) were 
included for the analyses of CXCL9 and CXCL10 levels. Cohort details are displayed in Table 
1. Median modified Localized Scleroderma Skin Severity Index (mLoSSI)117 was 13 (Inter 
Quartile Range 6-25) and median Localized Scleroderma Damage Index (LoSDI)118 was 7 
(IQR 4-15). Over two-thirds of the patients (n=51, 64%) were treatment naïve at inclusion. The 
majority of the remaining patients (n=29, 36%) received methotrexate with or without systemic 
corticosteroids. 
CXCL9 and CXCL10 serum concentrations were determined via Enzyme-Linked Immuno 
Sorbent Assay (Human CXCL9/MIG Quantikine ELISA Kit, R&D Systems) and Luminex assay 
(supplemental material), respectively. Cytokine values below the lower limit of detection were 
set to half of the lower limit of detection for analysis. Median values for CXCL9 were substantially 
higher in LoS patients (57.81 pg/ml, IQR 15.63-232.2 pg/ml), compared to controls where 
CXCL9 levels were below threshold of detection in 22 out of 23 individuals (median CXCL9
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ELISA & Luminex Monocyte Gene 
Expression
Skin Transcriptome 
Sequencing
LoS HC LoS HC LoS HC
Number 80 23 45 25 8 5
Age, Median (IQR) 45 22-59 41 27-56 53 33-65 43 27-56 65 45-68 47 36-54
Sex, No. (%)
Female 47 59% 18 78% 29 64% 20 80% 3 37.5% 5 100%
Male 33 41% 5 22% 16 36% 5 20% 5 62.5% 0 0%
Subtype
Circumscribed 8 10% n/a n/a 6 45% n/a n/a 4 50% n/a n/a
Linear 30 38% n/a n/a 16 13% n/a n/a 2 25% n/a n/a
Deep 5 6% n/a n/a 2 36% n/a n/a 0 0% n/a n/a
Generalized 16 20% n/a n/a 12 27% n/a n/a 2 25% n/a n/a
Eosinophilic Fasciitis 21 26% n/a n/a 9 20% n/a n/a 0 0% n/a n/a
Disease Onset, No. (%)
Adult onset 64 80% n/a n/a 45 100% n/a n/a 8 100% n/a n/a
Paediatric onset 16 20% n/a n/a 0 0% n/a n/a 0 0% n/a n/a
Clinical Scores, Median (IQR)
mLoSSI 13 6-25 n/a n/a 15 8-26 n/a n/a 17 14-24 n/a n/a
LoSDI 7 4-15 n/a n/a 8 5-15 n/a n/a 8 5-14 n/a n/a
PGA-A 16 4-36 n/a n/a 20 13-40 n/a n/a 29 17-40 n/a n/a
PGA-D 17 8-30 n/a n/a 17 8-27 n/a n/a 18 8-23 n/a n/a
Treatment, No. (%)
Naive 51 64% 23 100% 30 67% 25 100% 8 100% 5 100%
Methotrexate 20 25% n/a n/a 11 24% n/a n/a 0 0% n/a n/a
Systemic Corticosteroids 13 16% n/a n/a 6 13% n/a n/a 0 0% n/a n/a
Miscellaneous 3 4% n/a n/a 2 4% n/a n/a 0 0% n/a n/a
Table 1 Participant demographics and characteristics.
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15.63 pg/ml, IQR 15.63-15.63 pg/ml, P<0.0001, Figure 1a). Median CXCL10 concentrations 
were also elevated in LoS patients (424.2 pg/ml, IQR 245.0-74.3 pg/ml) versus controls (153.3 
pg/ml, IQR 110.2-223.8 pg/ml, P<0.0001, Figure 1b). CXCL9 serum concentrations strongly 
correlated with CXCL10 serum concentrations (Spearman’s rho (rs)=0.715, P<0.0001). Both 
CXCL9 and CXCL10 concentrations significantly correlated with the mLoSSI (CXCL 9: rs= 
0.4904, P<0.0001, Figure 1c, CXCL10: rs= 0.4065, p=0.0006 Figure 1d), but not with LoSDI 
(rs= 0.0443, P=0.710, rs= 0.09, P=0.449). Next, normal ranges of both chemokine serum 
concentrations were defined as mean plus two standard deviations observed in controls and 
patients with concentrations above the normal range were termed ‘positive’. The proportion 
of positive patients was investigated in patients with active (mLoSSI>5, n=65) and inactive 
(mLoSSI≤4, n=28) disease. The proportion of CXCL9 and CXCL10 positive patients were 
both increased at active disease (55% and 52%, respectively), compared to the proportions at 
inactive disease (21% and 24%, respectively) (Figure 1e and 1f). Lastly, longitudinal serum 
samples were available for 18 patients and showed significantly lower values for both CXCL9 
(P=0.0007, Figure 1g) and CXCL10 (P=0.0001, Figure 1f) at inactive disease, compared to 
the serum concentration at disease onset, underscoring the relevance of these markers in 
measuring disease activity. 
To assess tissue expression of CXCL9 and CXCL10, high-throughput sequencing was 
performed on RNA collected from skin samples of 8 LoS patients and 5 controls (supplemental 
material). In LoS patients, skin biopsies were taken from: the inflammatory border (I) and the 
sclerotic centre (II) of affected skin and from unaffected skin (III) (Figure 2a). CXCL9 and 
CXCL10 gene expression was significantly increased at the inflammatory border, and to a 
lesser extent at the sclerotic centre of affected tissue when compared to healthy controls, 
whereas unaffected tissue from LoS patients did not show any differences in gene expression 
for both the genes (Figure 2b and 2C). Further investigation revealed very strong correlation 
between CXCL9 and CXCL10 gene expression (rs=0.902, P<0.0001, Figure 2d). Lastly, both 
CXCL9 and CXCL10 gene expression strongly correlated with CD68 expression (Figure 2e 
and 2f) suggestion the involvement of myeloid cells in the high expression of these chemokines.
Next, we investigated CXCL9 and CXCL10 gene expression in monocytes from the circulation 
of 45 adult LoS patients and 25 controls. For this purpose, peripheral blood mononuclear cells 
(PBMCs) were isolated from whole blood using ficoll separation.276 Subsequently, monocytes, 
among other cell subsets, were isolated by positive selection from freshly isolated PBMCs 
using immunomagnetic labelling (CD14 MicroBead kits, Miltenyi Biotec) and cells were lysed 
consecutively. RNA was isolated and used for Real-Time PCR (supplemental material). In 
monocytes, CXCL9 and CXCL10 gene expression did not significantly differ between patients 
and controls (CXCL9 median fold change=1.12, P=0.513, CXCL10 median fold change 
=0.884, P=0.778).
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Figure 1 Serum concentration of CXCL9 (a) and CXCL10 (b). Spearman’s rank correlation coefficient 
(rs) between modified Localized Scleroderma Severity Index (mLoSSI) and CXCL9 (c) and CXCL10 (d). 
Proportion of patients with elevated CXCL9 (e) and CXCL10 (f) levels in active and inactive disease. 
Longitudinal serum CXCL9 (g) and CXCL10 (h) concentrations during active and inactive disease. 
mLoSSI, modified Localized Scleroderma Skin Severity Index.
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DISCUSSION
Our study confirms increased concentrations of CXCL9 and CXCL10 in LoS serum and 
correlation of CXCL9 to mLoSSI, a validated measure for disease activity. In addition to that, 
we also observe correlation between CXCL10 and mLoSSI. Our analysis demonstrates no 
relations between the presence of disease damage, captured by the LoSDI score, and both 
CXCL9 and CXCL10. Torok et al. reported a similar correlation (rs=0.34) between CXCL10 
and mLoSSI and no significant correlation between CXCL10 and LoSDI scores in cohort 
of 69 paediatric LoS patients.66 The strong correlation between CXCL9 and CXCL10 serum 
concentrations combined with the similar trends in correlations between clinical measures and 
both chemokines, suggest equal biomarker capabilities for both CXCL9 and CXCL10.
Furthermore, we demonstrate increased CXCL9 and CXCL10 gene expression at both 
the inflammatory border and the sclerotic centre of affected LoS tissue, with normal gene 
expression at unaffected tissue of LoS patients. A strong correlation between CD68 and 
CXCL9 and CXCL10 gene expression together with the lack of an association between 
circulating monocytes and these chemokines not only suggests a relationship between the 
presence of local macrophages and CXCL9/CXCL10 production, it also underscores that LoS 
is a disease confined to the skin where inflammatory markers are measured in the circulation 
as the result from “leakage” from the inflammatory sites. 
CONCLUSION
We confirm the potential of CXCL9 as biomarker for disease activity in LoS. Interestingly, 
CXCL10 serum concentrations showed similar biomarker capabilities. Lastly, increased 
CXCL9 and CXCL10 gene expression in LoS skin, and absence of increased gene expression 
in monocytes, supports the hypothesis, postulated by O’Brien et al., that LoS may result from 
skin-directed immune dysregulation rather than the systemic presence of inflammation on 
contrast to that observed in SSc.
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SUPPLEMENTAL MATERIAL AND METHODS
Serum collection and storage and cytokine measurements
Blood was collected in a Vacutainer® SST II tube (BD Vacutainer) and serum was isolated 
after centrifugation at 1500g for 10 min at room temperature and stored at -80oC prior to use. 
CXCL9 serum concentrations were determined via Enzyme-Linked Immuno Sorbent Assay 
(Human CXCL9/MIG Quantikine ELISA Kit, R&D Systems). CXCL10 Luminex measurements 
were performed using an in-house developed and validated (ISO9001 certified) multiplex 
immunoassay (Laboratory of Translational Immunology, University Medical Centre Utrecht) 
based on Luminex technology (xMAP, Luminex Austin TX USA). The assay was performed 
as described previously.277 A-specific heterophilic immunoglobulins were preabsorbed from 
all samples with heteroblock (Omega Biologicals, Bozeman MT, USA). Acquisition was 
performed with the Biorad FlexMAP3D (Biorad laboratories, Hercules USA) in combination 
with xPONENT software version 4.2 (Luminex). Data was analysed by 5-parametric curve 
fitting using Bio-Plex Manager software, version 6.1.1 (Biorad). Cytokine values below the 
lower limit of detection were set to half of the lower limit of detection for analysis.
Skin biopsy storage, RNA isolation and High-Throughput Sequencing
Samples were fresh frozen in Tissue-Tek®. For RNA extraction, 30x20µm cryotomes cut and 
RNA was extracted via an AllPrep Universal kit (Qiagen). High throughout sequencing (HTS) 
was performed at GenomeScan B.V., Plesmanlaan 1d, 2333 BZ, Leiden, The Netherlands. 
The NEBNext Ultra Directional RNA Library Prep Kit for Illumina was used to process the 
samples. The sample preparation was performed according to the protocol “NEBNext Ultra 
Directional RNA Library Prep Kit for Illumina”(NEB #E7 420S/L). Briefly, mRNA was isolated 
from total RNA using the oligo-dT magnetic beads. After fragmentation of the mRNA, a CDNA 
synthesis was performed. This was used for ligation with the sequencing adapters and PCR 
amplification of the resulting product. The quality and yield after sample preparation was 
measured with a fragment analyser. Next, clustering and DNA sequencing using the Illumina 
cBot and HiSeq 4000 was performed according to the manufacturer’s protocols. Concentration 
of 3.0 nM of DNA was used. HiSeq control software HCS v3.4.0 was used. Image analysis, 
base calling, and adapter and primer trimming were performed with the Illumina data analysis 
pipeline TA v2.7.7. 
The HTS provided us with approximately 20 million 150 bp paired-ended reads for each 
sample. The sample qualities were assessed by FastQC and the sequencing reads were 
aligned to human genome (GRCh38 build 79) using STAR aligner. (2, 3, 4) Gene expression 
data for the annotated genes was generated using HTSeq-count. (5) Since the isolation and 
library preparation of the samples were performed in two different batches, this resulted in 
a batch effect. The batch effect was corrected using R package Ruse. (6) The variance-
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stabilizing transformation normalized expression values (normalized read counts or NRC) for 
the genes were calculated using R package DESeq2. (7)
Monocyte Isolation and gene expression
For monocyte isolation, 7 lithium-heparin tubes were collected and peripheral blood 
mononuclear cells (PBMCs) were isolated using Ficoll gradient centrifugation as previously 
described.276 Thereafter, the isolation of monocytes, among other cell subsets, was performed 
by magnetic bead isolation (MACS) using the Monocyte (CD14) positive selection kit 
according to the manufacturer’s protocol (Miltenyi Biotec, Auburn, CA). Purity of the monocyte 
population was investigated using flow cytometry. Monocytes were lysed and used for total 
RNA extraction by AllPrep Universal kits (Qiagen). Total RNA was converted to cDNA using 
Iscript cDNA Synthesis Kits (Bio-Rad). Primers were designed for CXCL9 and CXCL10 and 
GUSB was used as a housekeeping gene (HKG). Real time PCR (RT-PCR) was run using 
Bio-Rad SYBER Green assays and a Quantstudio 12 K Flex Real-Time PCR system was 
used to run the PCR. Cycle threshold (Ct) values were obtained from the RT-PCR. Delta 
Ct (∆Ct)-values for CXCL9 and CXCL10 genes were calculated against the HKG (Cttarget-
CTHKG=∆Ct). Delta delta Ct (∆∆Ct) for each sample were calculated to the median ΔCt of the 
control samples (ΔΔCt =ΔCtsample – ΔCtcontrol median). Fold Changes were calculated for each 
sample by log2 transformation of the ∆∆Ct (FC = 2–ΔΔCt) and median FCs were compared 
between morphea and controls.
Statistical Analysis
Descriptive statistics including median (interquartile range) for continuous variables and 
percentages for categorical data were used. The Mann–Whitney test was used to compare 
continuous variables between patients and controls. The Wilcoxon signed-rank test was 
performed to compare longitudinal serum concentration measures of morphea patients. 
Spearman’s rank correlation coefficient (rs) was used to explore correlations among different 
cytokines, cytokines and clinical outcome measures and between tissue expression of 
different genes. Correlations were reported by Spearman’s rho (rs) and p-values. A p-value 
of 0.05 or less was regarded statistically significant. Statistical analyses were performed with 
SPSS software, version 24 (IBM Corp., Armonk, NY).
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ABSTRACT
BACKGROUND: Localized Scleroderma (LoS) encompasses a group of idiopathic skin 
conditions characterized by (sub)cutaneous inflammation and subsequent development 
of fibrosis. Currently, lack of accurate tools enabling disease activity assessment leads to 
suboptimal treatment approaches.
OBJECTIVE: To investigate serum concentrations of cytokines and chemokines implicated in 
inflammation and angiogenesis in LoS and explore their potential to be utilized as biomarker of 
disease activity. Additionally, to investigate the implication of potential biomarkers in disease 
pathogenesis. 
METHODS: A 39-plex Luminex immuno-assay was performed in serum samples of 74 LoS 
and 22 Healthy Controls. The relation between a validated clinical measure of disease activity 
(mLoSSI) and serum analytes was investigated. Additionally, gene and protein expression 
were investigated in circulating cells and skin biopsies.
RESULTS: From the total of 39, 10 analytes (CCL18, CXCL9, CXCL10, CXCL13, TNFRII, 
Galectin-9, TIE-1, sVCAM, IL-18, CCL19) were elevated in LoS serum. Cluster analysis of 
serum samples revealed CCL18 as most important analyte to discriminate between active 
and inactive disease. At individual patient level, CCL18 serum levels correlated strongest with 
mLoSSI-scores (rs= 0.4604, P <0.0001) and in longitudinal measures CCL18 concentrations 
normalized with declining disease activity upon treatment initiation. Additionally, CCL18 was 
elevated in LoS serum, and not in (juvenile) dermatomyositis or spinal muscular atrophy. 
Importantly, CCL18 gene and protein expression was increased at the inflammatory border 
of cutaneous LoS lesions, with normal expression in unaffected skin and circulating immune 
cells.
CONCLUSION: CCL18 is specific for disease activity in LoS thereby providing relevance as 
a biomarker for this debilitating disease. 
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INTRODUCTION
Localized Scleroderma (LoS), also known as morphea, encompasses a group of idiopathic 
skin conditions which are characterized by development of cutaneous and subcutaneous 
fibrosis. Early clinical manifestations are characterized by the presence of inflammation and 
the expansion of sclerotic lesions.48 227 The goal of anti-inflammatory treatment is to slow 
down disease progression and prevent the development of irreversible sequalae, such as 
cutaneous and subcutaneous atrophy. Early and accurate disease activity assessment is 
vital for prompt treatment initiation. However, currently available clinical scoring tools and 
imaging modalities fail to accurately assess disease activity in large proportions of patients. 
Specifically, deep involvement is notoriously difficult to monitor and most likely leads to 
debilitating sequelae, such as contractures, immobility of joints and severe atrophy of affected 
limbs.5 278 The lack of available tools underscores the need for biomarkers of disease activity 
in LoS. Ultimately, identification of additional tools to determine disease activity should aid 
caregivers to individualize and optimize treatment regimen. 
The exact driving mechanisms behind LoS pathogenesis remain to be elucidated. However, 
extensive extracellular matrix formation and autoimmune dysfunction are thought to be key 
pathogenic processes.46-48 Likewise, these mechanisms are considered crucial in systemic 
sclerosis (SSc) pathogenesis. The similarities between LoS and SSc have led to many theories 
about their relatedness and most theories for LoS pathogenesis are therefore deduced from 
SSc research.230 In SSc, endothelial dysfunction and immune dysregulation have been shown 
to precede collagen deposition.49 50 We therefore questioned whether signals in inflammation 
and angiogenesis could be regarded early pathophysiological mechanisms responsible for 
progression of the disease. Here, we investigated serum concentrations of cytokines and 
chemokines involved in angiogenesis and inflammation in LoS and investigate their potential 
as biomarker of disease activity in LoS. 
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MATERIAL AND METHODS
Participants/Patients
Eligible patients were ≥4 years old and visited the outpatient clinics of dermatology or 
rheumatology of the University Medical Centre (UMC) Utrecht or Radboud UMC, Nijmegen, 
The Netherlands. All patients or legal guardians signed informed consent previous to study 
participation. The study was conducted in accordance with principles of the Declaration of 
Helsinki and approved by the Institutional Review Board of the UMC Utrecht (NL13046.091.06). 
Disease/Subtype classification & clinical assessments
Patients were classified as described by Laxer and Zulian22, with the addition of eosinophilic 
fasciitis (EF) as a distinct subtype. Diagnosis of EF was established by clinical picture of 
fascia involvement and demonstration of eosinophils at the fascia in histological investigation 
of deep skin biopsies.
At study visit, information regarding demographics and disease history were collected. Extent 
of skin involvement was assessed by the Localized Scleroderma Cutaneous Assessment 
Tool (LoSCAT). LoSCAT is a composite of the modified Localized Scleroderma Skin Severity 
Index117 (mLoSSI), capturing disease activity features, and Localized Scleroderma Skin 
Damage Index118 (LoSDI), capturing disease damage features.
For control groups, patients affected by (juvenile) dermatom
yositis (J)DM)) and spinal muscular atrophy (SMA), and healthy controls (HCs) were included. 
Patients with DM were included if they met the Bohan and Peter criteria for definite or probable 
JDM. 279 Paediatric and adult patients with SMA were diagnosed by genetic confirmation of a 
homozygous loss of function of the survival motor neuron 1 gene. 280 Adult healthy volunteers 
were included as healthy controls.
Serum collection, storage and cytokine measurements
Blood was collected in a Vacutainer® SST II tube (BD catalogue no. 367985) and serum was 
isolated after centrifugation at 1500g for 10 min at room temperature and stored at -80oC prior 
to use. Serum concentrations were evaluated for 39 chemokines and cytokines implicated 
in angiogenesis and inflammation via Luminex (Details in supplemental Material and 
Methods). 
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Peripheral Mononuclear Blood Cells (PBMCs) isolation
Lithium-heparin (BD catalogue no. 367880) tubes were collected and PBMCs were isolated by 
density-gradient centrifugation using Ficoll-Paque.276 Isolated PBMCs were lysed (RLT-PLUS) 
and stored at -30oC prior to use. 
Gene expression in circulating immune cells
Detailed description in supplemental Material and Methods.
Skin samples
For selected adult patients, three skin biopsies were taken from: the inflammatory border (I) 
and the sclerotic centre (II) of affected skin and from unaffected skin (III). In addition, control 
samples were acquired from abdominal corrective surgery leftover material. Skin samples 
were fresh frozen in Tissue Tec OCT compound (Miles Scientific, Naperville, USA) at -80oC 
prior to use.  
Gene expression in skin samples
Detailed description in supplemental Material and Methods.
Immunohistochemistry of skin samples 
Detailed description in supplemental Material and Methods.
Statistical Analyses
Descriptive statistics including medians [interquartile range (IQR)] for continuous variables and 
percentages for categorical data were used. The Mann–Whitney test was used to compare 
continuous variables between patients and controls. Log-transformed cytokine values were 
subjected to unsupervised hierarchical clustering (Euclidian distance measure and the Ward’s 
linkage method). A partial least squared – discriminant analysis (PLS-DA) was performed to 
investigate clustering of active (mLoSSI>5) and inactive (mLoSSI≤5) samples. In addition, 
importance of analytes (‘loadings’) for the visualized clustering was depicted in a loadings-
plot and quantified in a variable importance on projection (VIP)-score. Clustering analyses 
were performed in the ClustVis server (http://biit.cs.ut.ee/clustvis/) or the MetaboAnalyst 
server (http://biit.cs.ut.ee/clustvis). The performance of analytes as biomarkers to detect 
the disease activity was assessed by receiver operating characteristics (ROC) curves and 
reported as Areas Under the Curves (AUC) with 95% confidence interval and P-values. Ideal 
cut-off concentration to discriminate between active and inactive disease was calculated 
by Youden’s Index. Additionally, cut-off concentrations were defined as above 2 standard 
deviations of the mean serum concentrations of HCs for every analyte and frequency of 
elevated concentrations were calculated. Spearman’s rank correlation coefficient was used to 
explore relations among different cytokines or chemokines, and cytokines or chemokines and 
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clinical outcome measures. Correlations were reported by Spearman’s rho (rs) and p-values. 
The Wilcoxon signed-rank test was performed to compare longitudinal serum concentration 
measures. The Kruskal-Wallis with Dunn’s multiple comparisons post-hoc test was performed 
when comparing continuous variables between 3 or more groups. A raw p-value of 0.05 or 
less was regarded statistically significant. For the Luminex assay, a Bonferroni correction (P= 
0.0017) was assessed to account for multiple comparisons (39) within assay. All analyses 
were performed using GraphPad Prism 7.0 (GraphPad Software, Inc., La Jolla, CA) and 
SPSS Statistics v.25 (IBM, Armonk, NY, U.S.A.). 
RESULTS
Demographics and clinical information
For this study, 74 unique LoS patients and 22 healthy controls (HCs) were included. The 
vast majority (80%, n=59) had adult-onset disease and the median age at study participation 
was 45 years [IQR, 23-60](Table 1). Over half of the patients were female (n=43, 58%). The 
majority of patients were affected by the linear (n=27, 36%), EF (n=20, 27%) or generalized 
subtype (n=15, 20%). The median mLoSSI and LoSDI were 13 [IQR, 6-23] and 7 [IQR, 4-15], 
respectively. At inclusion, 47 patients (63%) were systemic treatment naïve. The remaining 
patients received a combination of MTX and SCS (n=7, 9%), MTX monotherapy (n=12, 16%), 
SCS monotherapy (n=6, 8%) or a miscellaneous treatment (n=2, 3%). Longitudinal serum 
samples were collected for 19 patients. All 74 patients, plus the longitudinal samples (n=19), 
were used for the Luminex immunoassay. Additional experiments, such as gene expression 
investigation in circulating immune cells and skin samples or immunohistochemistry staining 
were performed in selected groups of patients from the Luminex cohort (Sample overview: 
Supplemental Figure 1). Supplemental Table 1 contains a detailed description of the 
different groups of patients included for every experiment.
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Biological Group HC LoS
No. 22 74
Age, Median [IQR] 43 [27-56] 45 [23-60]
Sex, No. (%)
Female 18 (82%) 43 (58%)
Male 4 (18%) 31 (42%)
Subtype
Circum. Sup. n/a 8 (11%)
Linear n/a 27 (36%)
Deep n/a 4 (5%)
Generalized n/a 15 (20%)
Eosinophilic Fasciitis n/a 20 (27%)
Disease Onset, No. (%)
Adult-Onset n/a 59 (80%)
Paediatric-Onset n/a 15 (20%)
Clinical Scores, Median [IQR]
Disease Activity
mLoSSI n/a 13 [6-23]
PGA-A n/a 16 [3-32]
Disease Damage
LoSDI n/a 7 [4-15]
PGA-D n/a 17 [8-29]
Treatment, No. (%)
Naïve 22 (100%) 47 (63%)
MTX and SCS n/a 7 (9%)
MTX monotherapy n/a 12 (16%)
SCS monotherapy n/a 6 (8%)
Miscellaneous n/a 2 (3%)
Antinuclear Antibodies n/a 23 (43%)*
Table 1 Cohort characteristics. 
HC, Healthy Control; LoS, Localized Scleroderma; Circum. Sup., Circumscribed Superficial Subtype; 
mLoSSI, modified Localized Scleroderma Skin Severity Index; LoSDI, Localized Scleroderma Damage 
Index; PGA-A, Physician’s Global Assessment of disease activity; PGA-D, Physician’s Global Assessment 
of disease damage; MTX, Methotrexate; SCS, Systemic Corticosteroids. 
*Antinuclear Antibody test results were available for 54 patients.
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Identification of elevated cytokines and chemokines in localized scleroderma
The following cytokines and chemokines, implicated in angionesis and inflammation, were 
investigated in serum by Luminex Immunoassay: IL-18, TWEAK, OSM, CCL2, CCL4, CCL17, 
CCL18, CCL19, CCL22, CCL27, CXCL9, CXCL10, CXCL13, VEGF, TNFRII, SPARC, 
sVEGFR-1, PIGF, Gal-1, Gal-3, Gal-9, sP-selectin, sE-selectin, Thrombomodulin, Endoglin, 
OSF-2, Angiopoietin-1, Angiopoietin-2, TIE-1, TIE-2, PDGFBB, YKL-40, PAI-1, sICAM-1, 
sVCAM, C5a, Fetuin, Fibronectin and THBS-1. 
Median serum concentrations were calculated for LoS (n=74) and HCs (N=22) and the 
following analytes were significantly elevated in LoS: CCL18, CXCL9, CXCL10, CXCL13, 
TNFRII, Galectin-9, TIE-1, sVCAM, IL-18, CCL19, sICAM, and YKL-40 (Table 2, individual 
plots Supplemental Figure 1). Ten out of 12 analytes remained significantly elevated after 
Bonferroni correction for 39 comparisons and were further investigated for biomarker potential. 
Median serum concentrations for all 39 analytes are depicted in Supplemental Table 2.
Analyte Unit
Healthy Control, N=22 Localized Scleroderma, N=74
P-value
Median IQR Median IQR
CCL18 pg/ml 7 158 2 772-14 069 20 902 8 497-32 040 <0.0001*
CXCL9 pg/ml 15.63 15.63-15.63 64.28 15.63-232.0 <0.0001*
CXCL10 pg/ml 153.3 110.2-223.8 412.5 235.8-762.2 <0.0001*
CXCL13 pg/ml 0.56 0.56-5.92 11.02 1.74-40.15 <0.0001*
TNFRII pg/ml 1 515 1 129-1 999 2 226 1793-2901 <0.0001*
Gal-9 pg/ml 2 497 2 160-3 024 3 825 2793-5678 <0.0001*
TIE-1 pg/ml 3 468 1 272-5 538 8 983 6 296-13 237 <0.0001*
sVCAM ng/ml 1 830 1 494-2 012 2 232 1969-2642 <0.0001*
IL-18 pg/ml 54.45 28.71-101.9 115.9 78.16-176.7 0.0002*
CCL19 pg/ml 104.9 67.51-139.50 144 118.5-240.6 0.0010*
sICAM ng/ml 207.94 169.73-258.45 278.24 212.06-357.67 0.0039
YKL-40 ng/ml 50.17 42.06-67.54 67.03 47.32-102.80 0.037
Table 2 Ten cytokines and chemokines were elevated in localized scleroderma serum samples compared 
to healthy controls.
P-values were calculated by Mann-Whitney test.
*comparisons that remained significant after Bonferroni Correction 0.0013 (0.05/39=0.0013)
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What clinical phenotype is associated with high levels of serum concentrations of 
chemokines and cytokines? 
First, unsupervised hierarchical clustering analyses of all patients (n=74) and HCs (n=22) 
was performed based on the serum concentrations of ten significantly different analytes. Two 
large clusters could be identified: one consisted almost exclusively of LoS patients (‘Localized 
Scleroderma Cluster’, n=56, containing 54 LoS samples) and the other cluster was comprised 
of nearly all HCs and the remainder of LoS patients (‘Normal-like cluster’, n=40, containing 20 
LoS samples) (Figure 1). 
Figure 1 Unsupervised hierarchical clustering and heatmap of localized scleroderma (LoS) and healthy 
control (HC) samples based on serum cytokine and chemokine concentrations. Two large clusters could 
be identified: one consisted almost exclusively of LoS patients (‘Localized Scleroderma Cluster’, n=56, 
containing 54 LoS samples) and the other cluster was comprised of nearly all HCs and the remainder 
of LoS patients (‘Normal-like cluster’, n=40, containing 20 LoS samples). Depicted are the transformed 
serum concentrations values (see Materials and Methods) from LoS patients and HCs. Unit variance 
scaling is applied to rows. Heatmap colours represent the serum concentrations in a color-coded way: 
blue (low) to red (high). Clustering was performed with ClustVis (http://biit.csut.ee/clustvis/)  using 
Euclidean distance and Ward linkage and is depicted as dendrograms for columns and rows.
The LoS patients that ended up in the ‘Localized scleroderma-cluster’ (n=54) and ‘Normal-like 
cluster’ (n=20) were compared for several characteristics to determine the clinical phenotype 
that drove the observed clustering. The patients that clustered together in the ‘Localized 
Scleroderma Cluster’ had significantly higher disease activity scores (median mLoSSI=16 
[8-25]), compared to the LoS patients that ended up in the ‘normal-like cluster’ (median 
mLoSSI=8 [4-12]) (P 0.0047). Other investigated characteristics, such as treatment received 
or age at participation, did not differ significantly between the two groups (Supplemental 
Table 3).  
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CCL18 was identified as the most specific biomarker for disease activity in LoS 
Unsupervised hierarchical clustering revealed a cluster of LoS patients with more active 
disease that could clearly be distinguished from HCs. To further investigate the relation 
between the serum cytokine concentrations and disease activity, all LoS serum samples 
(n=93; including longitudinal samples n=19) were classified as active (mLoSSI>5, n=67) or 
inactive (mLoSSI≤5, n=26) disease. 
First, clustering of active and inactive samples was explored in a PLS-DA including all 39 
analytes. Separation of samples is displayed in Figure 2a. CCL18, CXCL13, CXCL9, CXCL10 
and TIE-1 were the most important analytes (loadings) for the visualised clustering (Figure 
2b). The variable importance on projection (VIP)-score, which quantifies the contribution of 
an analyte in the visualized model, demonstrated that CCL18 was the most important analyte 
for the separation of patients with active and disease (Figure 2c). This made CCL18 the most 
attractive analyte to investigate into more detail as biomarker of disease activity in LoS.
Figure 2 CCL18 was identified as the most important analyte for the visualized clustering of active and 
inactive disease. A partial least squared – discriminant analysis (PLS- DA) was performed to investigate 
clustering of active (mLoSSI>5) and inactive (mLoSSI≤5) patients including all 39 analytes (A). Importance 
of each analyte (‘loadings’) for the visualized clustering is depicted in a loadings-plot (B) and quantified 
in a variable importance on projection (VIP)-score (C). The PLS-DA was performed in the MetaboAnalyst 
server (http://biit.cs.utee/clustvis) 
The potential of CCL18 to function as a biomarker of disease activity was supported by 
spearman rank correlation coefficients (rs) between mLoSSI-scores and serum concentrations: 
CCL18 demonstrated the strongest correlation to mLoSSI (rs= 0.4604, P <0.0001) (Figure 
3a), followed by CXCL9 (rs= 0.4546, P <0.0001) and CXCL10 (rs= 0.4389, P <0.0001) 
(Supplemental Table 4 contains all analytes).
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Next, a cut-off concentration was defined as above 2 standard deviations of the mean serum 
concentrations of HCs for every analyte. The frequency of elevated serum concentrations was 
calculated in the groups with active and inactive disease. Of all analytes, CCL18 demonstrated 
the greatest difference (33%) between the 2 groups: 52% of the active (35 of 67) and only 19% 
of the inactive samples (5 out of 26) had elevated CCL18 values (Figure 3b). (Supplemental 
Table 5 contains all analytes).
Lastly, CCL18 demonstrated the highest AUC in ROC-analysis for the detection of active 
versus inactive disease (AUC=0.754, confidence interval, 0.643-0.864, P-value < 0.001) 
(Figure 3c). With an ideal cut-off concentration set at 11 800.00 pg/ml (Material and Methods), 
CCL18 serum concentrations had a sensitivity of 73% and a specificity of 75% to capture 
disease activity. (Supplemental Table 6 contains all analytes).
Longitudinal measures CCL18 serum concentrations reflect changes in disease 
activity
Longitudinal samples (n=18) for selected patients were collected at follow-up receiving 
treatment after being included with active disease at onset. Median serum concentrations 
significantly decreased from 25 313 pg/ml [14 408-67 909] at disease onset to 11 959 pg/ml 
[6 430-21 656] after treatment initiation (P=0.0056, Figure 3d). In addition, the proportion of 
patients with elevated CCL18 levels decreased from 67% (12 out of 18 patients) at disease 
onset to 22% (4 out 18) after receiving treatment. Lastly, one patient was included with inactive 
disease and resampled with flaring disease; CCL18 levels increased from 549.5 pg/ml at 
inactive disease to 99 537.06 pg/ml during the flare. These findings demonstrate that CCL18 
serum concentrations reflect disease activity changes within individual patients. 
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Figure 3 CCL18 serum concentrations demonstrated superior results to function as biomarker of disease 
activity via three approaches: CCL18 demonstrated the highest correlation coefficient to mLoSSI scores 
(A); II) CCL18 values were more frequently elevated (cut-off= 21 555 pg/ml) in active (mLoSSI>5) than 
in inactive (mLoSSI≤5) patients (B); CCL18 serum concentrations had the highest area under the curve 
(AUC) to discriminate between active and inactive samples in receiver operating characteristics (ROC) 
– curves analyses (C). In addition, longitudinal CCL18 serum concentrations are depicted for 18 LoS 
patients. CCL18 serum concentrations significantly decreased in individual patients when comparing 
concentrations at disease onset and after treatment initiation (D). The dotted-line represents the same 
cut-off value as utilized in figure b. Black and grey dots represent samples above and under the set cut-
off, respectively.
The relation between CCL18 serum concentrations and other clinical outcome 
measures
In this section, we briefly describe the relation between other relevant clinical variables and 
CCL18 serum concentrations.
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Treatment 
Longitudinal analyses demonstrated that CCL18 serum concentrations decreased after 
treatment initiation within individual patients. Comparison of groups with or without systemic 
treatment confirmed this observation; median CCL18 concentrations were 21 537pg/ml [9 380- 
40 343] for patients without treatment, compared to 11 893pg/ml [6 465-25 253] (p=0.0392) for 
patients receiving systemic treatment (Supplemental Figure 3a). In addition, median CCL18 
concentrations decreased stepwise from 24 187 pg/ml [16 058 – 60 049] in the group of 
patients with active disease without treatment to 7 223 pg/ml [4 912 – 17 235] in the groups 
of patients with inactive well-controlled disease without treatment (Supplemental Figure 3b).
Clinical outcome measures
Disease activity status was defined by mLoSSI throughout this paper. Similar correlations 
were found when correlating the Physician’s Global Assessment of disease activity to CCL18 
concentrations (rs= 0.5235, P <0.0001). No correlation was present with clinical scores 
capturing extent of disease damage: LoSDI (rs=0.06596 P=0.5439) and PGA-damage 
(rs=0.01484, P=0.8909).
Disease Subtypes
CCL18 concentrations were highest in the EF (median, 25 126 pg/ml [10 154- 95 000]) and 
linear subtypes (21 093 pg/ml [8 667-29 236]), followed by generalized LoS (19 820 pg/ml 
[6743 – 24 124]), Limited LoS (18 531 pg/ml [8 258-55 969] and finally Deep LoS (5 622 [2 
736-27 987] (Supplemental Figure 4).
CCL18 is elevated in LoS and not in (juvenile) dermatomyositis (JDM) and spinal 
muscular atrophy (SMA)
In addition to LoS samples, CCL18 serum concentrations were investigated in 119 (juvenile) 
dermatomyositis ((J)DM) and 43 spinal muscular atrophy (SMA) samples to investigate the 
specificity of CCL18 as a biomarker for LoS and not just general inflammatory processes 
(Characteristics are displayed in Supplemental Table 7). The median CCL18 serum 
concentration was significantly increased in LoS (20 902 pg/ml [8 497-32 040], P=0.0021) 
and not in (J)DM (3 911 pg/ml [199.9-10 558], P=0.454) or SMA (7 297 pg/ml [2 773-12 555], 
P>0.999) compared to HCs (7 158 pg/ml [2 772-14 069] (Figure 4a). In addition, 49% of the 
LoS patients had elevated CCL18 serum concentrations, compared to only 7% of the (J)DM 
and 7% of the SMA patients (Figure 4b). 
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Figure 4 The median CCL18 serum concentration was significantly increased in localized scleroderma 
(LoS) and not in (juvenile) dermatomyositis (JDM) or spinal muscular atrophy (SMA) compared to healthy 
controls (HC) (A). In addition, this specificity was also reflected in the frequency of patients with elevated 
serum concentrations of CCL18 (cut-off 21555 pg/ml): 49% of the LoS patients had increased CCL18 
serum concentrations, compared to only 8% of the (J)DM and 7% of the SMA patients (B).
CCL18 expression
CCL18 gene expression was investigated in circulating immune cells and full thickness skin 
biopsies. 
CCL18 is not differentially expressed in circulating immune cells of LoS patients 
versus HCs
CCL18 gene expression did not significantly differ in isolated PBMCs between 58 LoS patients 
and 22 healthy controls (median fold change (FC) = 0.98, P=0.6661). Moreover, no relation 
was present between CCL18 gene expression in PBMCs and CCL18 serum concentrations 
within individuals (rs= -0.1327, P=0.2632) (Supplemental Figure 5).
CCL18 gene and protein expression are increased in the inflammatory border of 
cutaneous LoS lesions
For selected patients (N=25), three skin biopsies were taken from: I) the inflammatory border 
and II) the sclerotic centre of affected skin, representing the active and inactive stage of 
LoS, respectively. A third biopsy was taken from unaffected skin (Figure 5a). CCL18 gene 
expression was significantly increased at the inflammatory border compared to healthy 
control biopsies (median FC=4.76 [2.35-10.30], P<0.0001) (Figure 5b), whereas CCL18 gene 
expression was not increased at the sclerotic centre of affected skin (median FC=1.54 [0.625-
4.665] P= 0.2491) and unaffected skin (median FC=0.86 [0.30-1.51], P>0.9999). Lastly, 
CCL18 protein expression was also increased at the inflammatory and to a lesser extent at 
the sclerotic centre, with minimal expression in the unaffected skin biopsy of patients and 
healthy controls. (Figure 5c).
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Figure 5 Tissue gene and protein expression of CCL18. Three skin biopsies were taken from: I) the 
inflammatory border and II) the sclerotic centre of affected skin, representing the active and inactive 
stage of LoS, respectively. A third biopsy (III) was taken from unaffected skin. (A) CCL18 gene expression 
was significantly elevated at the inflammatory border, and not at the sclerotic centre in LoS (B). CCL18 
protein expression was increased at the inflammatory border and sclerotic centre of LoS, and not at the 
unaffected tissue, compared to healthy controls (C).
DISCUSSION
The current lack of accurate and reliable tools to determine disease activity is leading to 
undesired treatment delays and suboptimal treatment approaches in LoS patients, which 
propelled us to investigate novel biomarkers for this debilitating condition. By screening 
39 inflammatory mediators for their relevance in LoS, we found elevated levels of CCL18, 
CCL19, TIE-1, CXCL13, IL-18, TNFRII, Galectin-9, CXCL9, CXCL10 and sVCAM. Of these 
elevated analytes, CXCL9 and CXCL10 have recently described as potential biomarkers of 
disease activity in LoS. 66 230 281 282 Increased levels of sVCAM have been described without a 
clear relation to disease activity. 61
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Cluster analyses of the 10 elevated inflammatory markers revealed that disease activity status, 
defined by mLoSSI, was the most important clinical feature that correlated with circulating 
levels. After the identification of the association between serum cytokine levels and disease 
activity status, we demonstrated that CCL18 was the most important analyte able to separate 
patients with active from inactive disease. The potential of CCL18 to function as biomarker of 
disease activity was confirmed by ROC-analyses: CCL18 demonstrated the highest AUC to 
discriminate between patients with active and inactive LoS. In addition, CCL18 had superior 
correlation coefficient to mLoSSI, and its level normalised in patients effectively treated with 
immunosuppressive therapies. Based upon these observations and the finding that increased 
CCL18 levels were specific for LoS, and not in JDM or SMA, we propose CCL18 as a novel 
biomarker for disease activity in LoS.  
CCL18 was originally termed pulmonary and activation-regulated chemokine (PARC) 283 
and is known to exhibit chemotactic activity, via the recently discovered receptor CCR8 284 
toward multiple immune cells. 283 285-288 In addition to the immunomodulatory effect, CCL18 also 
stimulates the production of collagen in pulmonary and cutaneous fibroblasts in vivo, and in 
murine models CCL18 overexpression induces pulmonary fibrosis.289 In line with experimental 
studies, high levels of CCL18 are observed in multiple inflammatory and fibrotic conditions. 290 
291 In patients with idiopathic pulmonary fibrosis, increased levels of serum CCL18 correlated 
with high collagen accumulation and T-lymphocyte infiltration in the lung. 292 Furthermore 
CCL18 also correlated with clinical outcome measures associated with a poor outcome 
such as lung function impairment and decline, and risk of future acute exacerbations and 
mortality at 6 months.293 Likewise, CCL18 serum concentrations have been demonstrated to 
be increased in SSc in 35% of the patients and CCL18 levels predicted progression of lung 
fibrosis, lung function decline and mortality at 5 and 10 years.294 295 Besides pulmonary fibrotic 
conditions, CCL18 has been demonstrated to be increased in diseases characterized by T and 
B lymphocyte dysfunction such as Sjogren syndrome, giant cell arteritis, rheumatoid arthritis 
and bullous pemphigoid.283 We demonstrated that CCL18 gene and protein expression is 
increased at the inflammatory border of cutaneous LoS lesions, with normal gene expression 
in unaffected skin and circulating immune cells. These observations suggest that the source 
of CCL18 is the inflammatory skin of LoS patients. How increased CCL18 levels are elicited 
may shed light on the pathogenesis of LoS but remains to be investigated.
For the current study we have utilized mLoSSI as outcome measure to define disease activity. 
However, mLoSSI is limited in several aspects: 1) it only captures superficial components of 
disease activity (erythema and thickening of the skin). This potentially leads to misclassification 
of disease activity status in patients with active and progressive deep LoS and EF; 2) Skin 
thickening, one of the mLoSSI-items, may be irreversible and consequentially mLoSSI-scores 
do not always accurately reflect disease activity status. This latter especially holds true for 
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EF; a recent study by our group describes irreversible skin fibrosis in large proportions of 
patients affected by this subtype 296; 3) No studies have investigated ideal cut-off values for 
mLoSSI to define inactive, minimally active or active disease. These limitations underscore 
the dire need of additional and accurate biomarkers for disease activity in LoS, but also create 
heterogeneity in the groups in this study. Secondly, the size of our cohort is limited, which 
restricts us to compare distinct molecular patterns between subtypes. Lastly, our study results 
warrant replication studies.
Clinical evaluation of LoS has demonstrated to be challenging with suboptimal treatment 
approaches as a result. In this study, we identified CCL18 as a specific biomarker for 
disease activity in LoS patients. Importantly, CCL18 serum concentrations will not replace 
but complement clinical assessment by experienced health care professionals. However, 
values below the set cut-off most likely reflect absence of residual inflammation, enabling the 
tapering of immunosuppressive medication, whereas rising levels may predict relapses and 
therefore indicate the need for intensification of treatment.
CONCLUSION
In this study we show that CCL18 is identified as a specific biomarker for disease activity 
in LoS which may aid therapeutic strategies. We propose that CCL18 is produced locally in 
inflamed skin. The understanding of the underlying pathways of this local production might 
lead to better insights in the disease pathogenesis and treatment of this debilitating disease. 
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SUPPLEMENTAL MATERIAL AND METHODS
Serum collection, storage and cytokine measurements
Blood was collected in a Vacutainer® SST II tube (BD catalogue no. 367985) and serum was 
isolated after centrifugation at 1500g for 10 min at room temperature and stored at -80oC prior 
to use. Serum concentrations were evaluated for 39 chemokines and cytokines implicated 
in angiogenesis and inflammation. Luminex measurements were performed using an in-
house developed and validated (ISO9001 certified) multiplex immunoassay (Laboratory of 
Translational Immunology, University Medical Centre Utrecht) based on Luminex technology 
(xMAP, Luminex Austin TX USA). The assay was performed as described previously.277 
A-specific heterophilic immunoglobulins were preabsorbed from all samples with heteroblock 
(Omega Biologicals, Bozeman MT, USA). Acquisition was performed with the Biorad 
FlexMAP3D (Biorad laboratories, Hercules USA) in combination with xPONENT software 
version 4.2 (Luminex). Data was analysed by 5-parametric curve fitting using Bio-Plex 
Manager software, version 6.1.1 (Biorad). Cytokine values below the lower limit of detection 
were set to half of the lower limit of detection for analysis.
Peripheral Mononuclear Blood Cells (PBMCs) isolation
Lithium-heparin (BD catalogue no. 367880) tubes were collected and PBMCs were isolated by 
density-gradient centrifugation using Ficoll-Paque.276 Isolated PBMCs were lysed (RLT-PLUS) 
and stored at -30oC prior to use. 
Gene expression in circulating immune cells
Lysed PBMCs were used for total RNA extraction by AllPrep Universal kits (Qiagen). Total 
RNA was converted to complementary DNA (cDNA) using Iscript cDNA Synthesis Kits (Bio-
Rad). A primer was designed for CCL18 and GAPDH was used as a housekeeping gene 
(HKG). Real time PCR (RT-PCR) was run using Bio-Rad SYBER Green assays and the PCR 
was performed on a Quantstudio 12 K Flex Real-Time PCR system. Delta Ct (∆Ct)-values for 
the CCL18 gene were calculated against the HKG (CtCCL18t-CtHKG=∆Ct). Delta delta Ct (∆∆Ct) 
for each sample were calculated to the median ΔCt of the control samples (ΔΔCt =ΔCtsample – 
ΔCtcontrol median). Fold Changes were calculated for each sample by log2 transformation of the 
∆∆Ct (FC = 2–ΔΔCt) and median FCs were compared between LoS and controls.
Skin samples
For selected adult patients, three skin biopsies were taken from: the inflammatory border (I) 
and the sclerotic centre (II) of affected skin and from unaffected skin (III). In addition, control 
samples were acquired from abdominal corrective surgery leftover material. Skin samples 
were fresh frozen in Tissue Tec OCT compound (Miles Scientific, Naperville, USA) at -80oC 
prior to use.  
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Gene expression in skin samples
For RNA extraction, 30x20µm cryotomes were cut and RNA was extracted via an All Prep 
Universal kit (Qiagen). Total RNA was converted to complementary DNA (cDNA) using Iscript 
cDNA Synthesis Kits (Bio-Rad). Primers were designed for CCL18 and hARP (RPLP0) 
was used as a housekeeping gene. Real time PCR (RT-PCR) was run using Bio-Rad SYBER 
Green assays and the PCR was performed on a Quantstudio 12 K Flex Real-Time PCR 
system. Cycle threshold values were obtained from the RT-PCR. Delta Ct (∆Ct)-values for 
CCL18 gene were calculated against the HKG (Cttarget-CTHKG=∆Ct). Delta delta Ct (∆∆Ct) for 
each sample was calculated to the median ΔCt of the control samples (∆∆Ct =ΔCtsample – 
ΔCtcontrol median). Fold Changes were calculated for each sample by log2 transformation of the 
∆∆Ct (FC = 2–ΔΔCt) and median FCs were compared between the groups of different LoS biopsy 
locations and controls.
Immunohistochemistry of skin samples 
Sections were sliced 7µm thick and air-dried for 5 minutes. Next, sections were fixed in 
cold acetone for 10 minutes. For immunohistochemistry the sections were placed in PBS 
for 5 minutes. Sections were pre-incubated for 15 minutes using 5% normal rabbit serum. 
Consecutively, the sections were incubated with the primary polyclonal goat anti-human 
CCL18 antibody (R&D AF 394) in a 1:50 dilution or goat IgG (R&D Normal Goat IgG Control, 
AB-108C) in a 1:100 dilution in 1% BSA/PBS for 1 hour. Sections were washed in PBS for 2x 
5 minutes and incubated with secondary antibody rabbit anti-goat IgG biotinylated 1:200 in 1% 
BSA/PBS for 30 minutes. After repeated washing, sections were incubated for 30 minutes with 
ABC-complex 1:50 (Vectastain) and detected with 3-amino-9-ethylcarbazole (AEC). Washing 
and Haematoxylin (Sigma) was used to counterstain cell nuclei, slides were mounted with 
glycerol gelatine (Sigma).
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SUPPLEMENTAL FIGURES
Supplemental Figure 1 Sample overview for different experiments.
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Supplemental Figure 2 Serum Concentrations of significantly elevated chemokines and cytokines in 
localized scleroderma.
a, CCL18; b, CXCL9; c, CXCL10; d, CXCL13; e, TNFRII; f, Gal-9; g, TIE-1; h, sVCAM, i, IL-18; j, CCL19; 
k, sICAM; l, YKL-40.
Mann-Whitney tests were performed to compare continuous variables between the healthy controls and 
localized scleroderma group
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Supplemental Figure 3 CCL18 serum concentrations were higher in untreated patients compared to 
patients receiving systemic immunosuppressant treatment (a). In addition, 4 groups, typically representing 
the course the disease, were created; I) treatment naïve patients with active disease (Onset) II), patients 
receiving treatment with active disease, III) patients receiving treatment with inactive disease, and 
IV) patients without treatment and with inactive disease (Remission). Median CCL18 concentrations 
decreased stepwise from 24 187 [16 058 – 60 049] in the group of patients with active disease without 
treatment to 7 223 [4 912 – 17 235] in the groups of patients with inactive disease without treatment. 
However, as a result of stratification groups numbers have become small and the visual decline was not 
supported by significant differences in each step (b). 
The Kruskal-Wallis with Dunn’s multiple comparisons post-hoc test was performed for the comparison of 
the groups.
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Supplemental Figure 4 CCL18 serum concentrations in the different subgroups as defined by Zulian and 
Laxer with the addition of Eosinophilic Fasciitis as a distinct subtype.
The Kruskal-Wallis with Dunn’s multiple comparisons post-hoc test was performed for the comparison of 
the groups.
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Supplemental Figure 5 CCL18 gene expression in peripheral blood mononuclear cells (PBMCs) (a) and 
the absence of the relation between CCL18 serum concentrations and CCL18 PBMC gene expression (b).
Mann-Whitney tests were performed to compare continuous variables between the healthy controls and 
localized scleroderma group
Spearman’s rank correlation coefficient was used. rs, Spearman’s rho.
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SUPPLEMENTAL TABLES
Variable Serum Luminex Gene Expression 
PBMCs Skin
Biological Group HC LoS HC LoS HC LoS
Number 22 74 22 58 25 26
Age, Median [IQR] 43 [27-56] 45 [23-60] 39 [27-56] 56 [40-63] 42 [37-54] 61 [41-68]
Sex, No. (%)
Female 18 (82%) 43 (58%) 17 (77%) 37 (64%) 25 (100%) 18 (69%)
Male 4 (18%) 31 (42%) 5 (23%) 21 (36%) 0 (0%) 8 (31%)
Subtype
Circum. Sup. n/a 8 (11%) n/a 7 (12%) n/a 5 (19%)
Linear n/a 27 (36%) n/a 19 (31%) n/a 7 (27%)
Deep n/a 4 (5%) n/a 3 (5%) n/a 0 (0%)
Generalized n/a 15 (20%) n/a 12 (21%) n/a 8 (31%)
Eosinophilic Fasciitis n/a 20 (27%) n/a 17 (29%) n/a 6 (23%)
Disease Onset, No. (%)
Adult-Onset n/a 59 (80%) n/a 58 (100%) n/a 26 (100%)
Paediatric-Onset n/a 15 (20%) n/a 0 (0%) n/a 0 (0%)
Clinical Scores, Median [IQR]
mLoSSI n/a 13 [6-23] n/a 14 [8-25] n/a 20 [12-36]
LoSDI n/a 7 [4-15] n/a 7 [4-15] n/a 8 [5-14]
PGA-A n/a 16 [3-32] n/a 19 [8-40] n/a 29 [16-49]
PGA-D n/a 17 [8-29] n/a 17 [8-30] n/a 17 [8-28]
Treatment, No. (%)
Naïve 22 (100%) 47 (63%) 22 (100%) 38 (66%) 25 (100%) 18 (69%)
MTX and SCS n/a 7 (9%) n/a 6 (10%) n/a 1 (4%)
MTX monotherapy n/a 12 (16%) n/a 9 (16%) n/a 4 (15%)
SCS monotherapy n/a 6 (8%) n/a 4 (7%) n/a 3 (12%)
Miscellaneous n/a 2 (3%) n/a 1 (2%) n/a 0
Supplemental table 1 Characteristics of subjects included in the Luminex Immunoassay and gene 
expression experiments in circulating immune cells.
LoS, Localized Scleroderma; HC, Healthy Control; PBMCs, Peripheral Mononuclear Blood Cells Circum. 
Sup., Circumscribed Superficial Subtype; mLoSSI, modified Localized Scleroderma Skin Severity Index; 
LoSDI, Localized Scleroderma Damage Index; PGA-A, Physician’s Global Assessment of disease 
activity; PGA-D, Physician’s Global Assessment of disease damage; MTX, Methotrexate; SCS, Systemic 
Corticosteroids.
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Analyte Unit Healthy Control, N=22 Localized Scleroderma, N=74 P-valueMedian IQR Median IQR
CCL18 pg/ml 7158 2772-14069 20902 8497-32040 <0.0001*
CXCL9 pg/ml 15.63 15.63-15.63 64.28 15.63-232.0 <0.0001*
CXCL10 pg/ml 153.3 110.2-223.8 412.5 235.8-762.2 <0.0001*
CXCL13 pg/ml 0.56 0.56-5.92 11.02 1.74-40.15 <0.0001*
TNFRII pg/ml 1515 1129-1999 2226 1793-2901 <0.0001*
Gal-9 pg/ml 2497 2160-3024 3825 2793-5678 <0.0001*
TIE-1 pg/ml 3468 1272-5538 8983 6296-13237 <0.0001*
sVCAM ng/ml 1830 1494-2012 2232 1969-2642 <0.0001*
IL-18 pg/ml 54.45 28.71-101.9 115.9 78.16-176.7 0.0002*
CCL19 pg/ml 104.9 67.51-139.50 144 118.5-240.6 0.0010*
sICAM ng/ml 207.94 169.73-258.45 278.24 212.06-357.67 0.0039
YKL-40 ng/ml 50.17 42.06-67.54 67.03 47.32-102.80 0.037
PlGF pg/ml 20.85 16.39-25.85 24.33 19.15-31.56 0.0512
SPARC ng/ml 151.65 89.80-195.09 94.47 37.69-181.00 0.0566
C5a ng/ml 135 120.33-177.47 118.9 83.64-189.52 0.0897
sVEGFR pg/ml 1332 1038-1459 1430 1164-1726 0.0932
CCL17 pg/ml 273.2 167.6-402.7 310.1 239.2-455.2 0.0952
Tie-2 pg/ml 8547 7397-11120 10102 8398-11972 0.0952
CCL27 pg/ml 372.3 240.4-541.6 286.6 164.0-435.8 0.1062
Ang-2 pg/ml 3885 3152-5172 3462 2630-4541 0.1703
THBS-1 µg/ml 141.21 127.18-158.65 127.06 100.68-170.29 0.1993
VEGF pg/ml 126.7 94.19-215.3 171.3 108.0-230.9 0.2062
Ang-1 ng/ml 41.33 30.49-59.02 36.93 28.23-50.12 0.2158
OSM pg/ml 3.275 1.43-10.88 6.015 1.43-16.61 0.2536
PDGF-BB ng/ml 13.37 11.16-17.07 12.37 9.71-14.31 0.28
CCL4 pg/ml 126.9 92.37-190.2 147.9 114.2-188.5 0.3071
CCL2 pg/ml 142.3 105.5-220.7 155.6 111.6-227.2 0.308
Fibronectin µg/ml 113.58 85.24-142.44 130.73 88.14-162.91 0.3153
P-sel ng/ml 179.32 129.97-328.62 179.94 98.04-256.13 0.3199
Fetuin µg/ml 68.87 61.49-85.72 84.91 58.92-96.53 0.3649
Gal-1 ng/ml 18.63 15.95-21.58 19.41 15.81-21.88 0.6004
CCL22 pg/ml 796.2 677.4-906.0 845.3 651.3-1036 0.6064
FGF basic pg/ml 22.88 22.88-22.88 22.88 22.88-22.88 0.6279
PAI-1 ng/ml 1843.7 1482.00-2707.85 2001.3 1423.50-2483.26 0.6345
E-sel pg/ml 3989 2835-6093 4329 2716-6116 0.7077
Endoglin pg/ml 1223 859.7-1657 1155 920.7-1536 0.7521
TWEAK pg/ml 9053 7155-11433 8925 7224-10717 0.7707
Trombomod pg/ml 4002 3482-4380 3925 3073-4744 0.8849
OSF-2 ng/ml 45 39.37-53.22 44.35 39.60-54.02 0.9151
Gal-3 ng/ml 13.71 11.12-14.81 13.41 10.83-15.68 0.9845
SAA-1 pg/ml All OOR<  All OOR<  na
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Supplemental table 2 Median serum concentrations of all 39 analytes included in the Luminex 
immunoassay.
P-values were calculated by Mann-Whitney test. *comparisons that remained significant after Bonferroni 
Correction 0.0013 (0.05/39=0.0013). OOR< Out of range, below the detection level.
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Localized Scleroderma 
Cluster
Normal-like Cluster P-value
No. 54 20 na
Sex, No. (%)
Female 30 (56%) 13 (65%)
0.4646
Male 24 (44%) 7 (35%)
Subtype
Circum. Sup. 5 (9%) 3 (15%) 0.4800
Linear 21 (39%) 6 (30%) 0.4806
Deep 2 (4%) 2 (10%) 0.2874
Generalized 11 (20%) 4 (20%) 0.9719
Eosinophilic Fasciitis 15 (28%) 5 (25%) 0.811
Onset
Adult-Onset 45 (83%) 6 (30%)
0.2125
Paediatric-Onset 9 (17%) 14 (70%)
Clinical Scores, Median [IQR]
Disease Activity
mLoSSI 16 [8-25] 8 [4-12] 0.0047
PGA-A 20 [8-38] 8 [1-19] 0.0217
Disease Damage
LoSDI 8 [4-16] 6 [3-12] 0.3128
PGA-D 17 [8-29] 13 [6-29] 0.4677
Treatment, No. (%)
Naïve 37 (69%) 10 (50%) 0.1417
MTX and SCS 3 (6%) 4 (20%) 0.0594
MTX monotherapy 8 (15%) 4 (20%) 0.5910
SCS monotherapy 5 (9%) 1 (5%) 0.5511
Miscellaneous 1 (2%) 1 (5%) 0.4583
Antinuclear Antibodies 17 (45%)* 9 (38%)** 0.6234
Supplemental table 3 Comparison of the LoS patient characteristics of samples that ended up in the 
two clusters generated by unsupervised hierarchical clustering (‘Localized Scleroderma Cluster’ versus 
’Normal-Like Cluster’) based on serum analyte concentrations.
Chi-square test and Mann-Whitney tests were performed to compare categorical and continuous variables 
between the LoS-Cluster and Normal-like cluster.
* Antinuclear Antibody test results were available for 40 samples in the ‘LoS-cluster’
** Antinuclear Antibody test results were available for 30 samples in the ‘Normal-like cluster’ 
LoS, Localized Scleroderma; Circum. Sup., Circumscribed Superficial Subtype; mLoSSI, modified 
Localized Scleroderma Skin Severity Index; LoSDI, Localized Scleroderma Damage Index; PGA-A, 
Physician’s Global Assessment of disease activity; PGA-D, Physician’s Global Assessment of disease 
damage; MTX, Methotrexate; SCS, Systemic Corticosteroids.
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Analyte Correlation to mLoSSI
rs P-value
CCL18 0.4604 <0.0001
CXCL9 0.4546 <0.0001
CXCL10 0.4389 <0.0001
TIE-1 0.3635 0.0005
CXCL13 0.3581 0.0007
TNFRII 0.3011 0.0046
Gal-9 0.2555 0.0169
CCL19 0.1287 0.2349
IL-18 0.0733 0.4997
sVCAM 0.0587 0.5894
Supplemental table 4 Spearman’s rank correlation between serum concentrations and modified 
Localized Scleroderma Skin Severity Index.
Spearman’s rank correlation coefficient was used. rs, Spearman’s rho.
 Analyte
Active disease
n=67
Inactive disease
n=26
∆-%
(active-inactive)No. % No. %
CCL18 35 52.2% 5 19.2% 33.0%
CXCL9 37 55.2% 6 23.1% 32.1%
TIE1 35 52.2% 6 23.1% 29.2%
CXCL10 36 53.7% 7 26.9% 26.8%
Gal-9 28 41.8% 6 23.1% 18.7%
TNFRII 22 32.8% 4 15.4% 17.5%
CXCL13 41 61.2% 12 46.2% 15.0%
CCL19 14 20.9% 2 7.7% 13.2%
IL-18 19 28.4% 5 19.2% 9.1%
sVCAM 26 38.8% 12 46.2% -7.3%
Supplemental table 5 Frequency of elevated serum concentrations in the group of active and inactive 
disease.
A cut-off concentration was defined as above 2 standard deviations of the mean serum concentrations of 
HCs for every analyte.
Active disease: mLoSSI >5, inactive disease: mLoSSI≤5. 
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Analyte
Area
Under
Curve
P-value 95% Confidence  Interval
CCL18 0.754 <0.0001 0.643-0.864
CXCL10 0.713 0.002 0.601-0.825
TIE1 0.707 0.002 0.594-0.820
CXCL9 0.690 0.005 0.576-0.804
CXCL13 0.624 0.066 0.503-0.745
TNFRII 0.622 0.070 0.496-0.748
Gal-9 0.605 0.120 0.473-0.737
CCL19 0.538 0.568 0.415-0.662
sVCAM 0.499 0.986 0.362-0.636
IL-18 0.496 0.951 0.368-0.623
Supplemental table 6 Receiver operation characteristic (ROC) for the detection of active and inactive 
disease. 
Active disease: mLoSSI >5, inactive disease: mLoSSI≤5. 
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Biological group HC LoS (J)DM SMA
Number 22 74 119 43
Age, Median [IQR] 43 [27-56] 45 [23-60] 12.8 [23-7] 36 [28-35]
Sex, No. (%)
Female 18 (82%) 43 (58%) 74 (62%) 26 (60%)
Male 4 (18%) 31 (42%) 45 (38%) 17 (40%)
Disease Onset, No. (%)
Adult-Onset n/a 59 (80%) 36 (30%) 1 (2%)
Paediatric-Onset n/a 15 (20%) 83 (70%) 42 (980%)
Clinical Scores, Median [IQR]
LoS 
Clinical 
Scores
mLoSSI n/a 13 [6-23] n/a n/a
LoSDI n/a 7 [4-15] n/a n/a
PGA-A n/a 16 [3-32] n/a n/a
PGA-D n/a 17 [8-29] n/a n/a
(J)DM 
clinical 
Scores
Muscle weakness (%) n/a n/a 63 (53%) n/a
(J) DM skin symptoms (%) n/a n/a 70 (59%) n/a
CMAS score, Median [IQR] n/a n/a 48 [39-57] n/a
SMA motor score (HMFSE) n/a n/a n/a 4 [0-36]
Treatment, No. (%)
Naïve 22 (100%) 47 (63%) 58 (49%) 43 (100%)
MTX and SCS n/a 7 (9%) 22 (18%) 0 (0%)
MTX monotherapy n/a 12 (16%) 6 (5%) 0 (0%)
SCS monotherapy n/a 6 (8%) 13 (11%) 0 (0%)
Miscellaneous n/a 2 (3%) 20 (17%) 0 (0%)
Supplemental table 7 Characteristics of juvenile dermatomyositis and spinal muscular atrophy cohorts.
HC, Healthy control; LoS, Localized Scleroderma; (J)DM, (juvenile) dermatomyositis; SMA, spinal muscular 
atrophy; mLoSSI, modified Localized Scleroderma Skin Severity Index; LoSDI, Localized Scleroderma 
Damage Index; PGA-A, Physician’s Global Assessment of disease activity; PGA-D, Physician’s Global 
Assessment of disease damage; CMAS, childhood myositis assessment scale; HMFSE, Hammersmith 
Functional Motor Scale-Expanded; MTX, Methotrexate; SCS, Systemic Corticosteroids.
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GENERAL DISCUSSION
Localized Scleroderma (LoS), also known as morphea, encompasses a spectrum of 
idiopathic sclerotic skin diseases. The spectrum ranges from relatively mild phenotypes, 
such as morphea en plaque, which generally cause few problems besides local discomfort 
and visible disfigurement, to severe subtypes such as linear LoS or eosinophilic fasciitis 
(EF, Shulman syndrome). Patients affected by the latter subtypes often develop severe 
complications such as joint contractures, limb length- and circumferential discrepancies, and 
restrictive lung function impairment resulting from widespread cutaneous fibrosis.5 LoS and 
EF are characterized by an early inflammatory phase in which cutaneous and subcutaneous 
fibrotic lesions develop and expand, followed by development of irreversible sequelae, such 
as cutaneous and subcutaneous fibrosis, atrophy and pigment alterations.48 232 The majority of 
treatment options are anti-inflammatory agents which aim to reduce disease progression and 
thereby prevent irreversible sequalae to develop.225 227 253 Efficacy of treatment is depending 
on prompt treatment initiation as irreversible sequalae will not be resolved by these anti-
inflammatory agents. Accurate and sensitive detection of disease activity is therefore vital for 
adequate treatment in LoS and EF. 
What is the long-term clinical course of localized scleroderma and eosinophilic 
fasciitis?
Textbooks describe the active phase of LoS to generally last for 3 to 5 years before the 
disease becomes quiescent. However, in our clinical setting we often experience a more 
erratic disease course; patients often experience recurrent episodes of disease activity. In 
chapter 2.1, we have investigated the frequency and characteristics of episodes of recurrent 
disease in paediatric- and adult-onset LoS, and identified patient variables that are associated 
with a higher risk of disease recurrence. We performed a retrospective chart review of all 
patients with LoS at our study centre. In total, 344 patients were included in the analysis, 
of whom 119 (35%) had paediatric-onset LoS and 225 patients (65%) had adult-onset LoS. 
Disease recurrence was observed in 27% of the patients with paediatric-onset and in 17% 
of the adult-onset patients. Multivariate analysis identified that the difference in recurrence 
rates between paediatric and adult-onset LoS should be attributed to the difference in subtype 
distribution between these two groups. More precisely, our results demonstrated that patients 
with linear LoS of the limbs more frequently develop disease recurrences, independent of 
the age of disease onset. Morphea en plaque and generalized LoS, the two most frequently 
observed subtypes in adult-onset group, experience recurrences less frequently. The two 
subtypes with the lowest recurrence rates were the en coup de sabre (7%) and atrophoderma 
subtype (6%). Differences in recurrence rates between the paediatric and adult-onset group 
were therefore mainly explained by the difference in subtype distribution between these two 
groups. In addition, we demonstrated a median time between the initial episode of disease 
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activity and a recurrence of 26 months in paediatric-onset LoS and 27 months in adult-onset 
LoS. In some patients, recurrences occurred after up to 20 years of disease remission. 
Only few studies describing disease recurrences in LoS were performed previously to our 
study. Christen-Zaech et al.1 described a recurrence rate of 3.7% in a cohort exclusively 
composed of paediatric patients. In addition, this study lacked a clear definition of disease 
recurrence. The lack of adults and a clear definition of disease recurrence make it difficult to 
compare recurrence rates. Next, Piram et al.27 234 reported a recurrence rate of 28% in a group 
of patients with paediatric-onset linear LoS of the limbs. Pequet et al. described a recurrence 
rate of 27 % in a group of 114 paediatric-onset LoS patients. These results are comparable to 
the results we present in our paediatric-onset group. 
Interestingly, a recent report by Zulian et al.297 was the first to report the long-term course of 
the disease by the use of the validated clinical outcome measure ‘the Localized Scleroderma 
Cutaneous Assessment Tool (LoSCAT)’. LoSCAT is composed of two indices: the modified 
Localized Scleroderma Skin Severity Index (mLoSSI) to measure disease activity considering 
any new/enlarged lesion, erythema and thickening; and the Localized Scleroderma Skin 
Damage Index (LoSDI) evaluating tissue damage as dermal atrophy, subcutaneous atrophy 
and dyspigmentation.117 118 This study reported similar recurrence rates in a cohort of 126 
paediatric patients with 22% of the patients experiencing an episode of recurrent disease. 
This first flare was observed 20 months after first treatment discontinuation, which is the close 
to the time we describe. Interestingly, this study also reports increased recurrence rates in the 
more severe subtypes such as linear LoS of the limbs and pansclerotic morphea. 
At the time of publication, our study was the first to describe recurrence rates in a cohort of 
patients with LoS containing all subtypes and patients with both paediatric and adult-onset 
disease. We have demonstrated that recurrences in LoS occur in up to almost one-quarter 
of the patients, and were most frequent in the linear LoS of the limbs subtype, independent 
of age at disease onset. These observations have later been confirmed by another study 
investigating the long-term course of LoS.297 Awareness of the high recurrence rates may 
lead to early recognition of disease activity by both physicians and patients, thereby leading 
to a decreased delay in treatment initiation in the case of disease recurrence. The majority of 
treatment options in LoS consist of anti-inflammatory agents, which aim to hamper disease 
progression, thereby preventing irreversible sequalae to develop. Early detection of disease 
activity is therefore vital for early and adequate treatment.
As a result of our study and recent publications, we recommend instructing patients, specifically 
those affected by linear LoS, to be aware of potential disease flaring, even after many years 
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of quiescent disease, with the ultimate goal to decrease the delay in treatment initiation in the 
case of disease recurrence. 
In addition to describing recurrence of disease activity in the LoS spectrum, we aimed to 
investigate the amount of irreversible sequalae patients develop. Especially in the EF subtype, 
the observed heterogeneity in irreversible sequalae is striking; some patients develop severe 
irreversible contractures while some others recover without any serious functional impairment. 
The heterogeneous long-term outcome makes it difficult to determine the treatment patients 
should receive; undertreatment may lead to the development of more irreversible sequalae, 
while overtreatment with glucocorticoids has several known disadvantages, such increased 
risk at osteoporosis and weight gain. The amount of studies describing disease damage 
in EF is limited. In chapter 2.2, we therefore aimed to evaluate presence and extent of 
residual disease damage in patients with EF after long-term follow-up. Additionally, we aimed 
to identify patient characteristics associated with a poor outcome, defined as having more 
extensive disease damage. For this purpose, a cross-sectional study of 35 EF patients was 
performed. First, we demonstrated that all patients experienced disease damage. Irreversible 
damage most often consisted of residual deep fibrosis and consequential decreased 
range of motion (RoM) of affected joints. Over half of the participants (57.1%) experienced 
a decreased RoM of the ankles, followed by one third in the wrists and knees. Additional 
analysis revealed a relationship between the extent of disease damage and signs of severe 
disease at presentation, such as involvement of the trunk and neck, presence of extensive 
inflammation reflected in increased CRP and a longer time until achieving disease remission. 
Furthermore, our study confirms the concept, postulated by Endo et al, that presence of 
concomitant morphea represents a subset of EF patients that develop more residual damage. 
Additionally, a relationship between advanced age at disease onset and a poor outcome was 
demonstrated. To our knowledge, one retrospective study14 and one systematic review245 
have described residual fibrosis in EF and risk factors thereof. However, these studies only 
described residual cutaneous fibrosis and extent of damage was lacking. Therefore, head to 
head comparison of the results is impossible. 
As demonstrated in the previous section, the amount of studies investigating irreversible 
sequalae in EF is limited. Eosinophilic Fasciitis is often regarded part of the spectrum of LoS, 
we therefore consulted studies describing disease damage in (parts of) the LoS spectrum. 
With regard to long-term disease course and disease damage in the LoS spectrum, a recent 
study by Zulian et al 297 is of particular interest. This study investigated 126 paediatric patients 
affected by the complete spectrum of LoS and describes the extent of disease damage in this 
group of patients. For this purpose a 4-point semiquantitative score was used which describes 
the extent of residual disease damage. Based on these scores, this study demonstrated that 
only 2.4% experienced no disease damage, half of the patients (49.2%) had mild damage and 
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the remaining half of the patients experienced moderate to severe damage ( 32/126 (25.4%) 
moderate- and 29/126 (23.0%) severe score). In addition, 25/126 patients (19.8%) presented 
a significant functional limitation due to the scleroderma lesion. Importantly, this study did not 
investigate patients affected by EF. However, it does demonstrate that within the full spectrum 
of LoS large proportions of patients are affected by irreversible sequalae underscoring the dire 
need for additional therapeutic options and improved treatment strategies to prevent disease 
damage to develop.  
Another important observation reported in the same study in paediatric LoS patients 297 is 
the fact that no relation was found between the severity of tissue damage and the disease 
duration. The authors report severe disease damage was found in 27.8% of the patients with 
follow-up 2 years, in 21.4% of those followed for 2–5 years, in 20.6% of those with 5–10 years 
and in 25.0% of those with >10 years follow-up (p = 0.200). In addition to these observations 
we, we did not observe a relation between follow-up time and the extent of disease damage 
present at cross-sectional evaluation in our EF-cohort. These results imply irreversible 
sequalae develop in the early course of the disease and stress the fact that treatment should 
be initiated as soon as possible with the ultimate goal to prevent this damage to develop. The 
importance of this statement is underscored by the fact that patients with more severe disease 
damage reported substantially decreased health related quality of life (HRQoL). Impact on 
physical functioning was previously reported in the active stage of EF.201 247 However, the study 
reported in chapter 2.2 demonstrates that residual damage still impacts HRQoL after many 
years of quiescent disease The observed decreased QoL justifies aggressive treatment option 
in LoS and EF to prevent irreversible sequalae to develop. Especially facial lesion in ECDS 
greatly impact QoL by cosmetic disfigurement, while linear LoS and EF lead to debilitating 
contractures greatly decreasing limb functionality. 
Lastly, similar to chapter 2.1 we also investigated disease flaring in our EF cohort; we 
demonstrated that recurrence rates in EF were as high as 40% (n=14/35), which was 
significantly higher than the reported recurrence rates for the other phenotypes of the LoS-
spectrum in chapter 2.1.
Taken the observations from chapter 2 together, we conclude that LoS and EF are chronic 
conditions which are characterized by disease flaring in relatively large proportions of patients. 
Especially the more severe subtypes, such as Linear LoS of the limbs and EF are frequently 
affected by disease recurrences. In addition, we have demonstrated that all patients affected 
by EF are affected by some form of long-term residual disease damage and that patients 
with a more severe phenotype at presentation seem to be at higher risk to develop severe 
functional impairment. These observations are supported by- and could be generalized for 
the complete spectrum of LoS as a result of the recent publication by Zulian et al. which 
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investigated the extent of disease damage in paediatric LoS patients. Gaining insight in the 
frequency of disease recurrences and extent of disease damage is important as increased 
knowledge about the potentially flaring course of the disease should make physicians more 
vigilant and manage treatment more adequately in patients with a clinical phenotype at risk to 
undergo a more erratic disease course. 
The observations from chapter 2 demonstrate the chronicity of LoS and EF, either by 
episodes of recurrent disease requiring repeated treatment with immunosuppressant 
drugs or by the impact of irreversible sequalae on HRQoL. The development of irreversible 
sequelae underscores the importance of early and accurate treatment in LoS and EF. Early 
anti-inflammatory treatment aims to reduce disease progression, thereby limiting irreversible 
sequalae to develop.  Overall, treatment options are limited and additional therapeutic agents 
are required for a large group of patients. The majority of LoS and EF patients are co-managed 
by a dermatologist and rheumatologist at our study centre and we recommend that care-
providers should always take disease subtype, degree of activity, depth of involvement, age 
at onset and quality-of-life impairments into account when initiating treatment. Until recently, 
(treatment) guidelines were lacking for LoS and EF. At our study centre we treat patients 
conform the flow-chart presented in chapter 1.1 (figure 9, page 36-37); in most patients with 
circumscribed superficial subtypes, treatment with topical therapies suffices. In widespread 
superficial disease we recommend treatment with phototherapy or systemic treatment with 
methotrexate (MTX). For deep involvement, methotrexate (MTX) is considered first line 
treatment. The addition of systemic corticosteroids should be considered in case of severe 
disease, rapid progression or (looming) contractures. Last year, the European Dermatology 
Forum S1‐guideline225 containing a section about treatment of LoS was published. Most striking 
discrepancy between the guideline and our presented treatment algorithm consists of the use 
of systemic MTX in superficial subtypes of LoS. In our experience treatment of widespread 
superficial disease sometimes require additional treatment with systemic anti-inflammatory 
agents, whereas the recent guidelines only describe topical agents and phototherapy as 
treatment options for these subtypes. We believe that in a minority of patients affected by 
superficial LoS additional treatment is required and that especially in widespread or treatment 
refractory superficial disease systemic treatment is justified. 
What is the daily practice effectiveness of conventional methotrexate treatment in 
adult patients with localized scleroderma?
The chronicity of LoS often requires prolonged treatment with the previously described 
treatment options. This especially holds true for MTX, prescribed in weekly doses, as this 
treatment modality is most often used in patients with more severe disease (subtypes). 
Although we have extensive experience with MTX as therapeutic option at our study 
centre, little evidence exists for MTX in adults with LoS.227 In chapter 3.1, we investigated 
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drug survival for MTX treatment in a large long-term daily practice cohort of LoS patients. 
Drug survival analyses allows to evaluate the treatment duration with a particular drug with 
regard to different outcomes of interest. Drug survival is a comprehensive outcome covering 
effectiveness, safety, and patients’ and doctors’ preferences.228 For this study, data was 
gathered from our retrospective cohort of adult patients with LoS treated with MTX (n=107). 
In chapter 3.1 we present that 26% and 63% of the patients stopped MTX due to disease 
remission after 1 and 2 years, respectively. The median time to MTX discontinuation because 
of disease remission was 87 weeks. In contrast to stopping as a result of achieving disease 
remission, 24% of the patients stopped MTX due to treatment failure within a year, because 
of side-effects or treatment ineffectiveness. Comparing our results to other studies is difficult, 
as we present the first data regarding drug survival of MTX in LoS.  Most studies that describe 
MTX in LoS focus on a paediatric population.27 28 32 178 182-184 Only three original papers describe 
MTX as a treatment option in adult patients; Seyger et al. 180 reported a beneficial effect of 
MTX in 66% of 9 patients after 24 weeks. Kreuter et al 179 reported a beneficial effect of MTX in 
combination with pulsed intravenous methylprednisolone in 14 out of 15 patients. Lastly, Kroft 
et al 185 reported remission rates of 51% and 73% for MTX mono- and combination therapy 
with prednisone in a cohort that contained sclerotic diseases other than LoS. In contrast to 
the papers published for LoS, drug survival studies are more frequently reported in other 
conditions. However, in most diseases, remission is not a reason to stop treatment. Shalom 
et al.256 present drug survival rates of MTX of only 59,3% after 1 year in 2632 patients with 
psoriasis. Consequently, this means that 40,7% stopped treatment within a year. However, 
the lack of detailed description of the discontinuation reasons in this study makes it difficult to 
compare with the results we presented in LoS.
With regard to predictors of drug survival, we showed that younger age at treatment initiation 
was associated with higher rates of disease remission. A possible explanation could be that 
older patients are more frequently affected by comorbidities, which may lower the chance 
of treatment success. Secondly not being affected by other autoimmune diseases, also 
increased the chance of achieving disease remission. The group of patients suffering from 
other autoimmune diseases might reflect a group of patients with more severe forms of the 
disease. Regarding treatment failure, we show that prescription of folic acid protected against 
treatment failure. The protective effect of folic acid against side-effects caused by MTX is 
well known in other disease like rheumatic diseases and psoriasis.257-259 These findings, in 
combination with scarcity of alternative treatments for MTX in LoS, emphasize the necessity 
of the prescription of folic acid to decrease the likelihood of MTX failure. Secondly, our results 
imply that more severe disease subtypes (i.e. the linear or deep subtypes) are more difficult 
to treat successfully as the milder superficial subtype was associated with a lower risk of 
treatment failure compared the severe subtypes. Most interestingly, we showed that patients 
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with a longer delay in MTX initiation were at greater risk of stopping MTX due to treatment 
failure. These data suggest that early treatment, as is desired in other diseases such as 
rheumatoid arthritis, is also preferred in LoS. 260-262 A recent publication by Zulian et al. also 
hints towards a worse outcome; defined as flaring of disease and not achieving complete 
remission, with a longer time from diagnosis to start of treatment and the first medication 
used.297 
In conclusion, in chapter 3.1 we demonstrate that in adult patients with LoS, 26% and 63% 
stopped MTX due to disease remission after 1 and 2 years, respectively. We have identified 
that younger patients and patients without other autoimmune diseases achieve disease 
remission during MTX-treatment more often. In addition, 24% of the patients stopped due to 
treatment failure within a year. With regard to minimizing treatment failure, we showed that 
adding folic acid and a reduction of treatment delay could be the most important factors in 
clinical practice.
Is mycophenolate mofetil an alternative treatment option in patients with localised 
scleroderma resistant or intolerant to previous treatment with methotrexate?
The observation of MTX treatment failure in nearly a quarter of the patients stresses the 
need for alternative treatments option for LoS and EF. Multiple case reports and small series 
have described other therapeutic options, often derived from previous reports in Systemic 
Sclerosis (SSc), as alternative treatments for the LoS-Spectrum. Recent case reports describe 
imatinib 191-194, infliximab102 103, rituximab98, abatacept195, tocilizumab298 299, the mTOR-inhibitors; 
tacrolimus196 and everolimus197 and mesenchymal stem cell therapy198 as alternative treatment 
options in severe LoS.
In chapter 3.2, we describe our experience with mycophenolate mofetil (MMF, Cellcept) in 
patients with severe LoS resistant or intolerant to MTX treatment. Mycophenolate mofetil is 
an ester derivative of mycophenolic acid, which selectively and non-competitively inhibits an 
important enzyme, inosine monophosphate dehydrogenase, required for the proliferation 
of lymphocytes. Therefore, blocking this enzyme may specifically inhibit multiple functions 
of lymphocytes. Mycophenolate mofetil was initially used for prevention of organ transplant 
rejection and several years later use of MMF for dermatological conditions ensued. A previous 
case series described stabilization of lung disease in patients with diffuse cutaneous systemic 
sclerosis (dcSSC) treated with MMF.265 Furthermore, one prospective observational study 
of MMF reported a marked improvement of skin involvement in patients with progressive 
dcSSc.266 A review by Cappelli et al. describes several observational studies with encouraging 
results of MMF on the modified Rodnan Skin Score in patients with SSc.267 Systemic Sclerosis 
and LoS likely share a common pathway given that the same cytokines and chemokines are 
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activated, leading to increased collagen and extracellular matrix deposition.48 These findings 
further support that MMF could be efficacious in LoS patients as well. 
In chapter 3.2 we describe 7 LoS patients treated with MMF. The median age at MMF 
initiation was 15 years (range 7-74). Three patients received MMF due to MTX ineffectiveness 
and 4 patients due to MTX intolerance. Disease remission was achieved in 4 patients and 
maintained in 1 patient. One patient showed a favourable response but had to discontinue 
treatment due to elevated liver enzymes. The remaining patient experienced progression of 
disease. The current paucity of evidence of MMF treatment in LoS patients motivated us to 
analyze the efficacy and safety of MMF in LoS patients from our hospital. Our findings indicate 
that MMF may be a suitable alternative to MTX in patients who experience MTX-intolerance 
or insufficient disease control, considering that the majority of our patients achieved disease 
remission when using MMF. One patient, with an extensive history of LoS refractory to various 
medications, showed disease progression under MMF treatment. 
Compared to other immunosuppressant medications, including MTX, MMF has a favourable 
safety profile.268 Common side effects of MMF are gastro-intestinal symptoms such as 
diarrhea and nausea. Hematological abnormalities, most frequently leucopenia, and increased 
susceptibility to infections, such as urinary tract infections, are also commonly observed.264 In 
this case series, one patient developed elevated liver enzymes after three months of MMF 
treatment, and another patient suffered diarrhea at MMF doses exceeding 1000mg daily. No 
other side effects were reported. Reviews on LoS treatment mention the use of MMF in LoS 
patients intolerant or refractory to MTX.253 270 271 However, to date, only one case series by 
Martini et al. described the effect of MMF in LoS patients, emphasizing the need for additional 
evidence to support this proposition. Martini et al. describe continuation of MTX treatment, 
concomitantly with MMF in 6 patients.188 In our study, all patients discontinued treatment with 
MTX at start of MMF. Hence, our description of case series provides additional evidence for 
the efficacy and safety of MMF in LoS patients and facilitates the decision to opt for MMF in 
LoS. However, further randomized controlled studies are warranted to further evaluate the 
efficacy of MMF in LoS patients. 
Is an aggressive treatment with high-dose intravenous methotrexate a safe and 
effective therapeutic option for eosinophilic fasciitis? 
For EF, aggressive treatment with high-dose systemic glucocorticoids combined with low-dose 
weekly MTX is often indicated. However, disappointing results are observed in a proportion of 
patients.14 185 200 272 Similar to the LoS-spectrum in general, additional therapeutic options are 
necessary. This statement is supported by our observations presented in chapter 2.2, in which 
we demonstrate severe sequelae in large proportion of patients. In addition, our observation 
of treatment failure with MTX in LoS, presented in chapter 3.1, also holds true for EF in our 
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experience in daily practice. The combination of sequalae in a large proportion of patients and 
the observation of treatment failure of MTX in daily practice stresses the need for alternative 
and importantly more effective treatments. In daily practice, we observed increased efficacy of 
MTX exceeding the conventional dosages (to a maximum of MTX S.C. 50mg/week) in patient 
with widespread disease or a clinical presentation of restrictive pulmonary disease as a result 
of circumferential truncal fibrosis. Irrespective of these increased beneficial effects, clinical 
results were still not satisfactory enough. Therefore, we investigated high-dose intravenous 
(IV) pulse MTX as a treatment option for EF. In chapter 3.3, we investigated the safety and 
effect of IV MTX (4mg/kg) monthly for 5 months with folinic acid rescue 24 hours after MTX 
administration in a prospective single-arm study containing 12 patients diagnosed with biopsy 
specimen-proven EF. The primary outcome was improvement of the modified skin score 
(mSS) at month 5 versus baseline. Secondary outcomes were durometry, RoM, visual analog 
scale scores for disease activity and 36-item Short-Form Survey health questionnaires. 
Overall, 12 patients (11 females, between 37-69 years old) received a median monthly dose 
of 288mg (range, 230-336mg) MTX. The median mSS score improved from 17.5 (range, 8.0-
24.0) at baseline to 8.5 (range,1.0-20.0) at month 5 (P=0·001). Secondary outcome measures 
improved significantly, except for durometer scores and range of motion impairment of the 
elbows. In addition, we demonstrate that the improvement in our outcome measures are 
clinically relevant to the patients, because patients report a significant increase in physical 
functioning, measured by the SF-36. Regarding safety, we observed no serious adverse 
events and the treatment was relatively well tolerated. Observed adverse events, such as 
gastro-intestinal symptoms and stomatitis could be managed accordingly. Interestingly, 
IV pulse MTX was effective in a subgroup of patients in which disease progressed during 
conventional treatment. These results implicate that pulsed IV MTX might be an alternative 
treatment option in patients who fail on conventional MTX treatment. Alternative treatments to 
weekly MTX have only been reported in case reports.14 151 205 210 272-275 Comparing results of this 
study to observational studies with MTX in EF is difficult, as these studies are retrospective 
and only report partial and complete remission rates, without specifying outcomes in different 
disease parameters.14 185 200 272 From the study results we conclude that high-dose IV pulse 
MTX is a safe and effective treatment option in EF. 
Are serum concentrations of cytokines and chemokines implicated in angiogenesis 
and inflammation suitable biomarkers of disease activity in localized scleroderma and 
eosinophilic fasciitis?
In chapter 2 we investigated clinical parameters to gain additional information of phenotypes 
at risk for a poor outcome. In daily practice, disease activity assessment remains problematic 
in individual patients; currently available clinical scoring tools and imaging modalities fail to 
accurately assess disease activity in large proportions of patients. Specifically, deep involvement 
is notoriously difficult to monitor, but has tremendous potential to lead to debilitating sequelae. 
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For the spectrum in general, defining remission and recurrence is difficult but important to 
adequately and timely initiate, increase or stop therapy. For current studies, the modified 
Localized Scleroderma Severity Index (mLoSSI) is often reported as outcome of choice for 
monitoring disease activity. The mLoSSI is widely reported in LoS literature and is relatively 
easy to asses. However, mLoSSI is limited in several aspects: 1) it only captures superficial 
components of disease activity (erythema and thickening of the skin). This potentially leads 
to misclassification of disease activity status in patients with active and progressive deep LoS 
and EF; 2) Skin thickening, one of the mLoSSI-items, may be irreversible and consequentially 
mLoSSI-scores do not always accurately reflect disease activity status. This latter especially 
holds true for EF; in chapter 2.2 we describe irreversible skin fibrosis, and consequentially 
elevated mLoSSI scores, in large proportions of patients affected by this subtype after many 
years of quiescent disease; 3) No studies have investigated ideal cut off values for mLoSSI to 
define inactive, minimally active or active disease. These limitations underscore the dire need 
of additional and accurate biomarkers for disease activity in LoS. Identification of additional 
tools to determine disease activity should ultimately aid caregivers to individualize and 
optimize treatment regiments. 
A recent study by O’Brien et al. reported that CXCL9 and CXCL10 are present at increased 
concentrations in serum from LoS patients and that CXCL9, but not CXCL10, serum 
concentrations correlate with measures for disease activity.230 In chapter 4.1, we confirmed 
increased CXCL9 and CXCL10 serum concentrations in a cohort of 80 LoS patients. However, 
in contrast to O’Brien et al. we report similar correlations between measures for disease 
activity (modified Localized Scleroderma Skin Severity Index, mLoSSI) and both CXCL9 and 
CXCL10 serum concentrations. This observation suggests equal biomarker capabilities for 
both chemokines. In addition, high-throughput transcriptome sequencing of LoS skin samples 
demonstrated increased gene expression of both CXCL9 and CXCL10 in LoS skin. Lastly, 
we did not observe altered CXCL9 and CXCL10 gene expression in circulating monocytes, 
supporting the theory postulated by O’Brien et al., that LoS may result from skin-directed 
immune dysregulation rather than a systemic dysregulation as in SSc.
In addition to CXCL9 and CXCL10, 37 other chemokines and cytokines, involved in 
angiogenesis and inflammation, were investigated in our LoS and EF cohort. In chapter 4.2, 
we demonstrate that by screening 39 inflammatory mediators for their relevance in LoS, we 
found elevated levels of CCL18, CCL19, TIE-1, CXCL13, IL-18, TNFII, Galectin-9, CXCL9, 
CXCL10 and sVCAM in LoS. 
Cluster analyses of the 10 elevated inflammatory markers revealed that disease activity status, 
defined by mLoSSI, was the most important clinical feature that correlated with circulating 
levels. After the identification of the association between serum cytokine levels and disease 
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activity status, we demonstrated that CCL18 was the most important analyte able to separate 
active from inactive LoS patients. The potential of CCL18 to function as biomarker of disease 
activity was confirmed by ROC-analyses: CCL18 demonstrated the highest area under the 
curve (AUC) to discriminate between active and inactive LoS patients. In addition, CCL18 
had superior correlation coefficient to mLoSSI, and its level normalised in individual patients 
effectively treated with immunosuppressive therapies. Based upon these observations and 
the finding that increased CCL18 levels were specific for LoS, and not in JDM or SMA, we 
propose CCL18 as a novel biomarker for disease activity in LoS.  
CCL18 was originally termed pulmonary and activation-regulated chemokine (PARC) 283 
and is known to exhibit chemotactic activity, via the recently discovered receptor CCR8 284 
toward multiple immune cells.283 285-288 In addition to the immunomodulatory effect, CCL18 
also stimulates the production of collagen in pulmonary and cutaneous fibroblasts in vitro and 
in murine models. In line with experimental studies, high levels of CCL18 are observed in 
multiple inflammatory and fibrotic conditions. 290 291 In patients affected by idiopathic pulmonary 
fibrosis, increased levels of serum CCL18 correlated with high collagen accumulation and 
T lymphocyte infiltration in the lung. 292 Furthermore, CCL18 also correlated with clinical 
outcome measures associated with a poor outcome such as lung function impairment and 
decline, and risk of future acute exacerbations and mortality at 6 months 293. Likewise, CCL18 
serum concentrations have been demonstrated to be increased in SSc in 35% of the patients 
and CCL18 levels predicted progression of lung fibrosis, lung function decline and mortality at 
5 and 10 years. 294 295 Besides pulmonary fibrotic conditions, CCL18 has been demonstrated 
to be increased in diseases characterized by T and B lymphocyte dysfunction such as 
Sjogren syndrome, giant cell arteritis, rheumatoid arthritis and bullous pemphigoid 283 .We 
demonstrated that CCL18 gene and protein expression is increased at the inflammatory border 
of cutaneous LoS lesions, with normal gene expression in unaffected skin and circulating 
immune cells. These observations suggest that the source of CCL18 is the inflammatory skin 
of LoS patients. How increased CCL18 levels are elicited may shed light on the pathogenesis 
of LoS but remains to be investigated.
Clinical evaluation of LoS has demonstrated to be challenging with suboptimal treatment 
approaches as a result. In chapter 4.2, we identified CCL18 as a valuable biomarker for 
disease activity in LoS patients. Importantly, cytokine measurements such as CXCL9, CXCL10 
and CCL18 will not replace but complement clinical assessment by experienced health care 
professionals. However, values below the set cutoff most likely reflect absence of residual 
inflammation, enabling the tapering of immunosuppressive medication, whereas rising levels 
may predict relapses and therefore indicate the need for intensification of treatment.
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FUTURE PERSPECTIVES
In this thesis we have investigated the heterogeneous phenotype of LoS and EF. We have 
identified clinical predictors for a poor outcome and have identified serum concentrations of 
CCL18, CXCL9 and CXCL10 as potential biomarkers for disease activity in LoS and EF. First 
and foremost, replicational studies of our biomarker studies are warranted. Second, longitudinal 
measurement of clinical outcome measurements, such as LoSCAT, RoM measurements, and 
PROMs together with assessment of CCL18, CXCL9 and CXCL10 at baseline and during 
follow-up should gain more insight in the added value of these potential biomarkers. The 
ultimate goal of this near future study would be to identify: 1) a more sensitive tool for disease 
activity assessment, thereby allowing immunosuppressant drug management more carefully 
and informed, ultimately leading to less under-and overtreatment, and 2) prognostic markers 
for poor outcome of LoS/EF. 
Looking further ahead, studies should focus on unraveling inflammatory and fibrotic pathways 
involved in LoS and EF, thereby gaining insight in disease pathogenesis, and identify 
potential biomarkers and therapeutic targets. In this thesis we present molecular markers for 
disease activity, which are identified via hypothesis-driven methodology; preselected targets 
were identified for biomarker potential. This approach introduces selection bias, ‘interesting 
targets’ were selected based on current literature. However, more potent biomarkers for 
disease activity most likely exist, but are not investigated. Localized Scleroderma and EF 
pathogenesis most likely occurs in a background of complex interactions between multiple 
biological layers of the immune system. Unravelling disease pathogenesis and identifying 
molecular markers therefore also requires are a more holistic and exhaustive experimental 
approach investigating all these layers in an unbiased way. ‘Systems Medicine’ has emerged 
as a translational extension of systems biology and is such an approach. 300 ‘Systems 
medicine’ exploits a multitude of strategically exploited ‘OMICS’ layers (e.g. transcriptome, 
epigenome, proteome and metabolome of individual immune cells subsets or serum/plasma) 
and ultimately integrates these data layers with high performance computational modelling 
to an underlying network of nodes leading to disease. Via this approach potential biomarkers 
and treatment candidates could be potentially identified in future studies. Ideally, this individual 
marker or panel of markers reflects the active substrate of both superficial and deep LoS and 
EF, is assessed in easily assessed biofluids (e.g. dry-blood spots) and ultimately informs the 
physician about the future course of the disease.
In addition to future biomarker studies, investigations should focus on additional treatment 
options. In this thesis we described our investigations on high dose IV pulse MTX as a safe and 
alternative treatment option for EF. Future studies regarding high dose IV pulse MTX should 
focus on gaining evidence in a larger population, preferably in a multi-centre setting, and 
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potentially in a multi-arm setup comparing high dose IV MTX pulse to conventional treatment. 
In addition to primary clinical outcome measures and patient reported outcome measures, 
CXCL9, CXCL10 and CCL18 should be included as secondary outcome measures. Besides 
high-dose IV MTX, additional therapeutic options are still needed, specifically modalities 
reducing residual fibrosis are required. Potential treatment candidates could be deduced 
from SSc research. One such candidates is the tyrosine kinase inhibitor Imatinib (Gleevec), 
which already has successfully been prescribed to treatment refractory LoS patients at 
our study centre. Other potential candidates which have been described in case reports or 
small series are the IL-6 inhibitor Tocilizumab 210 298 299 or T-cell-inhibitor Abatacept. 195 301 302 
Additionally, multiple novel agents are currently being investigated in Phase II or III either 
targeting inflammation or fibrosis in SSc and depending on study results the efficacy could be 
investigated in a LoS/EF population.      
Future biomarker- and treatment studies should be conducted in close collaboration between 
the departments of dermatology and rheumatology as these patients often require expertise 
from both specialties.  In addition to collaboration between specialties, centralization of care 
in tertiary centres should add to quality of care for patients affected by these rare diseases. 
Disease activity assessment and treatment remains challenging and requires extensive 
clinical experience which should be warranted via centralization of care in expert centres. 
Centralization, collaboration and future research all aim to optimize care of patients affected 
by these debilitating conditions. 
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Het ziektebeeld gelokaliseerde sclerodermie (LoS), ook wel bekend als morphea, omvat 
een groep zeldzame aandoeningen waarbij de huid en het onderliggend bindweefsel 
verlittekenen. Over de ontstaanswijze van LoS is weinig bekend. Het ziektebeeld omvat 
een heterogene groep aandoeningen waarbij patiënten met relatief milde en oppervlakkige 
varianten, zoals ‘morfea en plaque’ , toch veel last kunnen hebben van lokaal ongemak door 
jeuk en pijn. Daarnaast bestaan ernstige en uitgebreide varianten waarbij diepe verlittekening 
van onderhuidse structuren, zoals vet of zelfs spieren, op kan treden. Voorbeelden van 
deze laatstgenoemde categorie zijn lineaire LoS, waarbij streepvormige verlittekening over 
gewrichten van extremiteiten kan lopen en zo tot invaliderende bewegingsbeperkingen en 
lengteverschil van de extremiteiten kan leiden. Een andere ernstige variant is Eosinofiele 
Fasciitis (EF), een ziekte ook wel bekend als het Shullman Syndroom. Bij EF verlittekent 
de fascie rondom spieren over grote gebieden van het lichaam en leidt zo tot invaliderende 
bewegingsbeperkingen waarbij soms de verlittekening zo uitgebreid is dat harnasvorming van 
de romp in een bedreigde ademhaling resulteert.
Het ziektebeloop bij LoS en EF bestaat grofweg uit twee delen. Vroege ziekte wordt 
gekarakteriseerd door ‘actieve ziekte’ met ontsteking van de huid en onderliggende structuren 
waarbij bestaande plekken uitbreiden en nieuwe plekken ontstaan. Vervolgens ontstaat een 
ziekte-episode met milde ontsteking, maar toenemend ziekteschade door verlittekening. 
Schade bestaat daarnaast uit verlies van aangedaan weefsel (atrofie van de huid of spieren) 
en hyper- of hypopigmentatie van de huid. 
Wat is het lange-termijn klinisch beloop van gelokaliseerde sclerodermie en 
eosinofiele fasciitis?
In de leerboeken staat vermeld dat de actieve fase van LoS veelal 3 tot 5 jaar duurt en 
dat de ziekte dan uitblust en rustig blijft. Echter, in de dagelijkse behandeling van patiënten 
ondervonden wij een grilliger ziektebeloop; een grote groep patiënten ontwikkelde meerdere 
episodes van ziekteactiviteit. In hoofdstuk 2.1, hebben wij onderzocht hoe vaak deze 
recidiverende episodes van ziekteactiviteit voorkwamen bij zowel kinderen en volwassen 
met LoS. Het betrof statusonderzoek van alle patiënten die het Radboud UMC bezocht 
hebben vanaf 1990. De studiepopulatie omvatte 119 (35%) patiënten waarbij de ziekte op 
kinderleeftijd ontstond en bij de resterende 225 (65%) patiënten ontstond de aandoening op 
volwassen leeftijd. Recidief van ziekteactiviteit werd geobserveerd bij 27% van de kinderen 
en 17% van de volwassenen met LoS. Verdere analyses richtten zich op het aantonen van 
ziekte- of patiënten karakteristieken die geassocieerd waren met een verhoogde kans op 
het ontwikkelen van een recidief. Aanvullende analyses toonden aan dat vooral patiënten 
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met het subtype lineaire LoS, ongeacht de leeftijd van het ontstaan van ziekte, een hoger 
risico op ziekte reactivatie hadden. Hernieuwde activiteit van ziekte werd tot wel 20 jaar na 
ziekteremissie gezien. Dit betekent dan ook dat zowel patiënten als behandeld artsen extra 
bedachtzaam moeten zijn op reactivatie van de ziekte, met name bij mensen met lineaire 
varianten van LoS. Het uiteindelijke doel van vroegdetectie van ziekte reactivatie is om zo 
snel mogelijk weer met therapie te kunnen starten om zo schade van ziekte te voorkomen. We 
adviseren dat patiënten met ernstige ziektevarianten langer poliklinisch gecontroleerd moeten 
worden en dat patiënten goed geïnstrueerd dienen te worden op tekenen van reactivatie bij 
ontslag uit poliklinische controle.
Naast het beschrijven van de ziekte-reactivatie, hebben we ook gekeken naar de mate van 
ontwikkeling van ziekteschade. Ziekteschade bestaat uit onomkeerbare verlittekening, verlies 
van aangedaan weefsel (resulterend in een dunne huid en/of verlies van subcutaan vet of 
spierweefsel) en verkleuring van de huid. Vooral in de groep patiënten met EF, de zeldzame 
maar ernstige ziektevariant in de groep van LoS, zien we vaak uitgebreide onomkeerbare 
schade. Echter, lang niet alle patiënten ontwikkelen deze mate van schade; sommige 
patiënten hebben geringe klachten en anderen zijn ernstig geïnvalideerd.  Dit heterogene 
beloop maakt het lastig om de optimale behandeling te kiezen; je wilt patiënten niet onder-
behandelen, omdat dit mogelijk tot meer ziekteschade leidt, maar overbehandeling kan tot 
meerdere ongewenste bijwerkingen van de gegeven medicijnen leiden. Er zijn maar weinig 
onderzoeken gedaan naar ziekteschade in EF.
In hoofdstuk 2.2, hebben we de mate van ziekteschade van alle patiënten met EF uit het 
Radboudumc onderzocht door middel van  lange-termijn follow-up. Daarnaast hebben we 
onderzocht welke patiënteigenschappen meer kans geven op het ontwikkelen van ernstige 
onomkeerbare schade. Voor deze studie zijn 35 EF patiënten eenmalig gezien op polikliniek 
dermatologie. Hierbij demonstreerden we dat alle 35 patiënten enige mate van ziekteschade 
hadden; de mate van schade varieerde hierbij van mild tot zeer ernstig. Allereerste toonden we 
aan dat meer dan de helft van de patiënten restverlittekening van de huid rondom de enkels 
ondervond met bewegingsbeperkingen van de enkels als gevolg. Polsen en knieën waren 
minder frequent aangedaan. Vragenlijstenonderzoek bij patiënten liet zien dat de mate van 
ziekteschade ook de kwaliteit van leven negatief beïnvloed. Mensen gaven in de vragenlijsten 
aan dat ze voornamelijk fysiek beperkt werden door de restafwijkingen. Nadere analyses 
demonstreerden dat mensen met ernstige ziekteverschijnselen bij presentatie ook op de 
lange termijn meer ziekteschade ontwikkelen. Ernstige ziekteverschijnselen in deze context 
zijn verhoogde ontstekingswaarden in het bloed en  bijkomende verlittekening van de romp en 
nek (c.q. de uitgebreidheid van de ziekte). Daarnaast toonden we aan dat oudere patiënten bij 
ontwikkelen van LoS meer ziekteschade ontwikkelden. Naar aanleiding van deze resultaten 
dient onderzocht te worden of patiënten met deze eigenschappen agressiever behandeld 
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moeten worden met het uiteindelijke doel om invaliderende ziekteschade te voorkomen. 
Patiënten met een verhoogde kans op het ontwikkelen van ernstige ziekteschade hebben 
mogelijk baat bij agressievere behandelingen om zo ziekteschade te beperken.
Samenvattend kunnen we naar aanleiding van hoofdstuk 2 concluderen dat zowel LoS als 
EF chronische aandoeningen zijn waarbij frequent meerdere episodes van ziekteactiviteit 
optreden. Reactivatie van de ziekte treedt frequenter op bij de ernstige subtypes zoals lineaire 
LoS en EF. Daarnaast toonden we dat EF patiënten zeer veel restschade kunnen ontwikkelen 
en dat patiënten met een ernstig beloop bij ziektepresentatie ook meer ziekteschade 
ontwikkelen. Risicogroepen moeten in de dagelijkse praktijk beter vervolgd worden door de 
behandeld arts. Het uiteindelijke doel hiervan is om reactivatie van ziekte vroeg te detecteren 
en therapie snel te hervatten zodat de ontwikkeling van nieuwe ziekteschade voorkomen kan 
worden.
Wat is de effectiviteit van conventionele methotrexaat behandeling bij volwassenen 
met gelokaliseerde sclerodermie in de dagelijkse praktijk?
Er is geen genezende behandeling voor LoS. De behandelingen zijn gericht op het verminderen 
van de symptomen en op het beperken van de uitbreiding van de plekken. Over het algemeen 
geldt dat de effectiviteit van de behandeling groter is in de vroege ‘actieve’ fase van de ziekte. 
Dit benadrukt het belang van gevoelige methoden om (vroege) ziekteactiviteit vast te stellen. 
Een vroegtijdige behandeling is namelijk van belang om de littekenvorming, verkleuring en 
uitbreiding van de plekken te voorkomen of te beperken. Bij ‘morphea en plaque’, de relatief 
milde vorm waarbij sprake is van één of enkele plekken, wordt vaak behandeld met een 
ontstekingsremmende zalf (corticosteroiden, calcineurineremmers of vitamine D3-analogen). 
Als deze vorm heel uitgebreid is, kan gekozen worden voor  een bepaald soort lichttherapie 
(UVA1).  Bij zeer uitgebreide of gecompliceerde en/of diepe ziekte kan ervoor gekozen 
worden om te behandelen met de immuunsysteem onderdrukkende medicijnen prednison en 
methotrexaat (MTX). Indien laatstgenoemde behandelingen falen dan wordt er veelal gebruikt 
gemaakt van immuunsysteem onderdrukkende medicijnen waarmee bij andere ziektebeelden 
ervaring is opgedaan. Echter, de bewijslast voor de effectiviteit van de meeste behandelingen 
voor LoS en EF is gering.
Zoals in hoofdstuk 2 beschreven heeft LoS veelal een chronisch beloop. Hierdoor worden 
patiënten vaak langdurig behandeld. Patiënten met een ernstig subtype hebben veelal een 
langdurig behandeltraject met daarbij ook zwaardere medicijnen die voorgeschreven moeten 
worden. Dit kan onder andere met wekelijkse dosis MTX per os of subcutaan toegediend. Er 
zijn maar weinig studies gedaan naar de effectiviteit van MTX bij volwassenen met LoS. In 
hoofdstuk 3.1 hebben we retrospectief onze ervaringen met MTX in LoS bij volwassenen 
(N=107) onderzocht. De voornaamste resultaten van deze studie lieten zien dat 26% van de 
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patiënten binnen 1 jaar kon stoppen met MTX omdat ziekteremissie bereikt was. Ditzelfde 
gold voor 63% van de patiënten binnen 2 jaar. De mediane behandelduur tot het bereiken van 
ziekteremissie was 87 weken. We lieten zien dat jongere patiënten vaker succesvol behandeld 
werden. Een mogelijke verklaring hiervoor is dat oudere mensen meer comorbiditeiten 
hebben wat mogelijk effect kan hebben op het succes van behandeling. Daarnaast zagen 
we dat mensen met andere autoimmuunaandoeningen ook een lagere kans hadden om 
succesvol behandeld te worden. Deze laatstgenoemde patiëntengroep reflecteert mogelijk 
een complexer ziektebeeld waarbij agressievere behandeling mogelijk gerechtvaardigd is.
Naast stoppen door het bereiken van ziekteremissie kunnen mensen ook met therapie 
stoppen door het optreden van bijwerkingen of door therapie falen. Bijna een kwart (24%) 
van de patiënten moest binnen 1 jaar stoppen met MTX door bijwerkingen of door het falen 
van therapie. We zagen hierbij dat het toevoegen van foliumzuur de kans op het stoppen 
door bijwerkingen verkleinde, hetgeen we kennen van  andere ziekten waarbij MTX een 
behandeloptie is (reumatoïde artritis en psoriasis). Nadere analyse toonde aan dat patiënten 
met ernstigere ziektesubtypes (i.e. lineaire of diepe LoS) frequenter met de MTX stopten door 
therapie falen. Deze observatie is extra wrang aangezien patiënten met deze subtypes veelal 
wel langdurige krachtige behandeling behoeven. Afsluitend observeerden we dat bij mensen 
waarbij langer gewacht werd met het starten van therapie de kans op therapie falen groter is. 
De observatie van deze laatste associatie suggereert dat vroegbehandeling zinvol is in LoS. 
Een gedachtegang welke reeds welgevestigd is in reumatische ziektebeelden en gebaseerd 
is op het feit dat het voorkomen van ziekteschade effectiever is bij behandeling vroeg in het 
ziektebeloop.
Is mycofenolaatmofetil een alternatieve behandeloptie voor patiënten met 
gelokaliseerde sclerodermie die voorheen gefaald hebben op methotrexaat?
Zoals we in hoofdstuk 3.1 hebben gedemonstreerd, is MTX bij  bijna een kwart van de patiënten 
niet voldoende effectief . Deze patiënten behoeven veelal alternatieve behandelingen. Echter, 
de bewijslast voor alternatieve behandelingen in LoS is gering. In hoofdstuk 3.2 tonen we 
onze ervaringen met mycofenolaatmofetil (MMF, Cellcept) bij 7 patiënten met LoS. MMF is 
een geneesmiddel dat het immuunsysteem onderdrukt en  frequent wordt voorgeschreven bij 
patiënten met systemische sclerose. In het Radboudumc is het een relatief frequent gekozen 
alternatief als patiënten falen op MTX. Onze kleine case series toonde aan dat bij 4 patiënten 
de ziekte rustig werd na starten van MMF. Bij 1 patiënt bleef de ziekte in remissie. De resterende 
2 patiënten moesten stoppen met MMF. Oorzaken voor het staken van MMF was bij 1 patiënt 
het optreden van bijwerkingen en bij de andere patiënt bleef de ziekte progressief en moet 
er derhalve voor een alternatieve behandeling gekozen worden. Deze case series laat zien 
dat MMF in sommige gevallen  een geschikt alternatief kan zijn voor patiënten met (ernstige) 
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LoS. In de toekomst zal verder onderzoek gedaan moeten worden naar de vergelijking tussen 
MMF en MTX.
Is agressieve behandeling met hoge dosis intraveneuze methotrexaat een veilige en 
effectieve behandeling voor eosinofiele fasciitis?
Voor EF is een agressieve behandeling met hoge dosis prednison in combinatie met wekelijks 
MTX geïndiceerd. Echter, bij deze behandeling zien we frequent teleurstellende resultaten 
en is er derhalve vraag naar alternatieve behandelingen. Dit wordt onderstreept door onze 
bevindingen in hoofdstuk 2.2 waarbij we ernstige onomkeerbare ziekteschade bij patiënten 
met EF aantoonden. In hoofdstuk 3.3 onderzochten we de veiligheid en effectiviteit van hoge 
dosis methotrexaat (4mg/kg/maand) in 12 patiënten met EF. Het voornaamste resultaat van 
de studie was dat de mate van huidverdikking significant afnam na 5 maanden behandeling 
met een hoge dosis MTX. Secundaire uitkomst maten zoals bewegingsbeperkingen en 
kwaliteit van leven gerapporteerd door patiënten herstelden ook ten tijde van de behandeling. 
Een interessante toevoeging was dat er in deze studie ook patiënten zaten welke gefaald 
hadden op conventionele therapie (orale, dan wel subcutane MTX) en derhalve zou hoge 
dosis IV MTX ook een behandeloptie kunnen zijn voor patiënten die eerder gefaald hebben 
op conventionele therapieën. Een andere belangrijke observatie was dat er geen ernstige 
bijwerkingen optraden en dat de behandeling redelijk getolereerd werd. De bijwerkingen 
die voornamelijk optraden waren misselijkheid en diarree welke goed behandeld konden 
worden middels ondersteunende therapie. De resultaten gepresenteerd in hoofdstuk 3.3 zijn 
veelbelovend en toekomstige studies dienen zich te richten op vergelijkende studies met hoge 
dosis IV MTX en de conventionele behandelingen voor EF. 
Zijn serumconcentraties van cytokines en chemokines die betrokken zijn 
bij angiogenese en ontsteking geschikte biomarkers voor ziekteactiviteit in 
gelokaliseerde sclerodermie en eosinofiele fasciitis?
Het bepalen van ziekteactiviteit van LoS blijft in de dagelijkse praktijk zeer uitdagend; met 
de huidige klinische scores en beeldvormende technieken kan ziekteactiviteit onvoldoende 
precies gedetecteerd worden. Dit is voornamelijk het geval bij patiënten waarbij diepe 
structuren zoals vetweefsel en/of spieren aangedaan zijn. Het detecteren van ziekteactiviteit 
is echter essentieel aangezien dit bepaalt of er immuunsysteem onderdrukkende therapie 
gestart, dan wel gestaakt dienen te worden. In hoofdstuk 4 onderzochten we of bepaalde 
cytokine- en chemokine-concentraties in het bloed verhoogd of juist verlaagd zijn in het 
geval van ziekteactiviteit en dientengevolge zouden kunnen fungeren als biomarker voor 
ziekteactiviteit in LoS. Het uiteindelijke doel hiervan is om extra handvatten te krijgen bij de 
besluitvorming omtrent starten en staken van therapie.
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Een recente studie van O’Brien et al. toonde aan dat CXCL 9 en CXCL 10 mogelijke goede 
markers voor ziekteactiviteit in LoS zijn. In hoofdstuk 4.1 bevestigen we dit; patiënten met 
actieve ziekte toonden verhoogde waardes van CXCL9 en CXCL 10 in het bloed. Nadere 
analyses lieten zien dat deze stoffen waarschijnlijk in de actieve LoS huid gemaakt worden en 
vanuit deze plek in het bloed terecht komen. In hoofdstuk 4.2 tonen we na het screenen van 
39 cytokines en chemokines dat CCL18, CCL19, TIE-1, CXCL13, IL-18, TNFII, Galectin-9, 
CXCL9, CXCL10 en sVCAM verhoogd zijn in LoS. In verdere analyses onderzochten 
we welke markers het best geschikt zouden zijn om ziekteactiviteit in LoS te detecteren. 
Hierbij toonden we aan dat CCL18 de meest geschikte kandidaat is om als biomarker voor 
ziekteactiviteit in LoS gebruikt te worden. Concluderend kunnen we stellen dat klinische 
monitoring in LoS op dit moment moeizaam is. We tonen in ons onderzoek in hoofdstuk 
4 aan dat CCL18, maar ook CXCL9 en CXCL10 geschikte biomarkers voor ziekteactiviteit 
in LoS zijn. Het idee is dat deze bloedwaardes extra informatie over de ziekteactiviteit van 
patiënten geven. Hoge waardes reflecteren ziekteactiviteit en rechtvaardigen (handhaving) 
van immuunsysteem onderdrukkende medicijnen waarbij lage waardes van deze cyto- en 
chemokines ziekteremissie reflecteren en derhalve een conservatief beleid rechtvaardigen. 
TOEKOMSTPERSPECTIEF
In deze thesis hebben we  het heterogene klinisch beloop van LoS en EF onderzocht. 
We hebben klinische eigenschappen beschreven die geassocieerd zijn met een slechter 
ziektebeloop. Daarnaast hebben we aangetoond dat CCL18, CXCL9 en CXCL10 
veelbelovende biomarkers zijn voor ziekteactiviteit in LoS. Allereerst dienen onze resultaten 
gerepliceerd te worden door andere studiegroepen voordat deze biomarkers routinematig 
ingezet kunnen worden. Daarnaast zouden de biomarkers nader onderzocht moeten worden 
in een longitudinaal onderzoek. De echte kracht van biomarkers is dat we eerder in het 
ziektebeloop nieuwe ziekteactiviteit zouden kunnen detecteren. Dit behoeft onderzoek van 
meerdere jaren waarbij op vaste momenten klinische gegevens en bloed van patiënten 
verzameld worden. Het ultieme doel van deze studies is: 1) onderzoeken of de biomarkers 
van toegevoegde waarde zijn in de besluitvorming betreffende starten of stoppen van 
immuunsysteemonderdrukkende medicijnen met het idee dat ze gevoeliger ziekteactiviteit 
kunnen detecteren, 2) onderzoeken of biomarkers prognostische informatie leveren over het 
beloop van de ziekt. Ontwikkelen mensen met hoge biomarker waardes meer restschade of 
frequent hernieuwde ziekteactiviteit?
Een belangrijk doel is om meer inzicht te krijgen in de ontstaanswijze van LoS. Inzicht krijgen 
in welk type ontsteking er speelt en hoe de verlittekening optreedt moet uiteindelijke leiden 
tot nieuwe therapeutische mogelijkheden. Tevens liggen er mogelijkheden in het uitgebreider 
testen van potentiële biomarkers. Middels recente technische ontwikkelingen kunnen we in 
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plaats van de 39 geteste cytokines en chemokines in onze studie,nu duizenden targets tegelijk 
onderzoeken. Hiermee neemt de kans op ontdekken van relevante biomarkers enorm toe.
Naast de identificatie van biomarkers zou het  onderzoek zich voornamelijk moeten richten op 
nieuwe behandelopties. In deze thesis beschrijven we dat een hoge dosis MTX intraveneus 
een  veelbelovende alternatieve behandeling is voor patiënten met  EF. Deze hoge dosis 
intraveneuze MTX  zal  in grotere patiëntengroepen onderzocht moeten worden, bij voorkeur in 
meerdere behandelcentra, en waar mogelijk vergeleken moeten worden met de conventionele 
behandeling. Naast klinische uitkomstmaten zoals huidscores en patiënt gerapporteerde 
uitkomstmaten zouden in deze studies de door ons onderzochte biomarkers (CCL18, CXCL9 
en CXCL10) meegenomen kunnen worden. Naast hoge dosis MTX intraveneus is er ook 
grote behoefte aan nieuwe medicijnen  voor de behandeling van EF.  Met name middelen die 
(rest)fibrose aan kunnen pakken zouden zeer interessante behandelmodaliteiten zijn. 
Al deze studies kunnen het beste plaatsvinden in samenwerking van dermatologie en 
reumatologie aangezien patiënten frequent door beide specialisten behandeld worden. 
Naast samenwerking tussen specialismen zou LoS- en EF-zorg gecentraliseerd moeten 
worden in enkele tertiaire centra met als uiteindelijke doel de zorg voor patiënten met deze 
zeer zeldzame ziektes te optimaliseren. Het monitoren van ziekteactiviteit blijft het meest 
uitdagende aspect van zorg en behoeft ervaring met het begeleiden van patiënten met deze 
ziekten. Centralisatie, samenwerking en toekomstig onderzoek moeten uiteindelijk leiden tot 
optimalisatie van de zorg van patiënten met deze invaliderende aandoeningen.
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This thesis is based on the results of human studies, which were conducted in accordance 
with the principles of the Declaration of Helsinki. The medical and ethical review board 
Committee on Research Involving Human Subjects Region Arnhem Nijmegen, Nijmegen, the 
Netherlands has given approval to conduct these studies.
Published data generated or analyzed in this thesis are part of published articles and its 
additional files are available from the associated corresponding authors on request.
The primary and secondary data obtained during my PhD at the Radboud university medical 
center (Radboudumc) have been captured and stored ‘Statistical Package for the Social 
Sciences’ (SPSS) files and  centrally stored and daily backed-up on the local Radboudumc 
server. During the course of this thesis, multiple databases were created to save the patient 
derived data. There are separate files for databases for the publications presented in chapter 
2 and 3, respectively. All databases were encrypted with a password and created using the 
latest versions of SPSS. The databases did not contain information regarding the identity of 
the patient (such as name or social security number) and only contained coded-anonymous 
information.
Regarding chapter 4, the participating patients signed informed consent before participatin. The 
physician filled in the research form on paper. The paper data were stored in the department 
archive (Radboudumc, dermatology). The isolated immune cells and skin samples are stored 
at the laboratory of translational immunology (LTI) in de UMC Utrecht. Files containing the 
exact location of each individuals’ material is stored at a centrally available file database at 
the UMC Utrecht. An audit trail was incorporated to provide evidence of the activities that has 
altered the original data. The privacy of the participants in this study is warranted by use of 
encrypted and unique individual subject codes. This code correspondents with the code on 
the patient- and physicians booklets. The code was stored separately from the study data. 
The data will be saved for 15 years after termination of the study (March 1, 2018). Using these 
patient data in future research is only possible after a renewed permission by the patient as 
recorded in the informed consent. The datasets analyzed during these studies are available 
from the corresponding author on reasonable request.
535444-L-bw-Mertens
Processed on: 12-9-2019 PDF page: 216
216                                   
535444-L-bw-Mertens
Processed on: 12-9-2019 PDF page: 217
DANKWOORD (ACKNOWLEDGEMENTS)
 217 
DANKWOORD (ACKNOWLEDGEMENTS)
Geachte prof. dr. De Jong, beste Elke! Dankjewel voor alles. Vooral dank voor de vrijheid en 
het vertrouwen. Je hebt me nooit een taak opgelegd; ik kon letterlijk doen waar ik zin in had 
en wat mij nuttig leek. Dit past enorm goed bij mijn persoonlijkheid en mede daardoor denk 
ik dat we mooi werk afgeleverd hebben. Ik heb me altijd erg begrepen gevoeld bij je en je 
supervisie heb ik als zeer fijn ervaren. Ik hoop dat je met net zoveel plezier terugkijkt op onze 
samenwerking als ik. Ik hoop dat we in de toekomst nog met elkaar samen mogen werken!
Geachte prof. dr. Radstake, beste Tim. Dankjewel voor het bieden van deze unieke kans 
om bij dit zeldzame ziektebeeld zulk onderzoek te doen. Ik bewonder en deel je visie over 
‘molecular reclassification’ van reumatische aandoeningen. Je hebt me inzicht gegeven hoe 
het er in het translationele onderzoek aan toe gaat en tevens heb ik kennisgemaakt met het 
fundamentele onderzoek. Ik dank je voor onze fijne en productieve meetings, waarbij deze 
soms in je prachtige huis in Breedeweg plaatsvonden.
Geachte dr. Seyger, beste Marieke. Bedankt voor de mogelijkheid om ook de kinderen met 
morfea en eosinofiele fasciitis bij het onderzoek te betrekken. Dit heeft veel bijgedragen aan 
de generaliseerbaarheid van onze resultaten. Tevens wil ik je bedanken voor je feedback bij 
de artikelen.
Dr. Marut, dear Wiola, thanks for the nice collaboration and for guiding me in the unknown 
world of fundamental science. I remember starting in Utrecht without any lab experience, but 
you made me feel comfortable in your group. I appreciate your help with everything. And of 
course we share our love for cats!!
Ik wil de leden van de manuscriptcommissie hartelijk danken voor de tijd en moeite om mijn 
manuscript te beoordelen.
Paranimfen Floris en Wulphert, bedankt dat jullie tijdens de verdediging naast mij willen staan. 
Verderop komen jullie nog “uitvoeriger” aan bod.
De afdeling reumatologie van het Radboud UMC, en dan vooral Rogier Thurlings, dank voor 
jullie samenwerking en input. Onze patiëntengroep viel veelal tussen beide specialismen en 
je/jullie input en behulpzaamheid met het verkrijgen van samples werden zeer gewaardeerd. 
Frank van den Hoogen, dank voor je hulp bij de intraveneuze methotrexaat studie; ik 
waardeerde zeer dat je zo betrokken was bij de totstandkoming van dit artikel.
535444-L-bw-Mertens
Processed on: 12-9-2019 PDF page: 218
218                                   
Dr. Kievit, beste Watske. Dank voor je feedback op het gebied van statistiek en methodologie. 
Zoals Elke veelal aangaf; ‘het statistisch geweten van onze klinische artikelen’! Ik heb onze 
samenwerking als erg plezierig ervaren.
Dr. Creemers, beste Marjonne. Dank voor het opzetten en uitvoeren van de intraveneuze 
methotrexaat studie. Jij en Elke hebben zeer belangrijk werk verricht voor dit ziektebeeld. 
Daarnaast dank voor het meeschrijven van het artikel. 
De bibliotheek, eindelijk is het zover; ik heb menig arts-onderzoeker zien komen en gaan. 
Jullie zorgden ervoor dat ik altijd met plezier naar het werk ging. Beetje ouwehoeren, beetje 
onderzoek doen, beetje brakke foto’s delen. Kortom … de mooiste baan die er is. We hebben 
lief en leed gedeeld en ik vind het jammer dat we later niet directe collega’s zullen zijn, maar 
zal jullie mogelijk in de consultensfeer tegenkomen.
De stafleden en arts-assistenten dermatologie, dank voor mogelijk maken van mijn promotie. 
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natuurlijk geen geschikte patiënten!
Het lab in Nijmegen, bedankt voor jullie feedback m.b.t. experimenten en dan voornamelijk 
van de huid. Joost, Ellen en Yvonne vooral dank voor hulp het CCL18 project! 
Dear colleagues from the Radstake group, thanks fort the fruitful discussions, but moreover 
thanks for the nice working environment. It’s lovely to work with people originating from all 
over the world, but also with different backgrounds professionally. Moreover, I enjoyed our 
yearly Radstake Retreats. Some special thanks to Kamil, Cornelis, Ralph, and Barbera.
Luuk, dank voor je input bij mijn projecten. Jij snapte waar de crux lag bij dit type onderzoek. 
Heerlijk hoe we kritisch konden zijn op onderzoek in het algemeen, onder het genot van een 
bakje gore UMC Utrecht koffie.
Judith, bedankt voor de fijne samenwerking. Ik denk dat we veel aan elkaar gehad hebben 
qua vergelijkingsziekten. Ik heb onze samenwerking altijd als zeer fijn ervaren. Ook wil ik jou, 
Femke en Annet bedanken dat we mee konden liften op jullie grote Luminex experiment. Dit 
is wat mij betreft een van de mooiere experimenten die ik gedaan heb gedurende mijn PhD.
Interne geneeskunde van het Jeroen Bosch Ziekenhuis. Dank voor de fijne introductie in de 
kliniek na lange tijd met onderzoek bezig te zijn geweest. Ik werk met veel plezier in de kliniek 
en het is me, nu terugkijkend, allemaal flink meegevallen.
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Geneviève, mw. Ector, ik wil je bedanken voor menig gezellige kroegavonden die we gehad 
hebben. Zaken als ‘misschien moeten we deze keer eerder de kroeg in zodat het minder uit 
de hand loopt’ klonken vooraf logischer dan achteraf. 
Young boy wonder, ik kan hier eigenlijk hetzelfde typen als bij Geneviève. Ik kan altijd met je 
lachen en je bent een gezellige collega! Succes met je promotie vanaf volgend jaar. 
Korstanje, bedankt voor de menige zatte avond die we samen beleefd hebben; je zorgde voor 
genoeg ontspanning zullen we maar zeggen! De tijden dat we alles wat los en vast zat in de 
fik zetten op Hoogeveldt voelt als de dag van gisteren, de realiteit leert echter dat dit alweer 
11 jaar geleden is!  
De rest van heren van HJC de Gaulle, bedankt voor de mooie studententijd en tegenwoordig 
met de minder frequente, maar niet minder gezellige, kerstdiners! Zoals het er nu naar uit ziet 
ben ik de enige die overblijft in Nijmegen!!
Floris en Tom. De bende van ellende van het Grotius College te Heerlen…. Hebben we toch 
maar even mooi geflikt dat we allemaal gepromoveerd zijn/gaan promoveren. Van de kelder 
in Landgraaf tot wintersport in Val’thorens, backpacken in Australië, kamperen in de Ardennen 
en op culturele reis naar de Santa Barbara de Nexe. Bij jullie kan ik mezelf zijn.
Het 5e wiel…Paulien en Wulphert, vooral bedankt voor dolle nachten die we gehad hebben in 
met name Nijmegen, maar ook in Rotterdam, Breda, Enschede en sinds kort Deventer. Rode 
draad bij deze avonden is toch vooral het casino en de bowlingbaan (en een dropje voor de 
jongens). Wulphert bedankt voor het sparren en klagen over onderzoek! Bart de Brouwer, 
internetgekkie en nu alweer een tijdje samenwonend met Marion, we zien elkaar helaas niet 
vaak genoeg, maar als we elkaar zien dan is het altijd lachen! Vinny en Marije ook bedankt 
natuurlijk! Het was altijd enorm gezellig als we met z’n allen op stap gingen.
Familie Boon, ik mag nu 11 jaar bij jullie in huis komen en ik moet altijd enorm gniffelen om hoe 
gezinnen verschillen. Bij mijn eigen familie is het veelal rustig thuiskomen, dan nu de familie 
Boon…..  emotie en chaos zijn hoe ik jullie gezin het beste omschrijf. Nu kan dit een negatieve 
lading hebben, maar dat is bij jullie zeker niet zo; ik kom altijd met enorm veel plezier bij jullie 
thuis. En Cok, jij bent echt iemand met het hart op de juiste plaats, enorm bedankt voor alle 
last minute autowissels en oppas momenten als er in ons huis iets moest gebeuren; je bent 
een topmens die altijd voor iedereen, maar vooral voor de familie klaarstaat!
Mam en pap, dank jullie wel voor mijn vrije opvoeding. Ik ben van mening dat jullie een 
belangrijke bijdrage geleverd hebben aan waar ik nu sta. Veel mensen om mij heen zullen 
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mij beschrijven als kritische en een (beetje) cynische man, iets wat ik erg herken in paps 
gedrag: “RTL-4 dat is allemaal in scène gezet” is iets wat ik maar al te vaak hoorde, maar wat 
er wel toe bijgedragen heeft dat ik altijd kritisch zal zijn op een boodschap van iets (artikel) 
of iemand. Een eigenschap die naar mijn mening zeer belangrijk is in het onderzoek en de 
medische wereld. Mam jij bedankt voor je steun en wekelijkse telefoontjes waarbij we de 
week doorspreken. Bedankt hoe je altijd begrip hebt voor mijn twijfels tijdens het wisselen 
van specialisme en hoe je het ook echt probeert te begrijpen. Ik hoop dat jullie beiden van 
het pensioen kunnen genieten en lekker op Pepijn en Hidde kunnen passen. Ik hoop dat jullie 
een mooie tijd tegemoet gaan en dat jullie maar lekker mogen genieten, jullie verdienen het!
Lara, Wesley, Pepijn en Hidde, vooral bedankt voor de leuke activiteiten die we in het weekend 
ondernamen. We zien elkaar relatief weinig, maar het voelt altijd goed als we elkaar zien. Jullie 
hebben het goed voor elkaar daar in Oirschot. Lara succes de komende periode als Wes op 
uitzending is! Dat we volgend jaar maar een keer met z’n allen naar de Efteling kunnen!!
Lieve Pien, eindelijk is het zo ver. Zoals het betaamd, had jij natuurlijk je boekje eerder 
afgerond dan ik, maar nu is het dan eindelijk klaar. Bedankt voor alles, je bent al jaren mijn 
steun en toeverlaat in een heleboel aspecten. Ik hou van je en ben trots op je dat je hier 
vandaag samen met me staat! Daarnaast wil ik je bedanken voor je feedback bij artikelen 
en presentaties. We hebben een druk jaar achter de rug met afronden van de boekjes, de 
verhuizing en onze opleidingen; 2 van de 3 zijn nu afgerond. Pien, ik hou van je! 
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